

SEER

SEER Extent of Disease 1988 Codes and Coding Instructions

Second Edition

NATIONAL INSTITUTES
OF HEALTH
National Cancer Institute

SEER EXTENT OF DISEASE -- 1988

CODES AND CODING INSTRUCTIONS

SECOND EDITION

JUNE 1992

Prepared by:

**Evelyn M. Shambaugh, M.A.
Lynn Gloeckler Ries, M.S.
John L. Young, Jr., Dr. PH
Mary A. Kruse**

**of the
Cancer Statistics Branch
Surveillance Program
Division of Cancer Prevention and Control
National Cancer Institute
U.S. Department of Health and Human Services
Public Health Service
National Institutes of Health**

and

**Charles E. Platz, M.D.
Robert F. Ryan, M.D.
Mildred A. Weiss, B.A.**

Effective for cases diagnosed January 1, 1988 forward

PUBLICATION HISTORY

First Edition May 1988
Revised January 1989
Revised January 1990
Revised January 1991
Second Edition June 1992

ACKNOWLEDGEMENTS

We wish to express our appreciation to Donald Henson, M.D., Chairman of the American Joint Committee on Cancer, and to Robert Hutter, M.D., Liaison of the American Joint Committee to the SEER Program.

The original 13-digit Extent of Disease code was prepared for the SEER Program by the Extent of Disease Committee: Evelyn M. Shambaugh, M.A., Editor; Robert F. Ryan, M.D.; Lillian M. Axtell, M.A.; Howard B. Latourette, M.D.; Charles E. Platz, M.D.; Mildred A. Weiss, B.A.; and Robert L. Schmitz, M.D.

The original 2-digit Extent of Disease code was prepared for the End Results Group by the Extent of Disease Advisory Group: Paula Baylis, Editor; Robert F. Ryan, M.D.; Eugene A. Foster, M.D.; William I. Lourie, Jr., MPH; Mildred A. Weiss, B.A.; and Eugene J. Donlan.

TABLE OF CONTENTS

	Page
PREFACE TO THE SECOND EDITION.....	vii
ABBREVIATIONS AND SYMBOLS.....	viii
 GENERAL INSTRUCTIONS.....	 1
 LIP, ORAL CAVITY, AND PHARYNX.....	 10
LIP (Vermilion or Labial Mucosa).....	12
BASE OF TONGUE, LINGUAL TONSIL.....	14
ANTERIOR 2/3's OF TONGUE, TIP, BORDER, AND TONGUE NOS.....	16
GUM (Gingiva), RETROMOLAR AREA.....	18
FLOOR OF MOUTH.....	20
HARD PALATE.....	22
SOFT PALATE, UVULA.....	24
OTHER MOUTH.....	26
CHEEK (Buccal) MUCOSA, VESTIBULE.....	28
PAROTID GLAND, OTHER MAJOR SALIVARY GLANDS.....	30
TONSIL, OROPHARYNX.....	32
NASOPHARYNX.....	34
PYRIFORM SINUS, HYPOPHARYNX, LARYNGOPHARYNX.....	36
PHARYNX NOS AND OTHER ILL-DEFINED ORAL CAVITY SITES.....	38
 DIGESTIVE SYSTEM SITES.....	 40
ESOPHAGUS.....	42
STOMACH.....	44
SMALL INTESTINE.....	46
COLON (incl. Flexures and Appendix)... ..	48
RECTOSIGMOID, RECTUM.....	50
ANAL CANAL, ANUS NOS, OTHER PARTS OF RECTUM.....	52
LIVER AND INTRAHEPATIC BILE DUCTS.....	54
GALLBLADDER, OTHER BILIARY, AND BILIARY NOS.....	56
EXTRAHEPATIC BILE DUCT(S).....	58
AMPULLA OF VATER.....	60
PANCREAS: HEAD, BODY, AND TAIL.....	62
PANCREAS: OTHER AND UNSPECIFIED.....	64
OTHER AND ILL-DEFINED DIGESTIVE ORGANS.....	66
 NASAL CAVITY AND MIDDLE EAR.....	 68
MAXILLARY SINUS.....	70
ACCESSORY (Paranasal) SINUSES (excl. Maxillary Sinus).....	72
LARYNX.....	74

TABLE OF CONTENTS (cont'd)

	Page
TRACHEA.....	76
BRONCHUS AND LUNG.....	78
HEART, MEDIASTINUM.....	80
PLEURA.....	82
OTHER AND ILL-DEFINED RESPIRATORY SITES AND INTRATHORACIC ORGANS.....	84
 BONES, JOINTS, AND ARTICULAR CARTILAGE.....	86
 SKIN (excl. Malignant Melanoma, Kaposi's Sarcoma, Mycosis Fungoides, Sezary's Disease, and Other Lymphomas).....	88
MALIGNANT MELANOMA OF SKIN, VULVA, PENIS, SCROTUM.....	90
MYCOSIS FUNGOIDES AND SEZARY'S DISEASE OF SKIN, VULVA, PENIS, SCROTUM.....	92
 PERIPHERAL NERVES AND AUTONOMIC NERVOUS SYSTEM; CONNECTIVE, SUB- CUTANEOUS, AND OTHER SOFT TISSUES...	94
RETROPERITONEUM AND PERITONEUM.....	96
 BREAST.....	98
 VULVA (incl. Skin of Vulva) (excl. Mal- ignant Melanoma, Kaposi's Sarcoma, Mycosis Fungoides, Sezary's Disease, and Other Lymphomas).....	100
VAGINA.....	102
CERVIX UTERI.....	104
CORPUS UTERI, UTERUS NOS, AND PLACENTA.....	107
OVARY.....	110
FALLOPIAN TUBE, BROAD AND ROUND LIGAMENTS, PARAMETRIUM, UTERINE ADNEXA.....	112
OTHER AND UNSPECIFIED FEMALE GENITAL ORGANS.....	114
 PENIS (excl. Body of penis) (excl. Malignant Melanoma, Kaposi's Sarcoma, Mycosis Fungoides, Sezary's Disease, and Other Lymphomas).....	116
BODY OF PENIS, OTHER AND UNSPECIFIED MALE GENITAL ORGANS (excl. Malignant Melanoma, Kaposi's Sarcoma, Mycosis Fungoides, Sezary's Disease, and Other Lymphomas of Scrotum).....	118
PROSTATE GLAND.....	120
TESTIS.....	122

TABLE OF CONTENTS (cont'd)

	Page
URINARY TRACT	
KIDNEY (Renal Parenchyma).....	126
RENAL PELVIS, URETER, and UNSPECIFIED URINARY ORGANS.....	128
BLADDER.....	130
URETHRA, PARAURETHRAL GLAND.....	132
CONJUNCTIVA (excl. Retinoblastoma, Malignant Melanoma, Kaposi's Sarcoma, and Lymphomas).....	134
MALIGNANT MELANOMA OF CONJUNCTIVA.....	136
UVEA AND OTHER EYE (excl. Retino- blastoma, Malignant Melanoma, Kaposi's Sarcoma, and Lymphomas)....	138
MALIGNANT MELANOMA OF UVEA AND OTHER EYE.....	140
LACRIMAL GLAND.....	142
ORBIT NOS.....	144
BRAIN AND CEREBRAL MENINGES.....	146
OTHER PARTS OF CENTRAL NERVOUS SYSTEM.	148
THYROID GLAND.....	150
THYMUS, ADRENAL GLAND, AND OTHER ENDOCRINE GLANDS.....	152
KAPOSI'S SARCOMA OF ALL SITES.....	154
RETINOBLASTOMA.....	156
HODGKIN'S DISEASE AND NON-HODGKIN'S LYMPHOMA OF ALL SITES (excl. Mycosis Fungoides and Sezary's Disease).....	158
HEMATOPOIETIC, RETICULOENDOTHELIAL, IMMUNOPROLIFERATIVE, AND MYELO- PROLIFERATIVE NEOPLASMS.....	160
OTHER AND ILL-DEFINED SITES, UNKNOWN PRIMARY SITE.....	162
APPENDIX A - CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988.....	165
INDEX.....	215

Preface to the Second Edition

This is the first complete reissue of SEER Extent of Disease -- 1988: Codes and Coding Instructions (EOD-88) since it was first published. The most significant difference between this edition and the first is that primary site codes are given in the World Health Organization's International Classification of Diseases for Oncology, 2nd ed. (WHO, 1990) (ICD-0-2).

Substantive changes from the first edition to the codes or rules are marked with change bars. Format changes, editorial changes, and changes necessitated by the adoption of ICD-0-2 are not so marked. Substantive changes made to the first edition in the past are not so marked, but are described in Appendix A.

Both the first and second editions of EOD-88 are compatible with the American Joint Committee on Cancer's (AJCC) Manual for Staging of Cancer, 3rd ed. (Lippincott, 1988). SEER intends to collect EOD-88 compatible with this third edition through 1993. A revision of EOD compatible with AJCC's Manual for Staging of Cancer, 4th ed., (Lippincott, 1992) is planned for implementation with 1994-diagnosed cases.

Interim versions of EOD-88, 2nd ed., have been previously distributed showing earlier dates. They should be discarded and replaced by the final published version.

Send suggestions and corrections to :

Jennifer E. Seiffert, MLIS, CTR
Head, SEER Quality Control
CST/SP/DCPC
National Cancer Institute
9000 Rockville Pike, EPN 343J
Bethesda, MD 20892

Definitions of Abbreviations and Symbols

AJCC	American Joint Committee on Cancer
C-	Topography code of the International Classification of Diseases for Oncology, Second Edition (ICD-O, 1990)
cm	centimeter
excl.	excluding, exclusive
FIGO	Federation Internationale de Gynecologie et d'Obstetrique
GE	Gastroesophageal
GI	Gastrointestinal
incl.	including, inclusive
KUB	Kidneys, Ureters, Bladder
L	left
M-	Morphology code of the International Classification of Diseases for Oncology, Second Edition (ICD-O, 1990)
mm	millimeter
MSB	Main Stem Bronchus
NOS	Not Otherwise Specified
R	right
SEER	Surveillance, Epidemiology and End Results
TNM	Primary Tumor, Regional Lymph Nodes, Distant Metastasis
<	less than
>	greater than
≤	less than or equal to
≥	greater than or equal to

**General Instructions
for Using the SEER Extent of Disease --1988
Codes and Coding Instructions**

The Extent of Disease schemes consist of a ten-digit code to be submitted for each and every site. It will be identified by a '4' in Section IV, Field 12. This scheme replaces the 13-digit (SEER), the 2-digit (ERG), the non-specific, and the SEER 1983-87 four-digit schemes. It will apply to January 1, 1988 diagnoses and later. Do NOT replace schemes for cases diagnosed prior to January 1, 1988 with this scheme; cases diagnosed prior to 1988 will remain coded to whatever scheme was in operation at that time.

For ALL sites, extent of disease is based on a combined clinical and operative/pathological assessment. Gross observations at surgery are particularly important when all malignant tissue is not removed. In the event of a discrepancy between pathology and operative reports concerning excised tissue, priority is given to the pathology report.

Clinical information, such as description of skin involvement for breast cancer and size of the primary lesion and distant lymph nodes for any site, can change the stage. Thus, be sure to peruse the clinical information carefully to ensure accurate extent of disease. If the operative/pathology information disproves the clinical information, code the operative/pathology information.

Autopsy reports are used in coding Extent of Disease just as are pathology reports, applying the same rules for inclusion and exclusion.

Death Certificate **only** cases are coded as '9999999999' in the SEER Extent of Disease 1988 scheme.

Extent of Disease should be limited to all information available **within two months after diagnosis for all cases**.

Metastasis which is known to have developed after the original diagnosis was made should be excluded.

In coding size of tumor, code the size given prior to radiation therapy for surgical patients pretreated by radiation therapy. Do NOT code size after radiation therapy is given.

General Instructions (cont'd)

Interpreting Ambiguous Terminology

- A. Tumor invasion "to", "into", "onto", or "encroaching upon" an organ or structure is to be interpreted as involvement whether the description is clinical or operative/pathological.
- B. "Probable", "suspected", "suspicious", "compatible with", or "consistent with" are to be interpreted as involvement by tumor.
- C. "Questionable", "possible", "suggests", or "equivocal" are **NOT** to be considered as evidence of involvement by tumor.
- D. "Induration" is used to describe surrounding fibrous or connective tissue adjacent to the tumor and is to be interpreted as extension of the malignant growth.
- E. "Fixation to another organ or tissue" or "fixed" should be interpreted as involvement of other organ or tissue.

General Instructions (cont'd)

Extent of Disease Fields

The fields of information required for extent of disease are Tumor Size, Extension, Lymph Nodes, and the Pathology Review of Lymph Nodes.

I. TUMOR SIZE

Record the exact size of the primary tumor for all sites except where stated to be 'not applicable'. Record in tenths of CENTIMETERS (._. cm). Code '999' is reserved for unknown size.

Always code the size of the tumor, not the size of the polyp, ulcer, or cyst.

Do NOT add pieces or chips together to create a whole; they may not be from the same location, or they may represent only a very small portion of a large tumor. However, if an excisional biopsy is performed, and residual tumor at time of resection of the primary is found to be larger than the excisional biopsy, code the size of the residual tumor.

The descriptions in code '998' take precedence over any mention of size. Code '998' is used only for the following sites:

Esophagus (C15.0-C15.5, C15.8-C15.9): Entire circumference
Stomach (C16.0-C16.6, C16.8-C16.9): Diffuse, widespread--3/4's or more, linitis plastica
Colorectal (M-8220/8221 with /2 or /3): Familial/multiple polyposis
Lung and main stem bronchus (C34.0-C34.3, C34.8-C34.9): Diffuse, entire lobe or lung
Breast (C50.0-C50.6, C50.8-C50.9): Diffuse, widespread--3/4's or more of breast, inflammatory carcinoma

For the following sites, size is not applicable:

Hematopoietic neoplasms
Hodgkin's and non-Hodgkin's lymphoma; Kaposi's sarcoma
Immunoproliferative diseases
Mycosis fungoides of skin
Myeloproliferative diseases
Malignant melanoma of skin, vulva, penis, scrotum, and conjunctiva
Sezary's disease of skin
Unknown and ill-defined primary sites (C76.0-C76.5, C76.7-C76.8, C80.9, C42._ and C77._)

For melanoma of skin, vulva, penis, scrotum, and conjunctiva SEER requires information on thickness of tumor instead of size to be coded in this field.

For Kaposi's sarcoma and lymphomas, SEER requires information on HIV/AIDS instead of size to be coded in this field.

For mycosis fungoides and Sezary's disease of skin, vulva, penis, and scrotum, SEER requires information on peripheral blood involvement instead of size to be coded in this field.

If size is not recorded, code as '999'.

For in situ lesions, code the size as stated.

General Instructions (cont'd)

Determining Descriptive Tumor Size

CENTIMETER EQUIVALENTS FOR DESCRIPTIVE TERMS

<u>Fruits</u>	<u>cm</u>	<u>Miscellaneous Food</u>	<u>cm</u>
Apple	7	Doughnut	9
Apricot	4	Egg	5
Cherry	2	Bantam	4
Date	4	Goose	7
Fig (dried)	4	Hen	3
Grape	2	Pigeon	3
Grapefruit	10	Robin	2
Kumquat	5	Lentil	<1
Lemon	8	Millet	<1
Olive	2		
Orange	9	<u>Money</u>	
Peach	6	Dime	1
Pear	9	Dollar (silver)	4
Plum	3	Dollar (half)	3
Tangerine	6	Nickel	2
		Quarter	2
		Penny	1
<u>Nuts</u>		<u>Other</u>	
Almond	3	Ball (golf)	4
Chestnut	4	Ball (ping-pong)	3
Chestnut (horse)	4	Ball (tennis)	6
Hazel	2	Baseball	7
Hickory	3	Eraser on pencil	<1
Peanut	1	Fist	9
Pecan	3	Marble	1
Walnut	3	Match (head)	<1
		Microscopic	<1
<u>Vegetables</u>			
Bean	1		
Bean (lima)	2		
Pea	<1		
Pea (split)	<1		

SIZES IN CENTIMETERS, MILLIMETERS, INCHES

10 millimeters (mm) = 1 centimeter (cm)

2.5 centimeters (cm) = 1 inch (in)

1 millimeter (mm) = 1/10 centimeter (cm)

1 centimeter (cm) = .394 inch (in)

General Instructions (cont'd)

II. EXTENSION

The description of the primary tumor growth within the organ of origin or its extension to neighboring organs, or its metastasis to distant sites is summarized in a two-digit code. It is a hierarchical code in which the most extensive disease is all that is coded. Thus, information about the extent of the tumor within the primary site is lost if the tumor extends to neighboring organs, and extension to neighboring organs is lost if there is distant metastasis. Code '99' is reserved for unknown extension.

A "localized, NOS" category is provided for those cases in which the only description is "localized with no further information." "NOS" codes should be used only after an exhaustive search for more specific information.

If a tumor is described as "confined to mucosa," determine if it is limited to the epithelium (in situ) or if it has penetrated the basement membrane to invade the lamina propria.

III. LYMPH NODES

Regional lymph nodes are listed for each site and then, as necessary, the regional (first station) lymph nodes are classified in terms of size, laterality, number of involved nodes, and distance of the lymph nodes from the primary site. It is a one-digit field, a hierarchical code, in which once distant lymph node involvement is observed, all mention of regional nodal involvement is lost.

Since in situ by definition means noninvasive, code lymph node involvement as '0'. If there is evidence of nodal involvement of a tumor described as in situ, it would indicate that an area of invasion was simply missed, and it is NOT an in situ lesion.

For solid tumors, the terms "fixed" or "matted" and "mass in the mediastinum, retroperitoneum, and/or mesentery" (with no specific information as to tissue involved) are considered involvement of lymph nodes. Any other terms, such as "palpable", "enlarged", "visible swelling", "shotty", or "lymphadenopathy" should be ignored; look for a statement of involvement, either clinical or pathological.

For lymphomas, any mention of lymph nodes is indicative of involvement.

When size of involved regional lymph nodes is required, code from pathology report. Code only the size of the largest involved node.

General Instructions (cont'd)

Regional lymph nodes are not palpable for inaccessible sites such as bladder, kidney, lung, liver, and ovary. The best description you will have concerning regional lymph nodes will be the surgeon's evaluation at the time of exploratory surgery or definitive surgery.

The terms "homolateral" and "ipsilateral" are used interchangeably. Any unidentified nodes included with the resected primary site specimen are to be considered as "Regional, NOS."

Codes are provided for "regional lymph node(s), NOS" and for "lymph nodes, NOS." "NOS" codes should be used only after an exhaustive search for more specific information.

General Instructions (cont'd)

IV. PATHOLOGY REVIEW OF REGIONAL LYMPH NODES

Number of REGIONAL lymph nodes: POSITIVE nodes (first two-characters) and nodes EXAMINED (second two-characters) for all sites except the hematopoietic, reticuloendothelial, immunoproliferative and myeloproliferative neoplasms, the brain, cerebral meninges, and other parts of the nervous system, and unknown or ill-defined primary sites which are coded 9999. (This is based on pathology information ONLY.)

NUMBER OF REGIONAL NODES

<u>POSITIVE</u>	<u>EXAMINED</u>
00 All nodes examined negative	00 No nodes examined
01 One positive lymph node	01 One node examined
02 Two positive lymph nodes	02 Two nodes examined
..	..
..	..
10 Ten positive lymph nodes	10 Ten nodes examined
11 Eleven positive lymph nodes	11 Eleven nodes examined
..	..
..	..
96 96+	..
97 Positive nodes but number of positive nodes not specified	97+
98 No nodes examined	98 Nodes examined, but number unknown
99 UNKNOWN if nodes are positive or negative; not applicable	99 UNKNOWN if nodes were examined; not applicable

UNKNOWN AND NOT APPLICABLE

UNKNOWN will only be used when there is no descriptive information or when there is insufficient information because of an inadequate workup. It is to be used only if more specific information cannot be found except for Death Certificate only cases which are always coded '9999999999'.

Size of the Primary Tumor	999 - Not stated; not applicable
Extension	99 - UNKNOWN; not applicable
Lymph Nodes	9 - UNKNOWN; not stated; not applicable
Pathology Review	9999 - UNKNOWN; not applicable

Code 9's to indicate that a field is not applicable. For example, "Lymph Nodes" is not an applicable field for brain tumors or leukemia.

General Instructions (cont'd)

DISEASES DISSEMINATED AT DIAGNOSIS

Hematopoietic and reticuloendothelial neoplasms such as leukemia, multiple myeloma, reticuloendotheliosis, and Letterer-Siwe's disease, as well as immunoproliferative and myeloproliferative neoplasms are considered disseminated disease at diagnosis. These conditions will always be coded as systemic disease under Extension, and 9's in the remaining fields.

HODGKIN'S DISEASE and NON-HODGKIN'S LYMPHOMA

All lymphomas, both nodal and extranodal, will be coded to the lymphoma scheme (histology codes (M-9590-9595, 9650-9698, 9702-9714) except for mycosis fungoides (M-9700) and Sezary's disease (M-9701) which have a separate scheme found under the skin site codes C44._.

KAPOSI'S SARCOMA and RETINOBLASTOMA

Kaposi's sarcoma (M-9140) and retinoblastoma (M-9510-9512) also have separate schemes based on morphology alone.

LIP, ORAL CAVITY, AND PHARYNX

DISTINGUISHING "IN SITU" AND "LOCALIZED" TUMORS FOR LIP, ORAL CAVITY, AND PHARYNX

Careful attention must be given to the use of the term "confined to mucosa" for lip, oral cavity, and pharynx.

Historically, carcinomas described as "confined to mucosa" have been coded as localized. In order to provide greater specificity and to rule out the possibility of classifying noninvasive tumors in this category, abstractors should determine:

- 1) if the tumor is confined to the epithelium, in which case it is in situ, OR
- 2) if the tumor has penetrated the basement membrane to invade the lamina propria, in which case it is localized and is coded to invasion of the lamina propria.

The mucosa lining the oral cavity consists of:

The EPITHELIAL LAYER which borders on the lumen and contains no blood vessels or lymphatics.

The BASEMENT MEMBRANE, a sheet of extracellular material, functions as a filtration barrier and a boundary involved in generating and maintaining tissue structure.

The LAMINA PROPRIA, composed of areolar connective tissue, contains blood vessels, nerves, and, in some regions, glands. Once tumor has broken through the basement membrane into the lamina propria, it can spread by way of the lymphatics and blood vessels to other parts of the body.

The lip, oral cavity, and pharynx do NOT have a MUSCULARIS MUCOSAE. Therefore, the lamina propria and the submucosa tend to merge, and the two terms are used interchangeably.

The SUBMUCOSA is a thick layer of either dense or areolar connective tissue. It contains blood vessels, lymphatic vessels, nerves, and, in some regions, glands. Only the GUM and HARD PALATE do NOT have a submucosa, but rather a mucoperiosteum.

The MUSCULARIS PROPRIA is muscle tissue which constitutes the wall of the organ. Only the GUM and HARD PALATE do NOT have a muscularis.

There is no SEROSA on any of these sites.

LIP, ORAL CAVITY, AND PHARYNX

LIP AND ORAL CAVITY						
PRIMARY SITE	MUCOSA	SUBMUCOSA	MUSCULARIS PROPRIA	SEROSA		
	Epithelium	Lamina Propria				
Lip (C00._)	Yes	Yes	Yes	Yes	No	
Tongue (C01._, C02._)	Yes	Yes	Yes	Yes	No	
Gum (C03._, C06.2)	Yes	Yes	No	No	No	
Floor of Mouth (C04._)	Yes	Yes	Yes	Yes	No	
Buccal Mucosa (C06.0-C06.1)	Yes	Yes	Yes	Yes	No	
Hard Palate (C05.0)	Yes	Yes	No	No	No	
Soft Palate (C05.1-C05.2)	Yes	Yes	Yes	Yes	No	
Other Mouth (C05.8-C05.9, C06.8-C06.9)	Yes	Yes	Yes	Yes	No	

For lip, oral cavity, and pharynx, if a tumor is described as "confined to mucosa," determine if it is limited to the epithelium (in situ) or if it has penetrated the basement membrane to invade the lamina propria.

LIP (Vermilion or Labial Mucosa)
C00.0-C00.6, C00.8-C00.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

000	No mass; no tumor found	
001	Microscopic focus or foci only	
	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 10 Invasive tumor confined to:
 - Lamina propria
 - Submucosa (superficial invasion)
 - Vermilion surface
 - Labial mucosa (inner lip)
 - Subcutaneous soft tissue of lip
 - Skin of lip
- 20 Musculature
- 30 Localized, NOS
- 50 Buccal mucosa (inner cheek)
 - Opposite (both) lip(s); commissure
- 51 Gingiva
- 70 Upper lip/commissure:
 - Maxilla
 Lower lip/commissure:
 - Mandible
- 75 Tongue
- 76 Nose for upper lip/commissure
 - Skin of face/neck
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

Note: AJCC includes labial mucosa (C00.3-C00.5) with buccal mucosa (C06.0).

LIP (Vermilion or Labial Mucosa)
C00.0-C00.6, C00.8-C00.9

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Facial: Buccinator for upper lip
Mandibular for lower lip
Parotid: Infra-auricular/pre-auricular for upper lip

Submandibular (submaxillary)
Submental
Internal jugular (upper and lower deep cervical):
jugulodigastric
jugulo-omohyoid
Cervical, NOS

Regional lymph node(s), NOS

- 1 One positive ipsilateral node
≤3 cm in greatest diameter
- 2 One positive ipsilateral node
>3-6 cm in greatest diameter
- 3 Multiple positive ipsilateral nodes ≤6 cm
- 4 Ipsilateral, node size not stated
- 5 Bilateral and/or contralateral positive nodes ≤6 cm or size not stated
- 6 Any positive node(s),
at least one >6 cm

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

Note: If laterality is not specified, assume nodes are ipsilateral.

BASE OF TONGUE, LINGUAL TONSIL
C01.9, C02.4

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 10 Invasive tumor on one side confined to:
 Lamina propria
 Submucosa
- 20 Musculature, intrinsic or NOS
- 30 Localized, NOS
- 40 Tumor crosses midline
- 50 Anterior 2/3's of tongue
 Lower gingiva
 Floor of mouth
- 53 Sublingual gland
- 60 Lateral pharyngeal wall (tonsillar pillars and fossae, tonsils)
 Vallecula, incl. pharyngoepiglottic and glossoepiglottic folds
 Epiglottis, lingual (pharyngeal) surface
 Soft palate, inferior surface/NOS
- 70 Mandible
- 75 Musculature, extrinsic:
 Hyoglossus
 Genioglossus
 Styloglossus
- 76 Skin
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

Note: AJCC includes base of tongue (C01.9) with oropharynx (C10._).

BASE OF TONGUE, LINGUAL TONSIL
C01.9, C02.4

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Submandibular (submaxillary)

Submental

Internal jugular (upper and
lower deep cervical):

jugulodigastric

jugulo-omohyoid

Cervical, NOS

Regional lymph node(s), NOS

1 One positive ipsilateral node
≤3 cm in greatest diameter

2 One positive ipsilateral node
>3-6 cm in greatest diameter

3 Multiple positive ipsilateral
nodes ≤6 cm

4 Ipsilateral, node size not stated

5 Bilateral and/or contralateral
positive nodes ≤6 cm or size
not stated

6 Any positive node(s),
at least one >6 cm

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

Note: If laterality is not specified, assume nodes are ipsilateral.

ANTERIOR 2/3's of TONGUE, TIP, BORDER, AND TONGUE NOS
C02.0-C02.3, C02.8-C02.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 10 Invasive tumor on one side confined to:
Lamina propria
Submucosa
- 20 Musculature, intrinsic or NOS
- 30 Localized, NOS
- 40 Tumor crosses midline
- 50 Base of tongue
Gingiva, lower (incl. retromolar trigone)
Floor of mouth
- 53 Sublingual gland
- 60 Lateral pharyngeal wall (tonsillar pillars and fossae, tonsils)
Soft palate, inferior surface
- 70 Mandible
Maxilla
- 75 Musculature, extrinsic:
Hyoglossus
Genioglossus
Styloglossus
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

ANTERIOR 2/3's of TONGUE, TIP, BORDER, AND TONGUE NOS
C02.0-C02.3, C02.8-C02.9

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Submandibular (submaxillary)

Submental

Sublingual

Internal jugular (upper and
lower deep cervical):

jugulodigastric

jugulo-omohyoid

Cervical, NOS

Regional lymph node(s), NOS

1 One positive ipsilateral node
≤3 cm in greatest diameter

2 One positive ipsilateral node
>3-6 cm in greatest diameter

3 Multiple positive ipsilateral
nodes ≤6 cm

4 Ipsilateral, node size not stated

5 Bilateral and/or contralateral
positive nodes ≤6 cm or size
not stated

6 Any positive node(s),
at least one >6 cm

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

Note: If laterality is not
specified, assume nodes are
ipsilateral.

GUM (Gingiva), RETROMOLAR AREA
C03.0-C03.1, C03.9, C06.2

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 10 Invasive tumor confined to mucoperiosteum (stroma)
- 30 Localized, NOS
- 50 Buccal mucosa (inner cheek)
 Labial mucosa (inner lip), lip

Upper gum only:
 Hard palate
 Soft palate

Lower gum/retromolar trigone only:
 Floor of mouth
 Tongue
- 55 Subcutaneous soft tissue of face
 Facial muscle, NOS
- 60 Lateral pharyngeal wall
 (tonsillar pillars and fossae, tonsils)
- 70 **Upper gum only:**
 Maxilla
Lower gum/retromolar trigone only:
 Mandible
- 73 Skull
- 74 **Upper gum only:**
 Nasal cavity
 Maxillary antrum (sinus)
- 76 Skin
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

GUM (Gingiva), RETROMOLAR AREA
C03.0-C03.1, C03.9, C06.2

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Facial: Mandibular
Submandibular (submaxillary)
Submental
Retropharyngeal for upper gum
Internal jugular (upper and
lower deep cervical):
jugulodigastric
jugulo-omohyoid
Cervical, NOS
Regional lymph node(s), NOS

- 1 One positive ipsilateral node
≤3 cm in greatest diameter
- 2 One positive ipsilateral node
>3-6 cm in greatest diameter
- 3 Multiple positive ipsilateral
nodes ≤6 cm
- 4 Ipsilateral, node size not stated
- 5 Bilateral and/or contralateral
positive nodes ≤6 cm or size
not stated
- 6 Any positive node(s),
at least one >6 cm

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

Note: If laterality is not specified, assume nodes are ipsilateral.

FLOOR OF MOUTH
C04.0-C04.1, C04.8-C04.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

000	No mass; no tumor found	
001	Microscopic focus or foci only	
	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 10 Invasive tumor on one side confined to:
Lamina propria
Submucosa
- 20 Musculature, extrinsic: Mylohyoid and hyoglossus
- 30 Localized, NOS
- 40 Tumor crosses midline
- 50 Gingiva (alveolar ridge), lower Anterior 2/3's of tongue
Base of tongue
- 53 Sublingual gland, incl. ducts
Submandibular (submaxillary) glands, incl. ducts
- 55 Subcutaneous soft tissue
- 60 Epiglottis, pharyngeal (lingual) surface
Lateral pharyngeal wall (tonsillar pillars and fossae, tonsils)
Vallecula, incl. pharyngo-epiglottic and glosso-epiglottic folds
- 70 Mandible
- 76 Skin of undersurface of chin/neck
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Submandibular (submaxillary)
Submental
Sublingual
Internal jugular (upper and
lower deep cervical):
 jugulodigastric
 jugulo-omohyoid
Cervical, NOS
Regional lymph node(s), NOS

- 1 One positive ipsilateral node
 ≤3 cm in greatest diameter
- 2 One positive ipsilateral node
 >3-6 cm in greatest diameter
- 3 Multiple positive ipsilateral
 nodes ≤6 cm
- 4 Ipsilateral, node size not stated
- 5 Bilateral and/or contralateral
 positive nodes ≤6 cm or size
 not stated
- 6 Any positive node(s),
 at least one >6 cm

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

Note: If laterality is not specified, assume nodes are ipsilateral.

HARD PALATE
C05.0

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

000	No mass; no tumor found	
001	Microscopic focus or foci only	
	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

00	IN SITU: Noninvasive; intraepithelial
10	Invasive tumor on one side confined to mucoperiosteum (stroma)
30	Localized, NOS
40	Tumor crosses midline
50	Soft palate Gingiva, upper Buccal mucosa (inner cheek)
70	Palatine bone Maxillary bone
74	Nasal cavity Maxillary antrum (sinus) Sphenoid bone Pterygoid plate
80	FURTHER extension
85	Metastasis
99	UNKNOWN if extension or metastasis

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Submandibular (submaxillary)

Submental

Internal jugular (upper and
lower deep cervical):

jugulodigastric

jugulo-omohyoid

Retropharyngeal

Cervical, NOS

Regional lymph node(s), NOS

1 One positive ipsilateral node
≤3 cm in greatest diameter

2 One positive ipsilateral node
>3-6 cm in greatest diameter

3 Multiple positive ipsilateral
nodes ≤6 cm

4 Ipsilateral, node size not stated

5 Bilateral and/or contralateral
positive nodes ≤6 cm or size
not stated

6 Any positive node(s),
at least one >6 cm

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

Note: If laterality is not
specified, assume nodes are
ipsilateral.

SOFT PALATE, UVULA
C05.1-C05.2

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

000	No mass; no tumor found	
001	Microscopic focus or foci only	
	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

00	IN SITU: Noninvasive; intraepithelial
10	Invasive tumor on one side confined to: Lamina propria Submucosa
20	Musculature invaded
30	Localized, NOS
40	Tumor crosses midline
50	Hard palate Gum (gingiva), upper Buccal mucosa (inner cheek)
60	Lateral pharyngeal wall (tonsillar pillars and fossae, tonsils)
70	Palatine bone (bone of hard palate) Maxilla Mandible
74	Nasopharynx Nasal cavity Maxillary antrum (sinus)
75	Tongue
80	FURTHER extension
85	Metastasis
99	UNKNOWN if extension or metastasis

Note 1: AJCC includes inferior surface of the soft palate (C05.1) and uvula (C05.2) with oropharynx (C09._, C10._).

Note 2: Soft palate excludes nasopharyngeal (superior) surface of soft palate (C11.3).

Note 3: Code C06.2, retromolar area, is included with gum (C03._).

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Submandibular (submaxillary)
Submental
Retropharyngeal
Internal jugular (upper and
lower deep cervical):
jugulodigastric
jugulo-omohyoid
Cervical, NOS
Regional lymph node(s), NOS

Note: If laterality is not specified, assume nodes are ipsilateral.

- 1 One positive ipsilateral node
≤3 cm in greatest diameter
- 2 One positive ipsilateral node
>3-6 cm in greatest diameter
- 3 Multiple positive ipsilateral
nodes ≤6 cm
- 4 Ipsilateral, node size not stated
- 5 Bilateral and/or contralateral
positive nodes ≤6 cm or size
not stated
- 6 Any positive node(s),
at least one >6 cm

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

OTHER MOUTH
C05.8-C05.9, C06.8-C06.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive;
intraepithelial
- 10 Invasive tumor confined to:
Lamina propria
Submucosa
- 20 Musculature
- 30 Localized, NOS
- 50 Adjacent oral cavity
- 60 Extension to oropharynx:
Lateral pharyngeal wall
Vallecula
Lingual surface of epiglottis
Inferior surface of soft palate
- 70 Extension to adjacent structures:
Maxilla, mandible, skull
Maxillary antrum; nasal cavity
Tongue
Skin of face/neck
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

OTHER MOUTH
C05.8-C05.9, C06.8-C06.9

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Submandibular (submaxillary)
Submental
Internal jugular (upper and
lower deep cervical):
jugulodigastric
jugulo-omohyoid
Cervical, NOS
Regional lymph node(s), NOS

Note: If laterality is not
specified, assume nodes are
ipsilateral.

- 1 One positive ipsilateral node
≤3 cm in greatest diameter
- 2 One positive ipsilateral node
>3-6 cm in greatest diameter
- 3 Multiple positive ipsilateral
nodes ≤6 cm
- 4 Ipsilateral, node size not stated
- 5 Bilateral and/or contralateral
positive nodes ≤6 cm or size
not stated
- 6 Any positive node(s),
at least one >6 cm

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

CHEEK (Buccal) MUCOSA, VESTIBULE
C06.0-C06.1

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+

999 Not stated

EXTENSION

00 IN SITU: Noninvasive; intraepithelial

10 Invasive tumor confined to:
 Lamina propria
 Submucosa

20 Musculature (buccinator)

30 Localized, NOS

50 Lip(s), incl. commissure

51 Gingiva

55 Subcutaneous soft tissue of cheek

60 Lateral pharyngeal wall (tonsillar pillars and fossae, tonsils)

70 Bone: Maxilla, mandible

73 Skull

75 Tongue

76 Skin of cheek (WITH or WITHOUT ulceration)

80 FURTHER extension

85 Metastasis

99 UNKNOWN if extension or metastasis

Note: ICD-0, C06.0 for buccal mucosa includes the membrane lining of the cheeks but not of the lips. (AJCC includes labial mucosa with buccal mucosa.)

CHEEK (Buccal) MUCOSA, VESTIBULE
C06.0-C06.1

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Facial: Buccinator, mandibular
Submandibular (submaxillary)
Parotid: Preauricular, infra-
auricular
Submental
Internal jugular (upper and
lower deep cervical):
jugulodigastric
jugulo-omohyoid
Cervical, NOS
Regional lymph node(s), NOS

Note: If laterality is not
specified, assume nodes are
ipsilateral.

- 1 One positive ipsilateral node
≤3 cm in greatest diameter
- 2 One positive ipsilateral node
>3-6 cm in greatest diameter
- 3 Multiple positive ipsilateral
nodes ≤6 cm
- 4 Ipsilateral, node size not stated
- 5 Bilateral and/or contralateral
positive nodes ≤6 cm or size
not stated
- 6 Any positive node(s),
at least one >6 cm

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

PAROTID GLAND, OTHER MAJOR SALIVARY GLANDS
 C07.9, C08.0-C08.1, C08.8-C08.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU; noninvasive
- 10 Invasive tumor confined to gland of origin
- 30 Localized, NOS
- 40 Periglandular soft/connective tissue
 Other major salivary gland (parotid, submaxillary, sublingual)
 Periosteum of mandible
 Skeletal muscle: Digastric, pterygoid, stylohyoid
Parotid gland only:
 Skin overlying gland
 External auditory meatus
 Facial nerve
 Pharyngeal mucosa
 Skeletal muscle: Sternocleidomastoid, masseter
Submandibular gland only:
 Skeletal muscle: Mylohyoid, hyoglossus, styloglossus
- 50 **Parotid gland only:**
 Skull; mastoid
 Mandible
 Nerves: Auricular, spinal accessory
 Major blood vessel(s): Carotid artery, jugular vein
Submandibular gland only:
 Mandible
 Nerves: Facial, lingual
 Major blood vessels: Facial artery or vein, maxillary artery
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

PAROTID GLAND, OTHER MAJOR SALIVARY GLANDS
C07.9, C08.0-C08.1, C08.8-C08.9

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Parotid gland only:

Intraparotid, infra-auricular,
preauricular

Submandibular gland only:

Submandibular (submaxillary)
Submental
Internal jugular (upper deep
cervical):
jugulodigastric

Parotid and Submandibular glands:

Cervical, NOS
Regional lymph node(s), NOS

- 1 One positive ipsilateral node
≤3 cm in greatest diameter
 - 2 One positive ipsilateral node
>3-6 cm in greatest diameter
 - 3 Multiple positive ipsilateral
nodes ≤6 cm
 - 4 Ipsilateral, node size not stated
 - 5 Bilateral and/or contralateral
positive nodes ≤6 cm or size
not stated
 - 6 Any positive node(s),
at least one >6 cm
-

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

Note: If laterality is not specified, assume nodes are ipsilateral.

TONSIL, OROPHARYNX

C09.0-C09.1, C09.8-C09.9, C10.0-C10.4, C10.8-C10.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

- 000 No mass; no tumor found
- 001 Microscopic focus or foci only
- mm cm
- 002 ≤2 ≤0.2
- 003 3 0.3
- ...
- ...
- 009 9 0.9
- 010 10 1.0
- ...
- ...
- 099 99 9.9
- 100 100 10.0
- ...
- ...
- 990 990+ 99.0+
- 999 Not stated

Anatomic Limits of Oropharynx

ANTERIOR WALL consists of the lingual (anterior) surface of the epiglottis and the pharyngoepiglottic and glossoepiglottic folds which bound the vallecula (the hollow formed at the junction of the base of the tongue and the epiglottis).

LATERAL WALLS include the tonsillar pillars, the tonsillar fossae, and the palatine (faucial) tonsils. On each side, the anterior pillar (glossopalatine fold) extends from the base of the tongue to the soft palate lying in front of the tonsillar fossa.

POSTERIOR WALL extends from a level opposite the free borders of the soft palate to the tip of the epiglottis.

AJCC has added a new subsite, Superior Wall, to the site of OROPHARYNX, which includes the inferior surface of the soft palate and uvula. SEER codes soft palate and uvula to ICD-0, C05.1 and C05.2.

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 10 Invasive tumor confined to one of the following subsites:
 - Anterior wall (incl. vallecula and lingual (anterior) surface of epiglottis)
 - One lateral wall
 - Posterior wall
- 20 Involvement of two or more subsites: Posterior, anterior or lateral wall(s)
- 30 Localized, NOS
- 40 Soft palate, inferior surface, incl. uvula, or soft palate, NOS
- 41 Pyriform sinus (incl. hypopharynx, NOS)
- 42 Soft palate, superior (nasopharyngeal) surface
Nasopharynx, NOS
- 50 Base of tongue
Laryngeal (posterior) surface of epiglottis, or larynx, NOS
Floor of mouth
Gum (gingiva)
Buccal mucosa (inner cheek)
- 55 Any of above WITH fixation
- 60 Prevertebral fascia or muscle
Soft tissue of neck
- 70 Bone
Extrinsic muscles of tongue: Mylohyoid, hyoglossus, styloglossus
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasi

TONSIL, OROPHARYNX
C09.0-C09.1, C09.8-C09.9, C10.0-C10.4, C10.8-C10.9

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

- Retropharyngeal
- Submandibular (submaxillary)
- Submental
- Internal jugular (upper and lower deep cervical):
 - jugulodigastric
 - jugulo-omohyoid
- Cervical, NOS
- Regional lymph node(s), NOS

Note 1: If laterality is not specified, assume nodes are ipsilateral.

Note 2: AJCC includes base of tongue (C01.9) with oropharynx (C09._, C10._).

Note 3: AJCC includes lingual (anterior) surface of epiglottis (C10.1) with larynx (C32._).

- 1 One positive ipsilateral node ≤ 3 cm in greatest diameter
- 2 One positive ipsilateral node $>3-6$ cm in greatest diameter
- 3 Multiple positive ipsilateral nodes ≤ 6 cm
- 4 Ipsilateral, node size not stated
- 5 Bilateral and/or contralateral positive nodes ≤ 6 cm or size not stated
- 6 Any positive node(s), at least one >6 cm

DISTANT Lymph Nodes

- 7 Other than above

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

NASOPHARYNX

C11.0-C11.3, C11.8-C11.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; physical examination--in priority order)

000	No mass; no tumor found	
001	Microscopic focus or foci only	
	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 10 Invasive tumor confined to one of the following subsites:
 - Posterior superior wall (vault)
 - One lateral wall
 - Inferior wall (superior surface of soft palate)
- 20 Involvement of two or more subsites:
 - Posterior, inferior, or lateral wall(s)
 - Lateral wall extending into eustachian tube/middle ear
- 30 Localized, NOS
- 40 Soft palate, inferior surface Oropharynx
- 50 Nasal cavity
- 52 Pterygopalatine fossa
- 55 Any of the above WITH fixation or tumor described **only** as FIXED
- 60 Bone, including skull
- 70 Brain, incl. cranial nerves
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

Anatomic Limits of Nasopharynx

POSTERIOR SUPERIOR WALL extends from the choana, or the opening of the nasal cavities into the nasopharynx, posteriorly to a level opposite the soft palate. The pharyngeal tonsils (adenoids) are located in this part of the nasopharynx.

LATERAL WALLS extend from the base of the skull to the level of the soft palate and include Rosenmuller's fossa (pharyngeal recess).

INFERIOR ANTERIOR WALL consists of the superior surface of the soft palate.

NASOPHARYNX
C11.0-C11.3, C11.8-C11.9

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

- Retropharyngeal
- Submandibular (submaxillary)
- Submental
- Internal jugular (upper and lower deep cervical):
 - jugulodigastric
 - jugulo-omohyoid
- Cervical, NOS
- Regional lymph node(s), NOS

Note: If laterality is not specified, assume nodes are ipsilateral.

- 1 One positive ipsilateral node ≤ 3 cm in greatest diameter
- 2 One positive ipsilateral node $>3-6$ cm in greatest diameter
- 3 Multiple positive ipsilateral nodes ≤ 6 cm
- 4 Ipsilateral, node size not stated
- 5 Bilateral and/or contralateral positive nodes ≤ 6 cm or size not stated
- 6 Any positive node(s), at least one >6 cm

DISTANT Lymph Nodes

- 7 Other than above

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

PYRIFORM SINUS, HYPOPHARYNX, LARYNGOPHARYNX

C12.9, C13.0-C13.2, C13.8-C13.9, C14.1

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; physical examination--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+

999 Not stated

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 10 Invasive tumor confined to one of the following subsites:
 Postcricoid area
 Pyriform sinus
 Posterior pharyngeal wall
- 20 Tumor involves adjacent subsite(s) (listed above) WITHOUT fixation
- 30 Localized, NOS
- 40 Oropharynx
- 50 Larynx
 Cervical (upper) esophagus
- 51 Any of the above WITH fixation of tumor or fixation, NOS
- 55 Fixation of hemilarynx or larynx
- 60 Prevertebral muscle(s)
 Soft tissue of neck, cartilage
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

Anatomic Limits of Hypopharynx

POSTCRICOID AREA (pharyngo-esophageal junction) extends from the level of the arytenoid cartilages and connecting folds to the inferior border of the cricoid cartilage.

PYRIFORM SINUS extends from the pharyngoepiglottic fold to the upper edge of the esophagus. It is bounded laterally by the thyroid cartilage and medially by the hypopharyngeal surface of the aryepiglottic fold and the arytenoid and cricoid cartilages.

POSTERIOR HYPOPHARYNGEAL WALL extends from the level of the tip of the epiglottis to the inferior margin of the cricoid cartilage and laterally to the posterior margins of the pyriform sinus.

PYRIFORM SINUS, HYPOPHARYNX, LARYNGOPHARYNX
C12.9, C13.0-C13.2, C13.8-C13.9, C14.1

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Retropharyngeal
Submandibular (submaxillary)
Submental
Internal jugular (upper and
lower deep cervical):
 jugulodigastric
 jugulo-omohyoid
Cervical, NOS
Regional lymph node(s), NOS

1 One positive ipsilateral node
 ≤3 cm in greatest diameter

2 One positive ipsilateral node
 >3-6 cm in greatest diameter

3 Multiple positive ipsilateral
 nodes ≤6 cm

4 Ipsilateral, node size not stated

5 Bilateral and/or contralateral
 positive nodes ≤6 cm or size
 not stated

6 Any positive node(s),
 at least one >6 cm

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

Note: If laterality is not
specified, assume nodes are
ipsilateral.

PHARYNX NOS AND OTHER ILL-DEFINED ORAL CAVITY SITES

C14.0, C14.2, C14.8

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; physical examination--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 10 Invasive tumor confined to site of origin
- 30 Localized, NOS
- 40 More than one region of pharynx involved (oropharynx, nasopharynx, hypopharynx)
- 50 Pharynx and oral cavity involved
- 55 Any of the above WITH fixation
- 60 Extension to adjacent structures
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

PHARYNX NOS AND OTHER ILL-DEFINED ORAL CAVITY SITES
C14.0, C14.2, C14.8

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Submandibular (submaxillary)

Submental

Internal jugular (upper and
lower deep cervical):

jugulodigastric

jugulo-omohyoid

Retropharyngeal

Cervical, NOS

Regional lymph node(s), NOS

1 One positive ipsilateral node
≤3 cm in greatest diameter

2 One positive ipsilateral node
>3-6 cm in greatest diameter

3 Multiple positive ipsilateral
nodes ≤6 cm

4 Ipsilateral, node size not stated

5 Bilateral and/or contralateral
positive nodes ≤6 cm or size
not stated

6 Any positive node(s),
at least one >6 cm

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

Note: If laterality is not
specified, assume nodes are
ipsilateral.

DIGESTIVE SYSTEM SITES

DISTINGUISHING "IN SITU" AND "LOCALIZED" TUMORS FOR THE DIGESTIVE SYSTEM

Careful attention must be given to the use of the term "confined to mucosa" for the esophagus, stomach, small intestine, colon and rectum.

Historically, carcinomas described as "confined to mucosa" have been coded as localized. In order to provide greater specificity and to rule out the possibility of classifying noninvasive tumors in this category, abstractors should determine:

- 1) if the tumor is confined to the epithelium, in which case it is in situ, **OR**
- 2) if the tumor has penetrated the basement membrane to invade the lamina propria, in which case it is localized and is coded to invasion of the lamina propria.

The mucosa of the digestive tract consists of:

The EPITHELIAL LAYER borders on the lumen. It contains no blood vessels or lymphatics.

The BASEMENT MEMBRANE, a sheet of extracellular material, functions as a filtration barrier and a boundary involved in generating and maintaining tissue structure.

The LAMINA PROPRIA, composed of areolar connective tissue, contains blood vessels, nerves, and, in some regions, glands. Once tumor has broken through the basement membrane into the lamina propria, it can spread by way of the lymphatics and blood vessels to other parts of the body.

The MUSCULARIS MUCOSAE is a thin layer of smooth muscle fibers. It is found in the wall of the digestive tract from the esophagus to the anal canal.

The SUBMUCOSA is a thick layer of either dense or areolar connective tissue. It contains blood vessels, lymphatic vessels, nerves, and, in some regions, glands.

The MUSCULARIS PROPRIA is a double layer of muscle tissue in most of the digestive tract; it constitutes the wall of the organ.

DIGESTIVE SYSTEM SITES

The SEROSA, the outermost layer covering most of the digestive tract, is a single layer of squamous epithelial cells, part of the visceral peritoneum. Just below the serosa (mesothelium) and sometimes considered part of the serosa, is a layer of connective tissue called the subserosa. The serosa and subserosa are present only in the peritonealized portions of the digestive tract. For the esophagus and in the rectum below the peritoneal reflection, there is no serosa. For the esophagus, the connective tissue of surrounding structures merges with the connective tissue of the esophagus and is called ADVENTITIA.

DIGESTIVE SYSTEM SITES

PRIMARY SITE	MUCOSA			SUB-MUCOSA	MUSCULARIS PROPRIA	Serosa
	Epithelium	Lamina Propria	Muscularis Mucosae			
Esophagus (C15._)	Yes	B/A/S	Yes	Yes	Yes	No
Stomach (C16._)	Yes	E/M/E	Yes	Yes	Yes	Yes
Sm. Intestine (C17._)	Yes	N/T	Yes	Yes	Yes	Yes
Colon (C18._)	Yes	M/E/M	Yes	Yes	Yes	Yes
Rectosigmoid (C19.9)	Yes	B/R/A	Yes	Yes	Yes	Yes
Rectum (C20.9)	Yes	N/E	Yes	Yes	Yes	No

ESOPHAGUS

C15.0-C15.5, C15.8-C15.9

SIZE OF PRIMARY TUMOR/LENGTH OF INVOLVED ESOPHAGUS

(from pathology report; operative report; endoscopic examination; radiographic report--in priority order)

000	No mass; no tumor found	
001	Microscopic focus or foci only	
	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
998	Entire circumference	
999	Not stated	

Anatomic Limits of Esophagus

CERVICAL ESOPHAGUS (C15.0): From the lower border of the cricoid cartilage to the thoracic inlet (suprasternal notch), about 18 cm from the incisors.

INTRATHORACIC ESOPHAGUS (C15.1-.5):
Upper thoracic portion (C15.3):
 From the thoracic inlet to the level of the tracheal bifurcation (18-24 cm)

Mid-thoracic portion (C15.4):
 From the tracheal bifurcation midway to the gastroesophageal (GE) junction (24-32 cm).

Lower thoracic portion (C15.5):
 From midway between the tracheal bifurcation and the gastroesophageal junction to the GE junction, including the abdominal esophagus (C15.2) between 32-40 cm.

EXTENSION

00	IN SITU: Noninvasive; intraepithelial
	Invasive tumor confined to:
10	Mucosa, NOS (incl. intramucosal)
11	Lamina propria
12	Muscularis mucosae
16	Submucosa
20	Muscularis propria invaded
30	Localized, NOS
40	Adventitia and/or soft tissue invaded; esophagus is described as "FIXED"
60	Cervical esophagus: Major blood vessel(s): Carotid and subclavian arteries, jugular vein Thyroid gland
	Intrathoracic, upper or mid-portion, esophagus: Major blood vessel(s): Aorta, pulmonary artery/vein, vena cava, azygos vein Trachea, incl. carina Main stem bronchus
	Intrathoracic, lower portion (abdominal), esophagus: Major blood vessel(s): Aorta, gastric artery/vein, vena cava Diaphragm Stomach, cardia
65	Cervical esophagus: Hypopharynx Larynx Trachea, incl. carina Cervical vertebra(e)
	Intrathoracic esophagus: Lung via bronchus Pleura Mediastinal structure(s), NOS Rib(s); thoracic vertebra(e)

ESOPHAGUS
C15.0-C15.5, C15.8-C15.9

EXTENSION (cont'd)

- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension
or metastasis

Note: Ignore intraluminal extension to adjacent segment(s) of esophagus and code depth of invasion or extra-esophageal spread as indicated.

LYMPH NODES

- 0 No lymph node involvement
-
- 1 REGIONAL Lymph Nodes (incl.
contralateral or bilateral)

Cervical only:
 Peri-/paraesophageal
 Superior mediastinal
 Internal jugular (upper
 deep cervical):
 jugulodigastric
 jugulo-omohyoid
 Cervical, NOS

**Intrathoracic, upper or
 middle, only:**
 Peri-/Paraesophageal
 Internal jugular (upper and
 lower deep cervical):
 jugulodigastric
 jugulo-omohyoid
 Cervical, NOS

Intratracheobronchial:
 peritracheal, carinal
 (bifurcation), hilar
 (pulmonary roots)
 Left gastric: Cardiac, lesser
 curvature, perigastric, NOS
 Posterior mediastinal

**Intrathoracic, lower (abdominal),
 only:**
 Peri-/Paraesophageal
 Left gastric: Cardiac, lesser
 curvature, perigastric, NOS
 Posterior mediastinal

Regional lymph node(s), NOS

DISTANT Lymph Nodes

- 6 Supraclavicular
 Scalene |
- 7 Other than above
-
- 8 Lymph nodes, NOS
- 9 UNKNOWN; not stated

STOMACH

C16.0-C16.6, C16.8-C16.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; radiographic report--in priority order)

000	No mass; no tumor found	
001	Microscopic focus or foci only	
	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
998	Diffuse; widespread; 3/4's or more: Linitis plastica	
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 05 (Adeno)carcinoma in a polyp, noninvasive
- Invasive tumor confined to:**
- 10 Mucosa, NOS (incl. intramucosal)
- 11 Lamina propria
- 12 Muscularis mucosae
- 13 Head of polyp
- 14 Stalk of polyp
- 15 Polyp, NOS
- 16 Submucosa (superficial invasion)
- 20 Muscularis propria invaded
- 30 Localized, NOS
- 40 Invasion through muscularis propria or muscularis, NOS
Extension through wall, NOS
Perimuscular tissue invaded
(Sub)serosal tissue/fat invaded
- 45 Extension to adjacent (connective) tissue:
Perigastric fat
Omentum, lesser, greater, NOS
Ligaments: Gastrocolic, gastrohepatic, gastrosplenic
Gastric artery
- 50 Invasion of/through serosa (mesothelium)
- 55 (45) + (50)
- 60 Spleen
Transverse colon (incl. flexures)
Liver
Diaphragm
Pancreas
Esophagus via serosa
Duodenum via serosa or NOS
Jejunum, ileum, small intestine, NOS

Note: Ignore intraluminal extension to esophagus and duodenum; code depth of invasion through stomach wall.

STOMACH
C16.0-C16.6, C16.8-C16.9

EXTENSION (cont'd)

- 70 Abdominal wall
Retroperitoneum
Kidney
Adrenal gland
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension
or metastasis

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Inferior (R) gastric:

- Greater curvature
- Greater omental
- Gastroduodenal
- Gastrocolic
- Gastroepiploic, right or NOS
- Gastrohepatic
- Pyloric, incl. sub-/infrapyloric
- Pancreaticoduodenal

Splenic:

- Gastroepiploic, left
- Pancreaticolienal
- Peripancreatic
- Splenic hilar

Superior (L) gastric:

- Lesser curvature
- Lesser omentum
- Gastropancreatic, left
- Gastric, left
- Paracardial; cardial
- Cardioesophageal

Perigastric, NOS

Nodule(s) in perigastric fat

- 1 Perigastric nodes ≤ 3 cm from the
primary tumor
- 2 Perigastric nodes > 3 cm from the
primary tumor
- 4 Celiac
Hepatic (excl. gastrohepatic)
- 5 Regional lymph node(s), NOS

DISTANT Lymph Nodes

7 Other than above

- 8 Lymph nodes, NOS
- 9 UNKNOWN; not stated

SMALL INTESTINE
C17.0-C17.3, C17.8-C17.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; radiographic report--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 05 (Adeno)carcinoma in a polyp, noninvasive
- Invasive tumor confined to:**
- 10 Mucosa, NOS (incl. intramucosal)
- 11 Lamina propria
- 12 Muscularis mucosae
- 13 Head of polyp
- 14 Stalk of polyp
- 15 Polyp, NOS
- 16 Submucosa (superficial invasion)
- 20 Muscularis propria invaded
- 30 Localized, NOS
- 40 Invasion through muscularis propria or muscularis, NOS
Extension through wall, NOS
Perimuscular tissue invaded
(Sub)serosal tissue/fat invaded
- 45 Adjacent connective tissue
Mesentery, incl. mesenteric fat
- 50 Invasion of/through serosa (mesothelium)
- 55 (45) + (50)
- 60 **Duodenum:**
Extrahepatic bile ducts, incl. ampulla of Vater
Pancreas
Pancreatic duct

Note: Ignore intraluminal extension to adjacent segment(s) of small intestine and code depth of invasion or spread outside the small intestine as indicated.

SMALL INTESTINE
C17.0-C17.3, C17.8-C17.9

EXTENSION (cont'd)

LYMPH NODES

- 65 **Duodenum:**
 Transverse colon, hepatic flexure
 Greater omentum; omentum, NOS
 Right or quadrate lobe of liver; liver, NOS
 Right kidney or ureter; kidney, NOS
 Major blood vessel(s): Aorta, superior mesenteric artery or vein, vena cava, portal vein, renal vein, gastroduodenal artery

 Jejunum and Ileum:
 Large intestine, incl. appendix
- 66 **Duodenum:**
 Stomach
- 67 **All small intestine sites:**
 Abdominal wall
 Retroperitoneum
- 68 **All small intestine sites:**
 Small intestine via serosa
- 70 **Jejunum and Ileum:**
 Bladder
 Uterus
 Ovary; fallopian tube
- 80 **FURTHER extension**
- 85 **Metastasis**
- 99 **UNKNOWN if extension or metastasis**

- 0 No lymph node involvement

- 1 **REGIONAL Lymph Nodes**

 Duodenum:
 Hepatic:
 Pancreaticoduodenal
 Infrapyloric
 Gastroduodenal

 Jejunum and Ileum:
 Posterior cecal (terminal ileum)
 Ileocolic (terminal ileum)
 Superior mesenteric; mesenteric, NOS

 Regional lymph node(s), NOS

- DISTANT Lymph Nodes
- 7 Other than above

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

**COLON (incl. Flexures and Appendix)
C18.0-C18.9**

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; radiographic report--in priority order)

000	No mass; no tumor found	
001	Microscopic focus or foci only	
	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
998	Familial/multiple polyposis (M-8220/8221)	
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 05 (Adeno)carcinoma in a polyp, noninvasive
- Invasive tumor confined to:**
- 10 Mucosa, NOS (incl. intramucosal)
- 11 Lamina propria
- 12 Muscularis mucosae
- 13 Head of polyp
- 14 Stalk of polyp
- 15 Polyp, NOS
- 16 Submucosa (superficial invasion)
- 20 Muscularis propria invaded
- 30 Localized, NOS/confined to colon, NOS
- 40 Invasion through muscularis propria or muscularis, NOS
Extension through wall, NOS
Perimuscular tissue invaded
(Sub)serosal tissue/fat invaded
- 45 Extension to adjacent (connective) tissue:
 - Mesentery (incl. mesenteric fat, mesocolon)--**all colon sites**
 - Retroperitoneal fat--**ascending and descending colon**
 - Greater omentum; gastrocolic ligament--**transverse colon/flexures**
 - Pericolic fat--**all colon sites**
- 50 Invasion of/through serosa (mesothelium)
- 55 (45) + (50)
- 60 Greater omentum--**cecum, appendix, ascending, descending and sigmoid colon**
Spleen--**descending colon**
Pelvic wall--**descending colon/sigmoid**
Liver, right lobe--**ascending colon**

Note: Ignore intraluminal extension to adjacent segment(s) of colon/rectum; code depth of invasion or extracolonic spread as indicated.

**COLON (incl. Flexures and Appendix)
C18.0-C18.9**

EXTENSION (cont'd)

- Transverse colon and flexures:**
 - Stomach
 - Spleen; liver
 - Pancreas
 - Gallbladder/bile ducts
 - Kidney
- All colon sites:**
 - Small intestine
- 65 **All colon sites:**
 - Abdominal wall
 - Retroperitoneum (excl. fat)
- 66 **Ureter/kidney**
 - Right--ascending colon
 - Left--descending colon
- 70 **Cecum, appendix, ascending, descending, and sigmoid colon:**
 - Uterus
 - Ovary; fallopian tube
- 75 **All colon sites unless otherwise stated above:**
 - Urinary bladder
 - Gallbladder
 - Adrenal gland
 - Diaphragm
 - Other segment(s) of colon via serosa
 - Fistula to skin
- 80 **FURTHER extension**
- 85 **Metastasis**
- 99 **UNKNOWN if extension or metastasis**

LYMPH NODES

- 0 No lymph node involvement
-
- REGIONAL Lymph Nodes**
- 1 **All colon subsites:**
 - Epicolic (adjacent to bowel wall)
 - Paracolic/pericolic
 - Colic, NOS
 - Nodule(s) in pericolic fat
- 2 **Cecum and Appendix:**
 - Cecal, anterior, posterior, NOS
 - Ileocolic
 - Right colic
- Ascending colon:**
 - Ileocolic
 - Right colic
 - Middle colic
- Transverse colon and flexures:**
 - Middle colic
 - Right colic for hepatic flexure only
 - Left colic for splenic flexure only
 - Inferior mesenteric for splenic flexure only
- Descending colon:**
 - Left colic
 - Sigmoid
 - Inferior mesenteric
- Sigmoid:**
 - Sigmoidal (sigmoid mesenteric)
 - Superior hemorrhoidal
 - Superior rectal
 - Inferior mesenteric
- 3 Mesenteric, NOS
- Regional lymph node(s), NOS
-
- DISTANT Lymph Nodes**
- 7 Other than above, incl. superior mesenteric
-
- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

RECTOSIGMOID, RECTUM
C19.9, C20.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; radiographic report; physical examination--in priority order)

000	No mass; no tumor found	
001	Microscopic focus or foci only	
	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
998	Familial/multiple polyposis (M-8220/8221)	
999	Not stated	

EXTENSION

00	IN SITU: Noninvasive; intraepithelial
05	(Adeno)carcinoma in a polyp, noninvasive
	Invasive tumor confined to:
10	Mucosa, NOS (incl. intramucosal)
11	Lamina propria
12	Muscularis mucosae
13	Head of polyp
14	Stalk of polyp
15	Polyp, NOS
16	Submucosa (superficial invasion)
20	Muscularis propria invaded
30	Localized, NOS
40	Invasion through muscularis propria or muscularis, NOS Extension through wall, NOS Perimuscular tissue invaded (Sub)serosal tissue/fat invaded
45	Extension to adjacent (connective) tissue: Mesentery (incl. mesenteric fat, mesocolon)-- rectosigmoid Pericolic fat-- rectosigmoid Rectovaginal septum-- rectum Perirectal fat-- all sites
50	Invasion of/through serosa (mesothelium)
55	(45) + (50)

Note: Ignore intraluminal extension to adjacent segment(s) of colon/rectum and code depth of invasion or extracolonic spread as indicated.

EXTENSION (cont'd)

- 60 **Rectosigmoid:**
 Small intestine
 Cul de sac (rectouterine pouch)
 Pelvic wall
- Rectum:**
 Rectovesical fascia, male
 Bladder, male
 Prostate
 Ductus deferens
 Seminal vesicle(s)
 Vagina
 Cul de sac (rectouterine pouch)
 Pelvic wall
 Skeletal muscle of pelvic floor
- 70 **Rectosigmoid:**
 Prostate
 Uterus
 Ovary; fallopian tube
 Bladder
 Ureter
 Colon via serosa
- Rectum:**
 Uterus
 Bladder, female
 Urethra
 Bones of pelvis
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

LYMPH NODES

- 0 No lymph node involvement

- REGIONAL Lymph Nodes
- 1 **Rectosigmoid:**
 Paracolic/pericolic
 Perirectal
 Nodule(s) in pericolic fat
- Rectum:**
 Perirectal
 Nodule(s) in perirectal fat
- 2 **Rectosigmoid:**
 Hemorrhoidal, superior or middle
 Left colic (incl. colic, NOS)
 Superior rectal
 Sigmoidal (sigmoid mesenteric)
 Inferior mesenteric
- Rectum:**
 Sigmoidal |
 Sigmoid mesenteric |
 Inferior mesenteric
 Hemorrhoidal, superior or inferior
 Sacral (lateral, presacral, sacral promontory (Gerota's), or NOS)
 Internal iliac (hypogastric)
- 3 Mesenteric, NOS
 Regional lymph node(s), NOS

- DISTANT Lymph Nodes
- 7 Other than above

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

ANAL CANAL, ANUS NOS, OTHER PARTS OF RECTUM
C21.0-C21.2, C21.8

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; radiographic report; physical examination--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+

999 Not stated

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- Invasive tumor confined to:**
- 10 Mucosa, NOS (incl. intramucosal)
- 11 Lamina propria
- 12 Muscularis mucosae
- 16 Submucosa (superficial invasion)
- 20 Muscularis propria (internal sphincter)
- 30 Localized, NOS
- 40 Rectal mucosa or submucosa
 Subcutaneous perianal tissue
 Perianal skin
 Skeletal muscles: Anal sphincter (external), levator ani
 Ischiorectal fat/tissue
- 60 Perineum
 Vulva
- 70 Bladder
 Urethra
 Vagina
- 75 Prostate
 Cervix Uteri
 Corpus Uteri
 Broad ligament(s)
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

**ANAL CANAL, ANUS NOS, OTHER PARTS OF RECTUM
C21.0-C21.2, C21.8**

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

1 Anorectal; perirectal

2 Internal iliac (hypogastric) and
lateral sacral, unilateral

3 Superficial inguinal (femoral),
unilateral

4 (3) plus (1) or (2)

5 Bilateral internal iliac
(hypogastric), lateral
sacral, and/or superficial
inguinal (femoral)

6 Regional lymph node(s), NOS

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

LIVER AND INTRAHEPATIC BILE DUCTS
C22.0-C22.1

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; radiographic report--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive
- 10 Single lesion (one lobe)
 WITHOUT intrahepatic vascular invasion, incl. NOS
- 20 Single lesion (one lobe)
 WITH intrahepatic vascular invasion
- 30 Multiple tumors (one lobe)
 WITHOUT intrahepatic vascular invasion, incl. NOS
- 40 Multiple tumors (one lobe)
 WITH intrahepatic vascular invasion
- 50 Confined to liver, NOS
 Localized, NOS
- 60 More than one lobe
 involved by contiguous growth (single lesion)
 Extension to extrahepatic blood vessel(s): hepatic artery, vena cava, portal vein
- 65 Multiple (satellite) nodules in
 more than one lobe of liver or
 on surface of parenchyma
 Satellite nodules, NOS
- 70 Extrahepatic bile duct(s)
 Diaphragm
- 75 Parietal peritoneum
 Gallbladder
 Ligament(s): Falciform,
 coronary, hepatogastric,
 hepatoduodenal, triangular
 Lesser omentum
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

LIVER AND INTRAHEPATIC BILE DUCTS
C22.0-C22.1

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

1 Hepatic: Hepatic pedicle, inferior vena cava, hepatic artery, porta hepatis (hilar)
Regional lymph node(s), NOS |

DISTANT Lymph Nodes

6 Cardiac
Diaphragmatic: Pericardial
Posterior mediastinal, incl. juxtaphrenic nodes
Aortic (para-, peri-, lateral)
Retroperitoneal, NOS

peripancreatic (near head of pancreas only)

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

GALLBLADDER, OTHER BILIARY, AND BILIARY NOS
C23.9, C24.8-C24.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; radiographic report--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

mm cm

002 ≤2 ≤0.2

003 3 0.3

...

...

009 9 0.9

010 10 1.0

...

...

099 99 9.9

100 100 10.0

...

...

990 990+ 99.0+

999 Not stated

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 10 Invasive tumor confined to:
Mucosa, NOS
Lamina propria
Submucosa (superficial invasion)
- 20 Muscularis propria
- 30 Localized, NOS
- 40 Perimuscular connective tissue
- 50 Invasion of/through serosa
- 55 (40) + (50)
- 60 Extension into liver, NOS
- 61 Extension into liver ≤2 cm
- 62 Extension to one of the following:
Extrahepatic bile duct(s), incl. ampulla of Vater
Pancreas
Omentum
Duodenum; small intestine, NOS
- 65 Extension to one of the following:
Large intestine
Stomach
- 70 Extension into liver >2 cm
Extension to two or more adjacent organs listed above in code 62 and/or code 65, OR liver involvement with any organ above in code 62 and/or code 65
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

**GALLBLADDER, OTHER BILIARY, AND BILIARY NOS
C23.9, C24.8-C24.9**

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

1 Cystic duct (node of the neck
of the gallbladder)
Pericholedochal (node around
common bile duct)
Hilar (in hilus of liver--in
hepatoduodenal ligament)
Node of the foramen of Winslow

2 Periportal, |
Periduodenal |
Peripancreatic (near head |
of pancreas only) |

3 Regional lymph node(s), NOS

5 Celiac

6 Mesenteric, superior

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

EXTRAHEPATIC BILE DUCT(S)
C24.0

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; radiographic report--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+

999 Not stated

EXTENSION

00 IN SITU: Noninvasive

10 Invasive tumor of bile duct(s) (cystic, hepatic, and common) confined to:
Mucosa, NOS
Lamina propria
Submucosa

20 Muscle wall (muscularis propria)

30 Localized, NOS

40 Periductal/perimuscular connective tissue

60 Duodenum
Gallbladder
Pancreas
Liver, porta hepatis

65 Blood vessels: Portal vein, hepatic artery
Stomach
Colon
Omentum

80 FURTHER extension

85 Metastasis

99 UNKNOWN if extension or metastasis

Note: Codes C24.8-C24.9, biliary tract, NOS, are included with gallbladder, C23.9

EXTRAHEPATIC BILE DUCT(S)

C24.0

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

1 Cystic duct (node of the neck of
the gallbladder)

Pericholedochal (node around
common bile duct)

Node of the foramen of Winslow

Hilar (in the hepatoduodenal
ligament)

2 Periportal, |
Periduodenal |
Peripancreatic (near head |
of pancreas only) |

3 Regional lymph node(s), NOS

5 Celiac

6 Mesenteric, superior

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

AMPULLA OF VATER
C24.1

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; radiographic report--in priority order)

000	No mass; no tumor found	
001	Microscopic focus or foci only	
	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 10 Invasive tumor confined to ampulla of Vater
- 30 Localized, NOS
- 40 Duodenum and/or distal common duct |
- 50 Tumor invasion into pancreas, incl. pancreatic duct, ≤2 cm and/or common duct, ≤2 cm |
- 55 Pancreas, NOS and/or common duct, NOS |
- 60 Tumor invasion into pancreas >2 cm and/or common duct, >2 cm |
- 65 Extrahepatic bile ducts |
- 70 Other adjacent organs
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

LYMPH NODES

0 No lymph node involvement

1 REGIONAL Lymph Nodes

Peripancreatic
Hepatic
Infrapyloric
Subpyloric
Celiac
Pancreaticoduodenal
Superior mesenteric
Retroperitoneal
Lateral aortic

Regional lymph node(s), NOS

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

PANCREAS: HEAD, BODY, AND TAIL
C25.0-C25.4

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; radiographic report--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive
- 10 Confined to pancreas
- 30 Localized, NOS
- 40 Extension to peripancreatic tissue, NOS
 Fixation to adj. structures/NOS
- 44 **Head of pancreas:**
 Extrahepatic bile ducts (incl. external right and left hepatic ducts, common hepatic duct, and common bile duct)
 Ampulla of Vater
 Duodenum
- Body and/or tail of pancreas:**
 Duodenum
- 48 **Body and/or tail of pancreas:**
 Extrahepatic bile ducts (incl. external right and left hepatic ducts, common hepatic duct, and common bile duct)
 Ampulla of Vater
- 50 **Head of pancreas:**
 Adjacent stomach
 Stomach, NOS
- Body and/or tail of pancreas:**
 Spleen
- 52 **Head of pancreas:**
 Body of stomach
- 54 **Head of pancreas:**
 Major blood vessel(s): Hepatic, pancreaticoduodenal and/or gastroduodenal arteries, superior mesenteric artery/vein, portal vein
 Transverse colon, incl. hepatic flexure
- 56 **Body and/or tail of pancreas:**
 Splenic flexure
 Major blood vessel(s): Aortic, celiac artery, hepatic artery, splenic artery/vein, superior mesenteric artery/vein, portal vein

Note: Islets of Langerhans are distributed throughout the pancreas, and, therefore, any extension code 00-85 can be used.

PANCREAS: HEAD, BODY, AND TAIL
C25.0-C25.4

EXTENSION (cont'd)

LYMPH NODES

62	Body and/or tail of pancreas: Stomach	0	No lymph node involvement - - - - -
64	Head of pancreas: Large intestine (other than transverse colon incl. hepatic flexure) Spleen Body and/or tail of pancreas: Large intestine (other than splenic flexure)	1	REGIONAL Lymph Nodes Peripancreatic Hepatic Infrapyloric (head only) Subpyloric (head only) Celiac (head only) Superior mesenteric Pancreaticolienal (body and tail only) Splenic (body and tail only) Retroperitoneal Lateral aortic Regional lymph node(s), NOS - - - - -
72	Body and/or tail of pancreas: Left kidney; kidney, NOS; left ureter; left adrenal (suprarenal) gland; retroperitoneal soft tissue (retroperitoneal space)		DISTANT Lymph Nodes
74	Head of pancreas: Peritoneum, mesentery, mesocolon, mesenteric fat Greater/lesser omentum Body and/or tail of pancreas: Ileum and jejunum Peritoneum, mesentery, mesocolon, mesenteric fat	7	Other than above - - - - -
76	Liver (incl. porta hepatis); gallbladder	8	Lymph Nodes, NOS
78	Head of pancreas: Kidney; ureter; adrenal gland; retroperitoneum; jejunum; ileum Body and/or tail of pancreas: Right kidney/right ureter; right adrenal gland Diaphragm	9	UNKNOWN; not stated
80	FURTHER extension		
85	Metastasis		
99	UNKNOWN if extension or metastasis		

PANCREAS: OTHER AND UNSPECIFIED
C25.7-C25.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; radiographic report--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

00 IN SITU: Noninvasive

10 Invasive tumor confined to pancreas

30 Localized, NOS

40 Peripancreatic tissue

45 Duodenum
 Bile ducts
 Ampulla of Vater

50 Stomach
 Spleen
 Colon
 Adjacent large vessels

80 FURTHER extension

85 Metastasis

99 UNKNOWN if extension or metastasis

LYMPH NODES

- 0 No lymph node involvement
- - - - -
- 1 REGIONAL Lymph Nodes
 - Peripancreatic
 - Hepatic

 - Superior mesenteric
 - Retroperitoneal
 - Lateral aortic

 - Regional lymph node(s), NOS
- - - - -
- DISTANT Lymph Nodes
- 7 Other than above
- - - - -
- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

OTHER AND ILL-DEFINED DIGESTIVE ORGANS
C26.0, C26.8-C26.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; radiographic report--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

mm cm

002 ≤2 ≤0.2

003 3 0.3

...

...

009 9 0.9

010 10 1.0

...

...

099 99 9.9

100 100 10.0

...

...

990 990+ 99.0+

999 Not stated

EXTENSION

00 IN SITU: Noninvasive

10 Invasion of submucosa

30 Localized, NOS

40 Adjacent connective tissue

60 Adjacent organs/structures

80 FURTHER extension

85 Metastasis

99 UNKNOWN if extension or metastasis

OTHER AND ILL-DEFINED DIGESTIVE ORGANS
C26.0, C26.8-C26.9

LYMPH NODES

- 0 No lymph node involvement

- 1 REGIONAL Lymph Nodes
 - Subdiaphragmatic
 - Intra-abdominal
 - Paracaval
 - Pelvic
 - Regional lymph node(s), NOS
 -
- DISTANT Lymph Nodes
- 7 Other than above

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

NASAL CAVITY AND MIDDLE EAR
C30.0-C30.1

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; radiographic report--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

00 IN SITU: Noninvasive
 10 Invasive tumor confined to site of origin
 30 Localized, NOS
 40 Adjacent connective tissue
 60 Adjacent organs/structures
 80 FURTHER extension
 85 Metastasis
 99 UNKNOWN if extension or metastasis

NASAL CAVITY AND MIDDLE EAR
C30.0-C30.1

LYMPH NODES

0 No lymph node involvement

1 REGIONAL Lymph Nodes

Submental
Submandibular (submaxillary)
Internal jugular (upper and
lower deep cervical):
jugulodigastric
jugulo-omohyoid
Retropharyngeal
Cervical, NOS
Regional lymph node(s), NOS

7 DISTANT Lymph Nodes

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

MAXILLARY SINUS

C31.0

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+

999 Not stated

EXTENSION

00 IN SITU: Noninvasive;
intraepithelial

10 Invasive tumor confined to mucosa
of maxillary antrum (sinus)

30 Localized, NOS

40 Invasion of infrastructure:
Palatine bone
Palate, hard
Middle nasal meatus
Nasal cavity (lateral wall,
floor, septum, turbinates)

60 Invasion of suprastructure:
Skin of cheek
Floor or posterior wall of
maxillary sinus
Floor or medial wall of orbit
Ethmoid sinus, anterior

65 Invasion of maxilla, NOS

70 Nasopharynx
Ethmoid sinus, posterior
Sphenoid sinus
Palate, soft
Base of skull
Cribriform plate
Pterygomaxillary or temporal
fossa
Orbital contents,
including eye

80 FURTHER extension

85 Metastasis

99 UNKNOWN if extension or metastasis

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Submental
Submandibular (submaxillary)
Internal jugular (upper and
lower deep cervical):
 jugulodigastric
 jugulo-omohyoid
Retropharyngeal
Cervical, NOS
Regional lymph node(s), NOS

- 1 One positive ipsilateral node
 ≤3 cm in greatest diameter
 - 2 One positive ipsilateral node
 >3-6 cm in greatest diameter
 - 3 Multiple positive ipsilateral
 nodes ≤6 cm
 - 4 Ipsilateral, node size not stated
 - 5 Bilateral and/or contralateral
 positive nodes ≤6 cm or size
 not stated
 - 6 Any positive node(s),
 at least one >6 cm
-

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

ACCESSORY (Paranasal) SINUSES
(excl. Maxillary Sinus)
C31.1-C31.3, C31.8-C31.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

000	No mass; no tumor found	
001	Microscopic focus or foci only	
	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 10 Invasive tumor confined to mucosa in one of the following:
Ethmoid air cells (sinus), unilateral
Frontal sinus
Sphenoid sinus
- 30 Localized, NOS
- 40 More than one accessory sinus invaded
Destruction of bony wall of sinus
- 50 Palate
Nasal cavity (floor, septum, turbinates)
- 60 Bone: Orbital structures, facial bones, pterygoid fossa, zygoma, maxilla
- 70 Nasopharynx
Muscles: Masseter, pterygoid
Soft tissue
Skin
Brain, incl. cranial nerves
Orbital contents, including eye
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

ACCESSORY (Paranasal) SINUSES
(excl. Maxillary Sinus)
C31.1-C31.3, C31.8-C31.9

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Retropharyngeal
Internal jugular (upper deep
cervical):

jugulodigastric
jugulo-omohyoid

Cervical, NOS

Regional lymph node(s), NOS

1 One positive ipsilateral node
≤3 cm in greatest diameter

2 One positive ipsilateral node
>3-6 cm in greatest diameter

3 Multiple positive ipsilateral
nodes ≤6 cm

4 Ipsilateral, node size not stated

5 Bilateral and/or contralateral
positive nodes ≤6 cm or size
not stated

6 Any positive node(s),
at least one >6 cm

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

LARYNX
 C32.0-C32.3, C32.8-C32.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; physical examination--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive
- 10 Invasive tumor confined to:
Supraglottis (one subsite):
 i.e., laryngeal (posterior) surface of epiglottis, aryepiglottic fold, arytenoid cartilage, or ventricular band (false cord)
Subglottis
- 11 One vocal cord (**glottic tumor**)
- 12 Both vocal cords (**glottic tumor**)
- 20 Tumor involves: More than one subsite of **supraglottis**
- 30 Tumor involves adjacent region(s) of larynx
- 35 Impaired vocal cord mobility (**glottic tumor**)
- 40 Tumor limited to larynx WITH vocal cord fixation
- 50 Localized, NOS
- 60 Pre-epiglottic tissues
 Postcricoid area
 Pyriform sinus
 Hypopharynx, NOS
 Vallecula
 Base of tongue
- 70 Extension to/through thyroid or cricoid cartilage and/or oropharynx, cervical esophagus, soft tissues of neck, extrinsic (strap) muscles, skin
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

Note: AJCC includes lingual (anterior) surface of epiglottis (C10.1) with larynx (C32._).

LARYNX
C32.0-C32.3, C32.8-C32.9

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes (incl. con-
tralateral or bilateral nodes)

Internal jugular (upper and |
lower deep cervical) |
jugulodigastric
jugulo-omohyoid

Anterior cervical: Prelaryngeal,
pretracheal, paratracheal,
laterotracheal (recurrent
laryngeal)

Submandibular (submaxillary) |
Submental

Cervical, NOS

Regional lymph node(s), NOS

1 One positive ipsilateral node
≤3 cm in greatest diameter

2 One positive ipsilateral node
>3-6 cm in greatest diameter

3 Multiple positive ipsilateral
nodes ≤6 cm

4 Ipsilateral, node size not stated

5 Bilateral and/or contralateral
positive nodes ≤6 cm or size
not stated

6 Any positive node(s),
at least one >6 cm

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

Note: If laterality is not
specified, assume nodes are
ipsilateral.

TRACHEA
C33.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; radiographic report--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

mm cm

002 ≤2 ≤0.2

003 3 0.3

...

...

009 9 0.9

010 10 1.0

...

...

099 99 9.9

100 100 10.0

...

...

990 990+ 99.0+

999 Not stated

EXTENSION

00 IN SITU: Noninvasive

10 Invasive tumor confined to trachea

30 Localized, NOS

40 Adjacent connective tissue

60 Adjacent organs/structures

80 FURTHER extension

85 Metastasis

99 UNKNOWN if extension or metastasis

LYMPH NODES

0 No lymph node involvement

1 REGIONAL Lymph Nodes

7 DISTANT Lymph Nodes

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

BRONCHUS AND LUNG
C34.0-C34.3, C34.8-C34.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; radiographic report--in priority order)

- 000 No primary tumor found
- 001 Microscopic focus or foci only
- 002 Malignant cells present in bronchopulmonary secretions

	<u>mm</u>	<u>cm</u>
003	≤3	≤0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+

- 998 Diffuse (entire lobe or lung)
- 999 Not stated

Note 1: Assume tumor ≥2 cm from carina if lobectomy, segmental resection, or wedge resection is done.

Note 2: If no mention is made of the opposite lung on a chest x-ray, assume it is not involved.

Note 3: "Bronchopneumonia" is not the same thing as "obstructive pneumonitis" and should not be coded as such.

Note 4: Ignore pleural effusion which is negative for tumor.

Note 5: If at mediastinoscopy/x-ray the description is mediastinal mass/adenopathy, assume that it is mediastinal nodes.

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 10 Tumor confined to one lung (excl. primary in MSB)
- 20 Tumor involving main stem bronchus ≥2 cm from carina (primary in lung or MSB)
- 25 Primary confined to the carina |
- 30 Localized, NOS
- 40 Extension to:
 - Pleura, visceral or NOS
 - Pulmonary ligament
 - Atelectasis/obstructive pneumonitis involving <entire lung (or NOS)
 - WITHOUT pleural effusion
- 50 Tumor of/involving main stem bronchus <2.0 cm from carina |
- 60 Extension to:
 - Chest (thoracic) wall
 - Parietal pericardium or NOS
 - Parietal (mediastinal) pleura
 - Brachial plexus from superior sulcus or Pancoast tumor (superior sulcus syndrome)
 - Diaphragm
 - Atelectasis/obstructive pneumonitis involving entire lung

Note 6: The words "no evidence of spread" or "remaining examination negative" are sufficient information to consider regional lymph nodes negative in the absence of any statement about nodes.

EXTENSION (cont'd)

LYMPH NODES

- 70 Carina; trachea; esophagus
Mediastinum, extrapulmonary
or NOS
Major blood vessel(s):
Pulmonary artery or vein;
superior vena cava (SVC
syndrome); aorta; azygos
vein
Nerve(s):
Recurrent laryngeal
(vocal cord paralysis);
vagus; phrenic; cervical
sympathetic (Horner's
syndrome)
- 71 Heart
Visceral pericardium
- 72 Malignant pleural effusion
Pleural effusion, NOS
- 73 Adjacent rib
- 75 Sternum
Vertebra(e)
Skeletal muscle
Skin of chest
- 78 Contralateral lung
Contralateral MSB
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension
or metastasis

- 0 No lymph node involvement

REGIONAL Lymph Nodes (Ipsilateral)
- 1 Intrapulmonary (incl.
interlobar, lobar,
segmental)
Hilar (proximal lobar)
Peribronchial
- 2 Subcarinal
Carinal
Mediastinal, anterior,
posterior, NOS
Peri/paratracheal (incl.
tracheobronchial,
lower peritracheal,
azygos)
Pre- and retrotracheal
(incl. precarinal)
Peri/paraesophageal
Aortic (above diaphragm) (incl.
peri/para-aortic, subaortic,
aortico-pulmonary window,
ascending aorta or phrenic)
Pulmonary ligament
Pericardial
- 5 Regional lymph node(s), NOS
- 6 Contralateral hilar or medias-
tinal (incl. bilateral)
Supraclavicular (transverse
cervical), ipsilateral or
contralateral
Scalene, ipsilateral or
contralateral

Note 7: "Vocal cord paralysis,"
"superior vena cava syndrome," and
"compression of the trachea or
the esophagus" are classified as
mediastinal lymph node involvement
unless there is a statement of in-
volvement by direct extension from
the primary tumor.

- DISTANT Lymph Nodes
- 7 Other than above (incl. cervical
neck nodes)

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

Note 8: AJCC (TNM) classifies
the lymph nodes in code 6 to N3.

HEART, MEDIASTINUM
C38.0-C38.3, C38.8

|

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; radiographic report--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

mm cm

002 ≤2 ≤0.2

003 3 0.3

...

...

009 9 0.9

010 10 1.0

...

...

099 99 9.9

100 100 10.0

...

...

990 990+ 99.0+

999 Not stated

EXTENSION

10 Invasive tumor confined to site of origin

30 Localized, NOS

40 Adjacent connective tissue

60 Adjacent organs/structures

80 FURTHER extension

85 Metastasis

99 UNKNOWN if extension or metastasis

LYMPH NODES

- 0 No lymph node involvement

- 1 REGIONAL Lymph Nodes

- 7 DISTANT Lymph Nodes

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

PLEURA
C38.4

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; radiographic report--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

	<i>mm</i>	<i>cm</i>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 10 Invasive tumor (mesothelioma) confined to pleura
- 20 Mesothelioma WITH nodule(s) beneath visceral pleural surface
- 30 Localized, NOS
- 40 Adjacent connective tissue
- 50 Mesothelioma nodule(s) which have broken through the visceral pleural surface to the lung surface; lung involvement, NOS
- 60 Extension to adjacent organs/structures such as:
 - Chest wall
 - Rib
 - Heart muscle
 - Diaphragm
- 70 Mesothelioma WITH malignant pleural fluid; pleural effusion
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

LYMPH NODES

- 0 No lymph node involvement

- 1 REGIONAL Lymph Nodes

- 7 DISTANT Lymph Nodes

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

OTHER AND ILL-DEFINED RESPIRATORY SITES AND INTRATHORACIC ORGANS
C39.0, C39.8-C39.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; radiographic report--in priority order)

EXTENSION

000	No mass; no tumor found		10	Invasive tumor confined to site of origin
001	Microscopic focus or foci only		30	Localized, NOS
	<u>mm</u>	<u>cm</u>	40	Adjacent connective tissue
002	≤2	≤0.2	60	Adjacent organs/structures
003	3	0.3	80	FURTHER extension
...			85	Metastasis
009	9	0.9	99	UNKNOWN if extension or metastasis
010	10	1.0		
...				
099	99	9.9		
100	100	10.0		
...				
990	990+	99.0+		
999	Not stated			

OTHER AND ILL-DEFINED RESPIRATORY SITES AND INTRATHORACIC ORGANS
C39.0, C39.8-C39.9

LYMPH NODES

- 0 No lymph node involvement

- 1 REGIONAL Lymph Nodes

- 7 DISTANT Lymph Nodes

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

BONES, JOINTS, AND ARTICULAR CARTILAGE

C40.0-C40.3, C40.8-C40.9, C41.0-C41.4, C41.8-C41.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; radiographic report; physical examination--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci onlymm cm

002 ≤2 ≤0.2

003 3 0.3

...

...

009 9 0.9

010 10 1.0

...

...

099 99 9.9

100 100 10.0

...

...

990 990+ 99.0+

999 Not stated

EXTENSION10 Invasive tumor confined to
cortex of bone20 Extension beyond cortex to
periosteum (no break in
periosteum)

30 Localized, NOS

40 Extension beyond periosteum to
surrounding tissues, incl.
adjacent skeletal muscle(s)

60 Adjacent Bone

70 Skin

80 FURTHER extension

85 Metastasis

99 UNKNOWN if extension or metastasis

BONES, JOINTS, AND ARTICULAR CARTILAGE
C40.0-C40.3, C40.8-C40.9, C41.0-C41.4, C41.8-C41.9

LYMPH NODES

- 0 No lymph node involvement

- 1 REGIONAL Lymph Nodes

- 7 DISTANT Lymph Nodes

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

SKIN (excl. Malignant Melanoma, Kaposi's Sarcoma, Mycosis Fungoides, Sezary's Disease, and Other Lymphomas)
C44.0-C44.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

00 IN SITU: Noninvasive; intraepidermal; Bowen's disease

10 Lesion(s) confined to dermis
For eyelid: Minimal infiltration of dermis (not invading tarsal plate)

20 **For eyelid:** Infiltrates deeply into dermis (invading tarsal plate)

25 **For eyelid:** At eyelid margin

30 Involves full eyelid thickness

40 Localized, NOS

50 Subcutaneous tissue (through entire dermis)

60 Adjacent structures for eyelid, incl. orbit

70 Underlying cartilage, bone, skeletal muscle

75 Metastatic skin lesion(s)

80 FURTHER extension

85 Metastasis

99 UNKNOWN if extension or metastasis

Note 1: In the case of multiple simultaneous tumors, code tumor with greatest extension.

Note 2: Skin ulceration does not alter the Extent of Disease classification.

Note 3: Skin of genital sites is not included in this scheme. These sites are skin of vulva (C51.0-C51.2, C51.8-C51.9), skin of penis (C60.0-C60.1, C60.8, C60.9) and skin of scrotum (C63.2).

SKIN (excl. Malignant Melanoma, Kaposi's Sarcoma,
Mycosis Fungoides, Sezary's Disease, and Other Lymphomas)
C44.0-C44.9

LYMPH NODES

- 0 No lymph node involvement

1 REGIONAL by primary site (bilateral or contralateral for head, neck, trunk)

Head and Neck - All subsites:

Cervical

Lip: Preauricular, facial, submental, submandibular

Eyelid/canthus:

Preauricular, facial, submandibular, infra-auricular

External ear/auditory canal:

Pre-/post-auricular (mastoid)

Face, Other (cheek, chin, forehead, jaw, nose and temple): Preauricular, facial, submental, submandibular

Scalp/neck:

Preauricular, occipital, spinal accessory (posterior cervical); mastoid (post-auricular) for scalp; submental, supraclavicular, axillary for neck

LYMPH NODES (cont'd)

Upper trunk

Cervical, supraclavicular, internal mammary, axillary

Lower trunk

Femoral (superficial inguinal)

Arm/shoulder

Axillary
Spinal accessory for shoulder
Epitrochlear for hand/forearm

Leg/hip

Femoral (superficial inguinal)
Popliteal for heel and calf

All sites

Regional lymph node(s), NOS

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

MALIGNANT MELANOMA OF SKIN, VULVA, PENIS, SCROTUM

C44.0-C44.9, C51.0-C51.2, C51.8-C51.9, C60.0-C60.1, C60.8-C60.9, C63.2
(M-8720-8790)

MEASURED THICKNESS (Depth)* OF TUMOR (Breslow's measurement)

Record Actual Measurement (in mm)
from Pathology Department

000 No mass; no tumor found

mm

001 0.01

002 0.02

...

...

074 0.74

075 0.75

076 0.76

...

...

103 1.03

104 1.04

105 1.05

...

...

990 9.90+

999 Not stated

EXTENSION

00 IN SITU: Noninvasive;
intraepithelial
Clark's level I
Basement membrane of the
epidermis is intact.

10 Papillary dermis invaded
Clark's level II

11 (10) WITH ulceration

20 Papillary-reticular dermal
interface invaded
Clark's level III

21 (20) WITH ulceration

30 Reticular dermis invaded
Clark's level IV

31 (30) WITH ulceration

40 Skin/dermis, NOS
Localized, NOS

41 (40) WITH ulceration

50 Subcutaneous tissue invaded
(through entire dermis)
Clark's level V

51 (50) WITH ulceration

60 Satellite nodule(s), NOS

62 Satellite nodule(s), ≤ 2 cm from
primary tumor

64 (50-51) plus (60) or (62)

70 Underlying cartilage, bone,
skeletal muscle

80 FURTHER extension

85 Metastasis to skin or subcutaneous
tissue beyond regional lymph nodes

87 Visceral metastasis; metastasis, NOS

99 UNKNOWN if extension or metastasis

*Thickness, NOT size, is coded.

Note: For melanoma of sites
other than those above, use
site-specific schemes.

MALIGNANT MELANOMA OF SKIN, VULVA, PENIS, SCROTUM

C44.0-C44.9, C51.0-C51.2, C51.8-C51.9, C60.0-C60.1, C60.8-C60.9, C63.2
(M-8720-8790)

LYMPH NODES

0 No lymph node involvement

REGIONAL by primary site (bilateral or contralateral for head, neck, trunk)

Head and Neck - All subsites:

Cervical

Lip: Preauricular, facial, submental, submandibular

Eyelid/canthus: Preauricular, facial, submandibular, infra-auricular

External ear/auditory canal: Pre-/post-auricular (mastoid)

Face, Other (cheek, chin, forehead, jaw, nose, and temple): Preauricular, facial, submental, submandibular

Scalp/neck: Preauricular, occipital, spinal accessory (post. cervical); mastoid (postauricular) for scalp; submental, supraclavicular, axillary for neck

LYMPH NODES (cont'd)

Upper trunk

Cervical, supraclavicular, internal mammary, axillary

Lower trunk

Femoral (superficial inguinal)

Arm/shoulder

Axillary

Spinal accessory for shoulder
Epitrochlear for hand/forearm

Leg/hip

Femoral (superficial inguinal)
Popliteal for heel and calf

Vulva/penis/scrotum

Femoral (superficial inguinal)
Deep inguinal

All sites

Regional, NOS

- 1 Lymph node(s) metastasis ≤ 3 cm
- 2 Lymph node(s) metastasis > 3 cm
- 3 In-transit metastasis
(Satellite lesion(s)/subcutaneous nodule(s) > 2 cm from the primary tumor, but not beyond the site of primary lymph node drainage)
- 4 (2) plus (3)
- 5 Size not given

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

MYCOSIS FUNGOIDES AND SEZARY'S DISEASE OF SKIN, VULVA, PENIS, SCROTUM
C44.0-C44.9, C51.0-C51.2, C51.8-C51.9, C60.0-C60.1, C60.8-C60.9, C63.2
(M-9700-9701)

PERIPHERAL BLOOD INVOLVEMENT

EXTENSION

000 No peripheral blood involvement

Plaques, papules, or erythematous patches ("plaque stage"):

Atypical circulating cells in peripheral blood:

10 <10% of skin surface, no tumors

001 <5%

20 ≥10% of skin surface, no tumors

002 >5%

003 % not stated

999 Not applicable

25 % of body surface not stated, no tumors

30 Skin involvement, NOS: extent not stated, no tumors
 Localized, NOS

Note: In approximating body surface, the palmar surface of the hand, including digits, is about 1%.

50 One or more tumors (tumor stage)

70 Generalized erythroderma (>50% of body involved with diffuse redness); Sezary's syndrome

85 Visceral (non-cutaneous, extra-nodal) involvement (other than peripheral blood)

99 UNKNOWN; not stated

Source: Developed by the Mycosis Fungoides Cooperative Group

MYCOSIS FUNGOIDES AND SEZARY'S DISEASE OF SKIN, VULVA, PENIS, SCROTUM
C44.0-C44.9, C51.0-C51.2, C51.8-C51.9, C60.0-C60.1, C60.8-C60.9, C63.2
(M-9700-9701)

LYMPH NODES

0 No lymph node involvement (No clinical adenopathy and either pathologically negative or no pathological statement)

Lymph Nodes

1 Clinically enlarged palpable lymph node(s) (adenopathy), and either pathologically negative nodes or no pathological statement

2 No clinically enlarged palpable lymph nodes(s) (adenopathy); pathologically positive lymph node(s)

3 Both clinically enlarged palpable lymph node(s) (adenopathy) and pathologically positive lymph nodes

9 UNKNOWN; not stated

**PERIPHERAL NERVES AND AUTONOMIC NERVOUS SYSTEM; CONNECTIVE, SUBCUTANEOUS,
AND OTHER SOFT TISSUES**

C47.0-C47.6, C47.8-C47.9, C49.0-C49.6, C49.8-C49.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; radiographic report; physical examination--in priority order)

EXTENSION

000 No mass; no tumor found

001 Microscopic focus or foci only

mm cm

002 ≤2 ≤0.2

003 3 0.3

...

...

009 9 0.9

010 10 1.0

...

...

099 99 9.9

100 100 10.0

...

...

990 990+ 99.0+

999 Not stated

10 Invasive tumor confined to site/tissue of origin

30 Localized, NOS

40 Adjacent connective tissue

60 Adjacent organs/structures

80 FURTHER extension

85 Metastasis

99 UNKNOWN if extension or metastasis

**PERIPHERAL NERVES AND AUTONOMIC NERVOUS SYSTEM; CONNECTIVE, SUBCUTANEOUS,
AND OTHER SOFT TISSUES**

C47.0-C47.6, C47.8-C47.9, C49.0-C49.6, C49.8-C49.9

LYMPH NODES

- 0 No lymph node involvement

1 REGIONAL by primary site (bilateral or contralateral for head, neck, trunk)

Head and Neck - All subsites:

- Cervical
- Lip: Preauricular, facial, submental, submandibular
- Eyelid/canthus:
Preauricular, facial, submandibular, infra-auricular
- External ear/auditory canal:
Pre-/post-auricular (mastoid)
- Face, Other (cheek, chin, forehead, jaw, nose and temple): Preauricular, facial, submental, submandibular
- Scalp/neck:
Preauricular, occipital, spinal accessory (posterior cervical); mastoid (post-auricular) for scalp; submental, supraclavicular, axillary for neck

LYMPH NODES (cont'd)

- Upper trunk
Cervical, supraclavicular, Internal mammary, axillary
- Lower trunk
Femoral (superficial inguinal)
- Arm/shoulder
Axillary
Spinal accessory for shoulder
Epitrochlear for hand/forearm
- Leg/hip
Femoral (superficial inguinal)
Popliteal for heel and calf
- All Sites
Regional lymph node(s), NOS

DISTANT Lymph Nodes

- 7 Other than above

8 Lymph Nodes, NOS
9 UNKNOWN; not stated

RETROPERITONEUM AND PERITONEUM
C48.0-C48.2, C48.8

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; radiographic report--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+

999 Not stated

EXTENSION

10 Tumor confined to site of origin
 30 Localized, NOS
 40 Adjacent connective tissue
 60 Adjacent organs/structures
 80 FURTHER extension
 85 Metastasis
 99 UNKNOWN if extension or metastasis

**RETROPERITONEUM AND PERITONEUM
C48.0-C48.2, C48.8**

LYMPH NODES

- 0 No lymph node involvement

- 1 REGIONAL Lymph Nodes
 - Subdiaphragmatic
 - Intra-abdominal
 - Paracaval
 - Pelvic
 - Regional lymph node(s), NOS-----
- DISTANT Lymph Nodes
- 7 Other than above

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

BREAST

C50.0-C50.6, C50.8-C50.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination; mammography examination--in priority order; if multiple masses, code largest diameter)

- 000 No mass; no tumor found; no Paget's disease
 - 001 Microscopic focus or foci only
 - 002 Mammography/xerography diagnosis only with no size given (tumor not clinically palpable)
- | | <u>mm</u> | <u>cm</u> |
|-----|-----------|-----------|
| 003 | ≤3 | ≤0.3 |
| ... | | |
| ... | | |
| 009 | 9 | 0.9 |
| 010 | 10 | 1.0 |
| ... | | |
| ... | | |
| 099 | 99 | 9.9 |
| 100 | 100 | 10.0 |
| ... | | |
| ... | | |
| 990 | 990+ | 99.0+ |
- 997 Paget's Disease of nipple with no demonstrable tumor
 - 998 Diffuse; widespread: 3/4's or more of breast; inflammatory carcinoma
 - 999 Not stated

Note 1: Changes such as dimpling of the skin, tethering, and nipple retraction are caused by tension on Cooper's ligament(s), not by actual skin involvement. They do not alter the classification.

Note 2: Consider adherence, attachment, fixation, induration, and thickening as clinical evidence of extension to skin or subcutaneous tissue; code '20'.

Note 3: Consider "fixation, NOS" as involvement of pectoralis muscle; code '30'.

EXTENSION

- 00 IN SITU: Noninfiltrating; intraductal WITHOUT infiltration; lobular neoplasia
- 05 Paget's disease (WITHOUT underlying tumor)
- 10 Confined to breast tissue and fat including nipple and/or areola
- 20 Invasion of subcutaneous tissue
Skin infiltration of primary breast including skin of nipple and/or areola
Local infiltration of dermal lymphatics adjacent to primary tumor involving skin by direct extension
- 30 Invasion of (or fixation to) pectoral fascia or muscle; deep fixation; attachment or fixation to pectoral muscle or underlying tissue
- 40 Invasion of (or fixation to) chest wall, ribs, intercostal or serratus anterior muscles
- 50 Extensive skin involvement: Skin edema, peau d'orange, "pigskin," en cuirasse, lenticular nodule(s), inflammation of skin, erythema, ulceration of skin of breast, satellite nodule(s) in skin of primary breast
- 60 (50) plus (40)
- 70 Inflammatory carcinoma, incl. diffuse (beyond that directly overlying the tumor) dermal lymphatic permeation or infiltration

Note 4:

If extension code is:	Behavior code must be:
00	2
05	2 or 3
10+	3

BREAST

C50.0-C50.6, C50.8-C50.9

EXTENSION (cont'd)

- 80 FURTHER extension:
Skin over sternum, upper abdomen, axilla or opposite breast
- 85 Metastasis:
Bone, other than adjacent rib
Lung
Breast, contralateral--if metastatic
Adrenal gland
Ovary
Satellite nodule(s) in skin other than primary breast
- 99 UNKNOWN if extension or metastasis

LYMPH NODES

- 0 No lymph node involvement

- REGIONAL Lymph Nodes (ipsilateral)
- Axillary
 - Level I/low: Adjacent to tail of breast
 - Level II/mid: Central, interpectoral, (Rotter's node)
 - Level III/high: Subclavicular, apical
- Infraclavicular
- Intramammary
- Nodule(s) in axillary fat
- Size of largest metastasis¹ in axillary node(s), ipsilateral (codes 1-4):
- 1 Micrometastasis (≤0.2 cm)
- 2 >0.2-<2.0 cm, no extension beyond capsule
- 3 <2.0 cm WITH extension beyond capsule
- 4 ≥2.0 cm
- 5 Fixed/matted ipsilateral axillary nodes
- 6 Axillary/regional lymph nodes, NOS
Lymph nodes, NOS
- 7 Internal mammary node(s), ipsilateral

- DISTANT Lymph Nodes
- 8 Cervical, NOS
Contralateral/bilateral axillary and/or internal mammary
Supraclavicular (transverse cervical)
Other than above

- 9 UNKNOWN; not stated

¹Effective date January 1, 1992 diagnoses

VULVA (incl. Skin of Vulva)
 (excl. Malignant Melanoma, Kaposi's Sarcoma,
 Mycosis Fungoides, Sezary's Disease, and Other Lymphomas)
 C51.0-C51.2, C51.8-C51.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative
 report; endoscopic examination;
 physical examination--in
 priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

mm cm

002 ≤2 ≤0.2

003 3 0.3

...

...

009 9 0.9

010 10 1.0

...

...

099 99 9.9

100 100 10.0

...

...

990 990+ 99.0+

999 Not stated

EXTENSION

00 IN SITU: Noninvasive; Bowen's
 disease, intraepidermal
 FIGO Stage 0

10 Invasive cancer confined to:
 Submucosa
 Musculature

FIGO Stage I if size ≤2.0 cm

FIGO Stage II if size >2.0 cm

30 Localized, NOS

60 Extension to:
 Vagina
 Urethra
 Perineum
 Perianal skin
 Anus
 FIGO Stage III

70 Rectal mucosa
 Perineal body

75 Extension to:
 Upper urethral mucosa
 Bladder mucosa
 Pelvic bone
 FIGO Stage IVA

80 FURTHER extension

85 Metastasis
 FIGO Stage IVB

99 UNKNOWN if extension or metastasis

Note 1: Melanoma (M-8720-8790) of
 vulva is included in the melanoma
 scheme.

Note 2: Mycosis fungoides (M-9700)
 and Sezary's disease (M-9701) of
 vulva are included in the mycosis
 fungoides scheme.

VULVA (incl. Skin of Vulva)
(excl. Malignant Melanoma, Kaposi's Sarcoma,
Mycosis Fungoides, Sezary's Disease, and Other Lymphomas)
C51.0-C51.2, C51.8-C51.9

LYMPH NODES

0 No lymph node involvement

- - - - -
REGIONAL Lymph Nodes (incl. con- |
tralateral or bilateral) |

1 Superficial inguinal (femoral)
Deep inguinal, Rosenmuller's
or Cloquet's node
Regional lymph nodes, NOS

2 (1) WITH fixation or ulceration

3 External iliac
Internal iliac (hypogastric)
Pelvic, NOS

4 (3) WITH fixation or ulceration

- - - - -
DISTANT Lymph Nodes

7 Other than above

- - - - -
8 Lymph Nodes, NOS

9 UNKNOWN; not stated

VAGINA
C52.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; physical examination--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 10 Invasive cancer confined to: Submucosa (stroma) FIGO Stage I
- 20 Musculature involved
- 30 Localized, NOS
- 40 Extension to:
 - Paravaginal soft tissue
 - Cervix
 - Vulva
 - Vesicovaginal septum
 - Rectovaginal septum
 FIGO Stage II
- 50 Extension to:
 - Bladder wall or NOS
 - Rectal wall or NOS
 - Cul de sac (rectouterine pouch)
 FIGO Stage II
- 60 Extension to pelvic wall
FIGO Stage III
- 70 Extension to bladder or rectal mucosa
FIGO Stage IVA
- 80 Extension beyond true pelvis
Extension to urethra
FIGO Stage IVA, not further specified
- 85 Metastasis
FIGO Stage IVB
- 99 UNKNOWN if extension or metastasis

Note: "Frozen pelvis" is a clinical term which means tumor extends to pelvic sidewall(s). In the absence of a statement of involvement, code as 60.

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Upper two-thirds of vagina:

- 1 Pelvic lymph nodes:
 - Iliac: Common
 - Internal (hypogastric)
 - External
 - Sacral promontory
 - Pelvic, NOS

Lower third of vagina:

- 2 Ipsilateral:
 - Inguinal
 - Femoral |
- 3 Bilateral:
 - Inguinal |
 - Femoral

Both parts of vagina:

- 5 Regional lymph node(s), unknown whether primary is in upper or lower vagina

DISTANT Lymph Nodes

- 6 Inguinal (upper two-thirds only)
 - Aortic (para-, peri-, lateral)
 - Retroperitoneal, NOS

- 7 Other than above

-
- 8 Lymph Nodes, NOS

- 9 UNKNOWN; not stated

CERVIX UTERI

C53.0-C53.1, C53.8-C53.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; physical examination--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

00 IN SITU: Preinvasive; noninvasive; intraepithelial Cancer in situ WITH endocervical gland involvement
FIGO Stage 0

01 CIN (Cervical intraepithelial neoplasia) Grade III

11 Minimal microscopic stromal invasion
FIGO Stage IA1

12 "Microinvasion"
Tumor WITH invasive component ≤5 mm in depth, taken from the base of the epithelium, and ≤7 mm in horizontal spread
FIGO Stage IA2

20 Invasive cancer confined to cervix and tumor larger than that in code 12
FIGO Stage IB

30 Localized, NOS; confined to cervix uteri or uterus, NOS

31 FIGO Stage I, not further specified

35 Corpus uteri

40 Extension to:
Upper 2/3's of vagina (incl. fornices and vagina/vaginal wall, NOS)
Cul de sac (rectouterine pouch)
FIGO Stage IIA

50 Extension to:
Parametrium (paracervical soft tissue)
Ligaments: Broad, uterosacral, cardinal
FIGO Stage IIB

Note 1: Involvement of anterior and/or posterior septum is coded as involvement of the vaginal wall.**Note 2:** "Frozen pelvis" is a clinical term which means tumor extends to pelvic sidewall(s). In the absence of a statement of involvement, code as 65.**Note 3:** If the clinician says "adnexa palpated" but doesn't mention lymph nodes, assume lymph nodes are not involved.**Note 4:** If either exploratory/definitive surgery is done with no mention of lymph nodes, assume nodes are negative.

CERVIX UTERI
C53.0-C53.1, C53.8-C53.9

EXTENSION (cont'd)

LYMPH NODES

60	Extension to: Lower 1/3 of vagina; vulva Rectal and/or bladder wall or NOS Bullous edema of bladder mucosa Ureter, intra- and extramural FIGO Stage IIIA	0	No lymph node involvement -----
		1	REGIONAL Lymph Nodes Paracervical Parametrial Iliac: Common Internal (hypogastric): Obturator External Pelvic, NOS Sacral (lateral, presacral, sacral promontory (Gerota's), uterosacral, or NOS)
65	Extension to: Pelvic wall(s) Hydronephrosis or nonfunctioning kidney (except if other cause) FIGO Stage IIIB		
70	Extension to rectal or bladder <u>mucosa</u> FIGO Stage IVA		Regional lymph node(s), NOS ----- DISTANT Lymph Nodes
80	FURTHER extension beyond true pelvis FIGO Stage IVA, not further specified	6	Aortic (para-, peri-, lateral)
		7	Other than above -----
85	Metastasis FIGO Stage IVB	8	Lymph Nodes, NOS
99	UNKNOWN if extension or metastasis	9	UNKNOWN; not stated

CORPUS UTERI

DISTINGUISHING "IN SITU" AND "LOCALIZED" TUMORS FOR THE CORPUS UTERI

Careful attention must be given to the use of the term "confined to endometrium" for corpus uteri.

- 1) Determine if the tumor is confined to the columnar epithelium, in which case it is in situ, **OR**
- 2) if the tumor has penetrated the basement membrane to invade the stroma (lamina propria), in which case it is localized and is coded to invasion of the stroma.

The endometrium (mucosa) consists of:

The EPITHELIAL LAYER contains no blood vessels or lymphatics.

The BASEMENT MEMBRANE, a sheet of extracellular material, functions as a filtration barrier and a boundary involved in generating and maintaining tissue structure.

The LAMINA PROPRIA, composed of areolar connective tissue, contains blood vessels, nerves, and, in some regions, glands. Once tumor has broken through the basement membrane into the lamina propria, it can spread by way of the lymphatics and blood vessels to other parts of the body.

There is NO MUSCULARIS MUCOSAE or SUBMUCOSA in the endometrium.

The MYOMETRIUM (muscularis) is composed of three layers of smooth muscle fibers; it constitutes the wall of the organ.

The SEROSA, the outermost layer covering the corpus uteri, is a serous membrane, part of the visceral peritoneum.

CORPUS UTERI

PRIMARY SITE	ENDOMETRIUM (mucosa)		MYOMETRIUM (3 layers)	SEROSA
	Columnar Epithelium	B A Stroma S (lamina propria) E		
Corpus Uteri (C54._)	Yes	M E M :	Yes	Yes

CORPUS UTERI, UTERUS NOS, AND PLACENTA
 C54.0-C54.3, C54.8-C54.9, C55.9, C58.9 |

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; physical examination--in priority order)

EXTENSION

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

00 IN SITU: Preinvasive, noninvasive
 FIGO Stage 0

No sounding done; sounding, NOS

10 FIGO Stage I not further specified

11 Confined to endometrium (stroma)

Extension to:

12 Myometrium--inner half

13 Myometrium--outer half

14 Myometrium--NOS

15 Serosa

Sounding of uterine cavity is ≤8.0 cm in length

20 FIGO Stage IA not further specified

21 Confined to endometrium (stroma)

Extension to:

22 Myometrium--inner half

23 Myometrium--outer half

24 Myometrium--NOS

25 Serosa

Sounding of uterine cavity is >8.0 cm in length

30 FIGO Stage IB not further specified

31 Confined to endometrium (stroma)

Extension to:

32 Myometrium--inner half

33 Myometrium--outer half

34 Myometrium--NOS

35 Serosa

40 Localized, NOS

50 Cervix uteri, incl. endocervix invaded
 FIGO Stage II

Note 1: Adnexa=tubes, ovaries and ligament(s)

Note 2: "Frozen pelvis" is a clinical term which means tumor extends to pelvic sidewall(s). In the absence of a statement of involvement, code as 60.

Note 3: If the clinician says "adnexa palpated" but doesn't mention lymph nodes, assume lymph nodes are not involved.

Note 4: If either exploratory/definitive surgery is done with no mention of lymph nodes, assume nodes are negative.

CORPUS UTERI, UTERUS NOS, AND PLACENTA
C54.0-C54.3, C54.8-C54.9, C55.9, C58.9

EXTENSION (cont'd)

LYMPH NODES

<p>60 Extension within true pelvis: Parametrium Ligaments: Broad, round, uterosacral Pelvic wall(s) Ovary(ies) and/or fallopian tube(s) Rectal and/or bladder wall or NOS Vagina FIGO Stage III</p>	<p>0 No lymph node involvement ----- REGIONAL Lymph Nodes</p>
<p>70 Extension to rectal or bladder <u>mucosa</u> FIGO Stage IVA</p>	<p>1 Parametrial Paracervical Iliac: Common Internal (hypogastric): Obturator External Pelvic, NOS Sacral (lateral, presacral, sacral promontory (Gerota's), uterosacral, or NOS)</p>
<p>80 Extension beyond true pelvis FIGO Stage IVA, not further specified</p>	<p>2 Aortic (para-, peri-, lateral) 5 Regional Lymph Nodes, NOS ----- DISTANT Lymph Nodes</p>
<p>85 Metastasis FIGO Stage IVB</p>	<p>6 Superficial inguinal</p>
<p>99 UNKNOWN if extension or metastasis</p>	<p>7 Other than above (incl. deep inguinal) ----- 8 Lymph Nodes, NOS 9 UNKNOWN; not stated</p>

OVARY
C56.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; physical examination--in priority order)

SIZE

000 No mass; no tumor found
001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

Note 1: Code size of tumor, not size of the cyst.

Note 2: Ascites WITH malignant cells changes FIGO Stages I and II to IC and IIC, respectively. Ascites, NOS is considered negative.

Note 3: Peritoneal implants outside the pelvis (codes 70-72) must be microscopically confirmed.

EXTENSION

- 00 IN SITU: Preinvasive; noninvasive; intraepithelial
- 10 Tumor limited to one ovary, capsule intact, no tumor on ovarian surface
FIGO Stage IA
- 20 Tumor limited to both ovaries, capsule(s) intact, no tumor on ovarian surface
FIGO Stage IB
- 30 Localized, NOS; unknown if capsule(s) ruptured or one or both ovaries involved
FIGO Stage I, not further specified
- 40 Tumor limited to ovary(ies), capsule(s) ruptured or tumor on ovarian surface
FIGO Stage IC
- 41 Tumor limited to ovary(ies) WITH malignant cells in ascites or peritoneal washings
FIGO Stage IC
- 42 (40) plus (41)
FIGO Stage IC, not further specified
- 50 Extension to or implants on:
Uterus
Fallopian tube(s)
Adnexa, NOS
FIGO Stage IIA
- 60 Extension to or implants on:
Pelvic wall
Pelvic tissue (broad ligament, adjacent peritoneum--mesovarium)
FIGO Stage IIB
- 62 (50) and/or (60) WITH malignant cells in ascites or peritoneal washings
FIGO Stage IIC

EXTENSION (cont'd)

LYMPH NODES

<p>65 FIGO Stage II, not further specified</p> <p>70 Microscopic peritoneal implants beyond pelvis, including peritoneal surface of liver FIGO Stage IIIA</p> <p>71 Macroscopic peritoneal implants beyond pelvis, ≤2 cm in diameter, including peritoneal surface of liver FIGO Stage IIIB</p> <p>72 Peritoneal implants beyond pelvis, >2 cm in diameter, including peritoneal surface of liver FIGO Stage IIIC</p> <p>75 Peritoneal implants, NOS FIGO Stage III, not further specified</p> <p>80 FURTHER extension</p> <p>85 Metastasis, including: Liver parenchymal metastasis Pleural fluid (positive cytology) FIGO Stage IV</p> <p>99 UNKNOWN if extension or metastasis</p>	<p>0 No lymph node involvement -----</p> <p>REGIONAL Lymph Nodes (incl. contralateral or bilateral nodes)</p> <p>1 Iliac: Common Internal (hypogastric): Obturator External Lateral sacral Pelvic, NOS</p> <p>2 Aortic (para-, peri-, lateral) Retroperitoneal, NOS</p> <p>3 Inguinal</p> <p>4 (2) plus (1) and/or (3)</p> <p>5 Regional Lymph Nodes, NOS -----</p> <p>DISTANT Lymph Nodes</p> <p>7 Other than above -----</p> <p>8 Lymph Nodes, NOS</p> <p>9 UNKNOWN; not stated</p>
--	---

Note 4: If implants are mentioned, determine whether they are in the pelvis or in the abdomen and code appropriately (60-62) or (70-72). If the location is not specified, code as outside the pelvis (70-72 or 75).

FALLOPIAN TUBE, BROAD AND ROUND LIGAMENTS, PARAMETRIUM, UTERINE ADNEXA
C57.0-C57.4 |

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; physical examination--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

mm cm

002 ≤2 ≤0.2

003 3 0.3

...

...

009 9 0.9

010 10 1.0

...

...

099 99 9.9

100 100 10.0

...

...

990 990+ 99.0+

999 Not stated

EXTENSION

00 IN SITU: Noninvasive

10 Tumor confined to tissue or organ of origin

30 Localized, NOS

40 Ovary, ipsilateral
 Corpus uteri; uterus, NOS

50 Peritoneum
 Fallopian tube for ligaments
 Broad ligament, ipsilateral
 for fallopian tube
 Mesosalpinx, ipsilateral

70 Omentum
 Cul de sac (rectouterine pouch)
 Sigmoid
 Rectosigmoid
 Small intestine
 Ovary, contralateral

80 FURTHER extension

85 Metastasis

99 UNKNOWN if extension or metastasis

FALLOPIAN TUBE, BROAD AND ROUND LIGAMENTS, PARAMETRIUM, UTERINE ADNEXA
C57.0-C57.4

|

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

1 Iliac: Common
Internal (hypogastric):
Obturator
External
Lateral sacral
Pelvic, NOS

2 Aortic (para-, peri-, lateral)
Retroperitoneal, NOS

3 Inguinal

4 (2) plus (1) and/or (3)

5 Regional Lymph Nodes, NOS

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

OTHER AND UNSPECIFIED FEMALE GENITAL ORGANS
C57.7-C57.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; physical examination--in priority order)

EXTENSION

000 No mass; no tumor found

001 Microscopic focus or foci only

mm cm

002 ≤2 ≤0.2

003 3 0.3

...

...

009 9 0.9

010 10 1.0

...

...

099 99 9.9

100 100 10.0

...

...

990 990+ 99.0+

999 Not stated

00 IN SITU: Noninvasive; intraepithelial

10 Confined to site of origin

30 Localized, NOS

40 Adjacent connective tissue

60 Adjacent organs/structures

80 FURTHER extension

85 Metastasis

99 UNKNOWN if extension or metastasis

**OTHER AND UNSPECIFIED FEMALE GENITAL ORGANS
C57.7-C57.9**

LYMPH NODES

- 0 No lymph node involvement

- 1 REGIONAL Lymph Nodes

- 7 DISTANT Lymph Nodes

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

PENIS (excl. Body of Penis) (excl. Malignant Melanoma, Kaposi's Sarcoma, Mycosis Fungoides, Sezary's Disease, and Other Lymphomas)
 C60.0-C60.1, C60.8-C60.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+

999 Not stated

EXTENSION

- 00 IN SITU: Noninvasive; Bowen's disease; intraepithelial
- 05 Noninvasive verrucous carcinoma
- 10 Invasive tumor limited to subepithelial connective tissue, but not involving corpus spongiosum or cavernosum
- 30 Localized, NOS
- 40 Corpus cavernosum
Corpus spongiosum
- 50 Satellite nodule(s) on prepuce or glans
- 60 Urethra
Prostate
- 70 Adjacent structures
Skin: Pubic, scrotal, abdominal, perineum
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

Note 1: Melanoma (M-8720-8790) of penis is included in the melanoma scheme.

Note 2: Mycosis fungoides (M-9700) or Sezary's disease (M-9701) of penis is included in the mycosis fungoides scheme.

PENIS (excl. Body of Penis) (excl. Malignant Melanoma, Kaposi's Sarcoma, Mycosis Fungoides, Sezary's Disease, and Other Lymphomas)
C60.0-C60.1, C60.8-C60.9

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

1 SINGLE superficial inguinal
(femoral)

2 Multiple OR bilateral
superficial inguinal
(femoral)

3 Deep inguinal: Rosenmuller's
or Cloquet's node

5 Regional lymph node(s), NOS

6 External iliac
Internal iliac (hypogastric)
Pelvic nodes, NOS

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

BODY OF PENIS, OTHER AND UNSPECIFIED MALE GENITAL ORGANS
(excl. Malignant Melanoma, Kaposi's Sarcoma, Mycosis
Fungoides, Sezary's Disease, and Other Lymphomas of Scrotum)
C60.2, C63.0-C63.2, C63.7-C63.9 |

SIZE OF PRIMARY TUMOR

(from pathology report; operative
report; endoscopic examination;
physical examination--in
priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+

999 Not stated

EXTENSION

00 IN SITU: Noninvasive;
intraepithelial

10 Confined to site of origin

30 Localized, NOS

40 Adjacent connective tissue

60 Adjacent organs/structures

80 FURTHER extension

85 Metastasis

99 UNKNOWN if extension or metastasis

Note 1: Melanoma (M-8720-8790) of
scrotum only is included in the
melanoma scheme.

Note 2: Mycosis fungoides (M-9700)
or Sezary's disease (M-9701) of
scrotum only is included in the
mycosis fungoides scheme.

BODY OF PENIS, OTHER AND UNSPECIFIED MALE GENITAL ORGANS
(excl. Malignant Melanoma, Kaposi's Sarcoma, Mycosis
Fungoides, Sezary's Disease, and Other Lymphomas of Scrotum)
C60.2, C63.0-C63.2, C63.7-C63.9

LYMPH NODES

0 No lymph node involvement

1 REGIONAL Lymph Nodes

- External iliac
- Internal iliac (hypogastric)
- Superficial inguinal
(femoral)
- Deep inguinal: Rosenmuller's
or Cloquet's node
- Pelvic, NOS
- Regional lymph node(s), NOS

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

PROSTATE GLAND
C61.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

000	No mass; no tumor found	
001	Microscopic focus or foci only	
	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

Note 1: Involvement of prostatic urethra does not alter the extension code.

Note 2: "Frozen pelvis" is a clinical term which means tumor extends to pelvic sidewall(s). In the absence of a statement of involvement, code as 70.

Note 3: If D1-D2 is based on involvement of lymph nodes only, code under lymph nodes and not extension.

Note 4: B can be further classified: B1, Small, discrete nodule(s) ≤1.5 cm, and B2 Nodule(s) >1.5 cm or in more than one lobe.

Source: The American Urological Association Staging System (A-D)

EXTENSION

00	IN SITU: Noninvasive; intraepithelial
	Incidentally found microscopic carcinoma (latent)
10	Number of foci not specified (A)
11	≤3 microscopic foci (A1 Focal)
12	>3 microscopic foci (A2 Diffuse)
20	Palpable nodule(s) confined to prostate (intracapsular)--one lobe (B)
25	Multiple nodules confined to prostate (intracapsular)--more than one lobe (B)
30	Localized, NOS; confined to prostate, NOS (B, not further specified)
40	Invasion of prostatic capsule (C1)
50	Extension to periprostatic tissue (C1): Extracapsular extension (beyond prostatic capsule) Extraprostatic urethra (membranous) Bladder neck and/or prostatic apex Through capsule, NOS
55	Extension to seminal vesicle(s) (C2)
56	Extension to periprostatic tissue, NOS (C, not further specified)
60	Extension to or fixation of other adjacent structures: Rectovesical (Denonvilliers') fascia Bladder, NOS; ureter(s) Rectum Skeletal muscle (levator ani) Fixation, NOS

EXTENSION (cont'd)

- 70 Pelvic bone
Pelvic wall(s)
- 80 FURTHER extension to bone,
soft tissue or other organs
(D2)
- 85 Metastasis (D2)
D, not further specified
- 99 UNKNOWN if extension or
metastasis

LYMPH NODES

- 0 No lymph node involvement

- REGIONAL Lymph Nodes (incl. con-
tralateral or bilateral nodes)
- Periprostatic
- Iliac: Internal (hypogastric):
Obturator
External
Iliac, NOS
- Pelvic, NOS
- Sacral (lateral, presacral,
sacral promontory (Gerota's),
or NOS)
- Regional lymph node(s), NOS
- 1 Single lymph node \leq 2 cm
- 2 Single lymph node >2-5 cm OR
multiple nodes, none
greater than 5 cm
- 3 Lymph node(s), at least one >5 cm
- 5 Size not stated

- DISTANT Lymph Nodes
- 6 Aortic (para-, peri-, lateral,
lumbar)
Retroperitoneal, NOS
Common iliac
Inguinal, superficial (femoral)
and/or deep
- 7 Other than above

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

TESTIS

C62.0-C62.1, C62.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci onlymm cm002 ≤ 2 ≤ 0.2

003 3 0.3

...

...

009 9 0.9

010 10 1.0

...

...

099 99 9.9

100 100 10.0

...

...

990 990+ 99.0+

999 Not stated

EXTENSION00 IN SITU: Noninvasive;
 intratubular10 Confined to body of testis/tunica
 albuginea; rete testis20 Tunica vaginalis involved
 Surface implants30 Localized, NOS
 Tunica, NOS

40 Epididymis

50 Spermatic cord, ipsilateral
 Vas deferens60 Scrotum, ipsilateral, incl.
 dartos muscle70 Extension to scrotum,
 contralateral
 Ulceration of scrotum

75 Penis

80 FURTHER extension

85 Metastasis

99 UNKNOWN if extension or metastasis

TESTIS
C62.0-C62.1, C62.9

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes (incl. con-
tralateral or bilateral nodes)

- Paracaval
- Aortic (para-, peri-, lateral)
- External iliac
- Retroperitoneal, NOS
- Pelvic, NOS
- Regional lymph node(s), NOS

- 1 Single lymph node \leq 2 cm
- 2 Single lymph node >2-5 cm OR
multiple nodes, none
greater than 5 cm
- 3 Lymph node(s), at least one >5 cm
- 5 Size not stated

DISTANT Lymph Nodes

- 6 Inguinal nodes, superficial
(femoral) and/or deep
- 7 Other than above

-
- 8 Lymph Nodes, NOS
 - 9 UNKNOWN; not stated

Note: Regardless of previous in-
guinal or scrotal surgery, invol-
vement of inguinal nodes is al-
ways considered distant by SEER.

URINARY BLADDER, RENAL PELVIS and URETERS

DISTINGUISHING "IN SITU" AND "LOCALIZED" TUMORS FOR URINARY SITES

Careful attention must be given to the use of the term "confined to mucosa" for urinary bladder.

Historically, carcinomas described as "confined to mucosa" have been coded as localized. However, pathologists almost uniformly use this designation for non-invasive tumor as well. In order to provide greater specificity and to rule out the possibility of classifying noninvasive tumors in this category, abstractors should determine:

- 1) if the tumor is confined to the epithelium, in which case it is in situ, OR
- 2) if the tumor has penetrated the basement membrane to invade the lamina propria, in which case it is localized and is coded to invasion of the lamina propria. Only if this separation cannot be made should the tumor be coded to "confined to mucosa."

The mucosa of the urinary tract consists of:

The EPITHELIAL LAYER contains no blood vessels or lymphatics.

The BASEMENT MEMBRANE, a sheet of extracellular material, functions as a filtration barrier and a boundary involved in generating and maintaining tissue structure.

The LAMINA PROPRIA, composed of areolar connective tissue, contains blood vessels, nerves, and, in some regions, glands. Once tumor has broken through the basement membrane into the lamina propria, it can spread by way of the lymphatics and blood vessels to other parts of the body.

The urinary sites do NOT have a MUSCULARIS MUCOSAE, and, therefore, the lamina propria and the submucosa are difficult to separate. These terms are used interchangeably.

The SUBMUCOSA is a thick layer of either dense or areolar connective tissue. It contains blood vessels, lymphatic vessels, nerves, and, in some regions, glands.

The MUSCULARIS PROPRIA is composed of multiple layers of muscle tissue; it constitutes the wall of the organ.

URINARY BLADDER, RENAL PELVIS and URETERS

The SEROSA, the outermost layer covering, is a serous membrane, part of the visceral peritoneum. It covers only the superior surface of the urinary bladder. There is no serosa on the renal pelvis or ureters. Where there is no serosa, the connective tissue of surrounding structures merges with the connective tissue of the urinary organs and is called ADVENTITIA.

URINARY BLADDER, RENAL PELVIS and URETERS

PRIMARY SITE	MUCOSA		MUSCULARIS PROPRIA	SEROSA
	Epithelium	Lamina Propria/ Submucosa		
Urinary Bladder (C67.9)	Yes	Yes	Yes	Yes, on superior surface
Renal pelvis (C65.9)	Yes	Yes	Yes	No
Ureter(s) (C66.9)	Yes	Yes	Yes	No

KIDNEY (Renal Parenchyma)
C64.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; radiographic report--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU
- 10 Invasive cancer confined to kidney cortex and/or medulla
- 20 Renal pelvis or calyces involved
Invasion of renal capsule
- 30 Localized, NOS
- 40 Perirenal (perinephric) tissue/
fat
Renal (Gerota's) fascia
Adrenal gland, ipsilateral
Retroperitoneal soft tissue
- 60 Extension to:
Blood vessels:
Extrarenal portion of renal vein; renal vein, NOS
Inferior vena cava
Tumor thrombus in a renal vein, NOS
- 65 Extension beyond Gerota's fascia to:
Ureter, incl. implant(s), ipsilateral
Tail of pancreas
Ascending colon from right kidney
Descending colon from left kidney
Duodenum from right kidney
Peritoneum
Diaphragm
- 70 Ribs
- 75 Spleen
Liver
Stomach
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

KIDNEY (Renal Parenchyma)
C64.9

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes (incl. con-
tralateral and bilateral)

Renal hilar
Paracaval
Aortic (para-, peri-, lateral)
Retroperitoneal, NOS
Regional lymph node(s), NOS

1 Single lymph node \leq 2 cm

2 Single lymph node >2-5 cm OR
multiple nodes, none
greater than 5 cm

3 Lymph node(s), at least one >5 cm

5 Size not stated

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

**RENAL PELVIS, URETER,
AND UNSPECIFIED URINARY ORGANS
C65.9, C66.9, C68.8-C68.9**

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; radiographic report--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

00 Carcinoma-IN SITU, NOS

05 Papillary noninvasive carcinoma

10 Subepithelial connective tissue (lamina propria, submucosa) invaded

20 Muscularis invaded

30 Localized, NOS

40 Extension to adjacent (connective) tissue:
Peripelvic/periureteric tissue
Retroperitoneal soft/connective tissue

60 Kidney parenchyma and kidney, NOS, from renal pelvis
Ureter from renal pelvis

65 Extension to bladder from distal ureter
Implants in distal ureter

66 Extension to major blood vessel(s):
Aorta, renal artery/vein, vena cava (inferior)
Tumor thrombus in a renal vein, NOS

70 Perinephric fat via kidney
Spleen
Pancreas
Liver
Ascending colon from right renal pelvis/ureter
Descending colon from left renal pelvis/ureter
Colon, NOS
Kidney parenchyma from other than renal pelvis
Bladder, other than from distal ureter, i.e., renal pelvis

Note:

If extension code is:	Behavior code must be:
00 or 05	2
10+	3

**RENAL PELVIS, URETER,
AND UNSPECIFIED URINARY ORGANS
C65.9, C66.9, C68.8-C68.9**

EXTENSION (cont'd)

- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

LYMPH NODES

- 0 No lymph node involvement
-
- REGIONAL Lymph Nodes (incl. con-
tralateral and bilateral)
- Renal Pelvis:**
 - Renal hilar
 - Paracaval
 - Aortic (para-, peri-, lateral)
 - Retroperitoneal, NOS
 - Regional lymph node(s), NOS
- Ureter:**
 - Renal hilar
 - Iliac: Common
 - Internal (hypogastric)
 - External
 - Paracaval
 - Periureteral
 - Pelvic, NOS
 - Regional lymph node(s), NOS
- 1 Single lymph node \leq 2 cm
- 2 Single lymph node >2-5 cm OR
multiple nodes, none
greater than 5 cm
- 3 Lymph node(s), at least one >5 cm
- 5 Size not stated
-
- DISTANT Lymph Nodes
- 7 Other than above
-
- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

BLADDER
C67.0-C67.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; x-ray report (KUB); physical examination--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

Note 1: The lamina propria and submucosa tend to merge when there is no muscularis mucosae, so these terms will be used interchangeably.

Note 2: The meaning of the terms "invasion of mucosa, grade 1" and "invasion of mucosa, grade 2" varies with the pathologist who must be queried to determine whether the carcinoma is "in situ" or "invasive."

Note 3:

If extension code is:	Behavior code must be:
00 or 05	2
10	2 or 3
15+	3

EXTENSION

- 00 Sessile (flat) carcinoma -IN SITU; Carcinoma-IN SITU, NOS
- 05 Noninvasive papillary (transitional) carcinoma
- 10 Confined to mucosa, NOS
- 15 Invasive tumor confined to: Subepithelial connective tissue (tunica propria, lamina propria, submucosa, stroma)
- Muscle (muscularis) invaded**
- 20 NOS
- 21 Superficial muscle--inner half
- 22 Deep muscle--outer half
- 23 Extension through full thickness of bladder wall
- 30 Localized, NOS
- 40 Subserosal tissue
Perivesical fat/tissue
Periureteral fat/tissue
- 50 Extension to/through serosa (mesothelium); peritoneum
- 60 Prostate
Urethra, including prostatic urethra
Ureter
- 65 Vas deferens; seminal vesicle
Rectovesical/Denonvilliers' fascia
Parametrium
Uterus
Vagina

Note 4: Periureteral in code 40 refers only to that portion of the ureter that is intramural to the bladder. All other periureteral involvement would be coded to 60.

EXTENSION (cont'd)

- 70 Bladder FIXED
- 75 Pelvic wall
Abdominal wall
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or
metastasis

LYMPH NODES

- 0 No lymph node involvement
-
- REGIONAL Lymph Nodes (incl. con-
tralateral and bilateral)
- Perivesical
- Iliac: Internal (hypogastric):
Obturator
- External
- Iliac, NOS
- Sacral (lateral, presacral,
sacral promontory (Gerota's),
or NOS)
- Pelvic, NOS
- Regional lymph node(s), NOS
- 1 Single lymph node ≤2 cm
- 2 Single lymph node >2-5 cm OR
multiple nodes, none
greater than 5 cm
- 3 Lymph node(s), at least one >5 cm
- 5 Size not stated
-
- DISTANT Lymph Nodes
- 6 Common iliac
- 7 Other than above
-
- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

URETHRA, PARAURETHRAL GLAND
C68.0-C68.1

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; radiographic report--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 Carcinoma-IN SITU, NOS
- 05 Noninvasive papillary, polypoid, or verrucous carcinoma
- 10 Subepithelial connective tissue (lamina propria, submucosa) invaded
- 20 Muscularis invaded
- 30 Localized, NOS
- 40 Periurethral muscle (sphincter)
 Corpus spongiosum
 Prostate
- 60 Beyond the prostatic capsule |
 Corpus cavernosum |
 Vagina, anterior or NOS |
 Bladder neck |
- 70 Other adjacent organs,
 incl. seminal vesicle(s) |
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

Note:

If extension code is:	Behavior code must be:
00 or 05	2
10+	3

URETHRA, PARAURETHRAL GLAND
C68.0-C68.1

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes (incl. con-
tralateral and bilateral)

Iliac: Common
Internal (hypogastric):
Obturator
External

Inguinal (superficial or deep)
Presacral, sacral NOS
Pelvic, NOS
Regional lymph node(s), NOS

1 Single lymph node ≤ 2 cm

2 Single lymph node $>2-5$ cm OR
multiple nodes, none
greater than 5 cm

3 Lymph node(s), at least one >5 cm

5 Size not stated

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

CONJUNCTIVA (excl. Retinoblastoma, Malignant Melanoma,
Kaposi's Sarcoma, and Lymphomas)
C69.0

SIZE OF PRIMARY TUMOR

(from pathology report; operative
report; radiographic report;
physical examination--in
priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

mm cm

002 ≤2 ≤0.2
003 3 0.3

...
...

009 9 0.9
010 10 1.0

...
...

099 99 9.9
100 100 10.0

...
...

990 990+ 99.0+

999 Not stated

EXTENSION

00 IN SITU

10 Tumor confined to conjunctiva

40 Intraocular extension

50 Adjacent extraocular extension,
excluding orbit

70 Orbit

80 FURTHER extension

85 Metastasis

99 UNKNOWN if extension or
metastasis

CONJUNCTIVA (excl. Retinoblastoma, Malignant Melanoma,
Kaposi's Sarcoma, and Lymphomas)
C69.0

LYMPH NODES

0 No lymph node involvement

1 REGIONAL Lymph Nodes

 Submandibular

 Parotid (preauricular)

 Cervical

 Regional lymph node(s), NOS

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

MALIGNANT MELANOMA OF CONJUNCTIVA
C69.0
(M-8720-8790)

MEASURED THICKNESS (Depth)* of TUMOR (Breslow's measurement)

Record actual measurement (in mm)
 from Pathology Department

000 No mass; no tumor found

	<u>mm</u>
001	0.01
002	0.02
...	
...	
074	0.74
075	0.75
076	0.76
...	
...	
103	1.03
104	1.04
105	1.05
...	
...	
990	9.90+
999	Not stated

EXTENSION

- 00 IN SITU
- 10 Tumor(s) of bulbar conjunctiva occupying one quadrant or less
- 12 Tumor(s) of bulbar conjunctiva occupying more than one quadrant
- 15 Tumor(s) of bulbar conjunctiva, NOS
- 20 Tumor involves:
 - Conjunctival fornix
 - Palpebral conjunctiva
 - Caruncle
- 30 Localized, NOS
- 70 Eyelid
 Cornea
 Orbit
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

*Thickness, NOT size, is coded.

MALIGNANT MELANOMA OF CONJUNCTIVA
C69.0
(M-8720-8790)

LYMPH NODES

- 0 No lymph node involvement

- 1 REGIONAL Lymph Nodes
 - Submandibular
 - Parotid (preauricular)
 - Cervical
 - Regional lymph node(s), NOS-----
- DISTANT Lymph Nodes
- 7 Other than above

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

UVEA AND OTHER EYE (excl. Retinoblastoma, Malignant
 Melanoma, Kaposi's Sarcoma, and Lymphomas)
 C69.1-C69.4, C69.8-C69.9

<u>SIZE OF PRIMARY TUMOR</u>			<u>EXTENSION</u>
(from pathology report; operative report; radiographic report; physical examination--in priority order)			
			00 IN SITU
			10 Tumor confined to site of origin
000	No mass; no tumor found		40 Intraocular extension
001	Microscopic focus or foci only		70 Adjacent extraocular extension
	<u>mm</u>	<u>cm</u>	80 FURTHER extension
002	≤2	≤0.2	85 Metastasis
003	3	0.3	
...			99 UNKNOWN if extension or metastasis
...			
009	9	0.9	
010	10	1.0	
...			
...			
099	99	9.9	
100	100	10.0	
...			
...			
990	990+	99.0+	
999	Not stated		

**UVEA AND OTHER EYE (excl. Retinoblastoma, Malignant
Melanoma, Kaposi's Sarcoma, and Lymphomas)
C69.1-C69.4, C69.8-C69.9**

LYMPH NODES

- 0 No lymph node involvement

- 1 REGIONAL Lymph Nodes
 - Submandibular
 - Parotid (preauricular)
 - Cervical
 - Regional lymph node(s), NOS-----
- DISTANT Lymph Nodes
- 7 Other than above

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

MALIGNANT MELANOMA OF UVEA AND OTHER EYE
 C69.1-C69.4, C69.8-C69.9
 (M-8720-8790)

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; radiographic report; physical examination--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

mm cm

002 ≤2 ≤0.2

003 3 0.3

...

...

009 9 0.9

010 10 1.0

...

...

099 99 9.9

100 100 10.0

...

...

990 990+ 99.0+

999 Not stated

EXTENSION

00 IN SITU

Iris

10 Tumor confined to iris

40 Tumor involves 1 quadrant or less, with invasion into anterior chamber angle

43 Tumor involves more than one quadrant, with invasion into anterior chamber angle

45 Invasion into anterior chamber angle, NOS

Ciliary Body

12 Tumor limited to the ciliary body

50 Tumor invades into anterior chamber and/or iris

55 Tumor invades choroid

Other Eye

15 Tumor elevation ≤2mm

17 Tumor elevation >2mm - ≤3mm

20 Tumor elevation >3mm - ≤5mm

25 Tumor elevation >5mm

30 Localized, NOS

MALIGNANT MELANOMA OF UVEA AND OTHER EYE
C69.1-C69.4, C69.8-C69.9
(M-8720-8790)

EXTENSION (cont'd)

LYMPH NODES

	All Above Sites	0 No lymph node involvement

70	Adjacent extraocular extension	1 REGIONAL Lymph Nodes
		Submandibular
		Parotid (preauricular)
80	FURTHER extension	Cervical
		Regional lymph node(s), NOS
85	Metastasis	-----
		DISTANT Lymph Nodes
99	UNKNOWN if extension or metastasis	7 Other than above

		8 Lymph Nodes, NOS
		9 UNKNOWN; not stated

LACRIMAL GLAND

C69.5

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; radiographic report; physical examination--in priority order)

000 No mass; no tumor found

001 Microscopic focus or foci only

mm cm

002 ≤ 2 ≤ 0.2

003 3 0.3

...

...

009 9 0.9

010 10 1.0

...

...

099 99 9.9

100 100 10.0

...

...

990 990+ 99.0+

999 Not stated

EXTENSION

00 IN SITU

10 Tumor confined to lacrimal gland/duct

40 Invading periosteum of fossa of lacrimal gland/duct

60 Orbital soft tissues
Optic nerve
Globe (eyeball)

70 Adjacent bone

80 FURTHER extension

85 Metastasis

99 UNKNOWN if extension or metastasis

LYMPH NODES

0 No lymph node involvement

1 REGIONAL Lymph Nodes

Submandibular
Parotid (preauricular)
Cervical
Regional lymph node(s), NOS

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

ORBIT NOS

C69.6

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; radiographic report; physical examination--in priority order)

000 No mass; no tumor found

001 Microscopic focus or foci only

mm cm

002 ≤2 ≤0.2

003 3 0.3

...

...

009 9 0.9

010 10 1.0

...

...

099 99 9.9

100 100 10.0

...

...

990 990+ 99.0+

999 Not stated

EXTENSION

00 IN SITU

10 Tumor confined to orbit

40 Diffuse invasion of orbital tissues and/or bony walls

60 Adjacent paranasal sinuses
Cranium

80 FURTHER extension

85 Metastasis

99 UNKNOWN if extension or metastasis

LYMPH NODES

0 No lymph node involvement

1 REGIONAL Lymph Nodes

 Submandibular

 Parotid (preauricular)

 Cervical

 Regional lymph node(s), NOS

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

BRAIN AND CEREBRAL MENINGES
 C70.0, C71.0-C71.9

SIZE OF PRIMARY TUMOR

(from pathology report;
 operative report; radiographic
 report--in priority order.)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU
- 10 Supratentorial tumor confined to
CEREBRAL HEMISPHERE (cerebrum)
 or **MENINGES of CEREBRAL HEMI-
 SPHERE** on one side:
 Frontal lobe
 Temporal lobe
 Parietal lobe
 Occipital lobe
- 11 Infratentorial tumor confined to
CEREBELLUM or **MENINGES of
 CEREBELLUM** on one side:
 Vermis: Median lobe of
 cerebellum
 Lateral lobes
- 12 Infratentorial tumor confined to
BRAIN STEM or **MENINGES of
 BRAIN STEM** on one side:
 Thalamus, hypothalamus
 Midbrain (mesencephalon)
 Pons
 Medulla oblongata
- 15 Confined to brain, NOS
 Confined to meninges, NOS
- 20 Infratentorial tumor:
Both cerebellum and brain stem
 involved WITH tumor on one side
- 30 Confined to ventricles or
 tumor invades or encroaches
 upon ventricular system
- 40 Tumor crosses the midline,
 involves corpus callosum (incl.
 splenium), or contralateral
 hemisphere
- 50 Supratentorial tumor extends
 infratentorially to involve
 cerebellum or brain stem
- 51 Infratentorial tumor extends
 supratentorially to involve
 cerebrum (cerebral hemisphere)

BRAIN AND CEREBRAL MENINGES
C70.0, C71.0-C71.9

EXTENSION (cont'd)

LYMPH NODES

- 60 Tumor invades:
 Bone (skull)
 Meninges (dura)
 Major blood vessel(s)
 Nerves--cranial nerves;
 spinal cord/canal
- 70 Extension to:
 Nasopharynx
 Posterior pharynx
 Nasal cavity
 Outside central nervous
 system (CNS)
 Circulating cells in cerebral
 spinal fluid (CSF)
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension
 or metastasis

- 9 Not Applicable

OTHER PARTS OF CENTRAL NERVOUS SYSTEM
C70.1, C70.9, C72.0-C72.5, C72.8-C72.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; radiographic report--in priority order)

EXTENSION

000	No mass; no tumor found	30	Localized, NOS
001	Microscopic focus or foci only	40	Meningeal tumor infiltrates nerve
			Nerve tumor infiltrates meninges (dura)
	<u>mm</u>	<u>cm</u>	
002	≤2	≤0.2	
003	3	0.3	
...			
009	9	0.9	
010	10	1.0	
...			
099	99	9.9	
100	100	10.0	
...			
990	990+	99.0+	
999	Not stated		
		50	Adjacent connective/soft tissue
			Adjacent muscle
		60	Major blood vessel(s)
			Sphenoid and frontal sinuses (skull)
			Brain, for cranial nerve tumors
		70	Brain, except for cranial nerve tumors
			Eye
			Bone, other than skull
		80	FURTHER extension
		85	Metastasis
		99	UNKNOWN if extension or metastasis

**OTHER PARTS OF CENTRAL NERVOUS SYSTEM
C70.1, C70.9, C72.0-C72.5, C72.8-C72.9**

LYMPH NODES

9 Not Applicable

THYROID GLAND
C73.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; radiographic report; physical examination--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

mm cm

002 ≤2 ≤0.2

003 3 0.3

...

...

009 9 0.9

010 10 1.0

...

...

099 99 9.9

100 100 10.0

...

...

990 990+ 99.0+

999 Not stated

EXTENSION

00 IN SITU: Noninvasive

10 Single invasive tumor confined to thyroid

20 Multiple foci confined to thyroid

30 Localized, NOS

40 Into thyroid capsule, but not beyond

50 Pericapsular soft/connective tissue

Parathyroid

Strap muscle(s): Sternothyroid, omohyoid, sternohyoid

Nerves: Recurrent laryngeal, vagus

60 Extension to:

Major blood vessel(s): Carotid artery, thyroid artery or vein, jugular vein

Sternocleidomastoid muscle

Esophagus

Larynx, incl. thyroid and cricoid cartilages

Tumor is described as "FIXED to adjacent tissues"

70 Trachea

Skeletal muscle, other than strap or sternocleidomastoid muscle

Bone

80 FURTHER extension

85 Metastasis

99 UNKNOWN if extension or metastasis

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Delphian node
Anterior cervical:
 prelaryngeal, laterotracheal,
 pretracheal (recurrent laryn-
 geal nerve chain)
Internal jugular (upper, middle, and lower deep cervical):
 Jugulodigastric
 Jugulo-omohyoid
Retropharyngeal
Cervical, NOS

1 Ipsilateral cervical nodes

2 Bilateral, contralateral, or
 midline cervical nodes

3 Tracheoesophageal (posterior mediastinal)
 Upper anterior mediastinal
 Mediastinal, NOS

5 Regional lymph node(s), NOS

DISTANT Lymph Nodes

6 Submandibular (submaxillary)
 Submental

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

THYMUS, ADRENAL GLAND, AND OTHER ENDOCRINE GLANDS
C37.9, C74.0-C74.1, C74.9, C75.0-C75.5, C75.8-C75.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+

999 Not stated

EXTENSION

00 IN SITU: Noninvasive
 10 Invasive carcinoma confined to gland of origin
 30 Localized, NOS
 40 Adjacent connective tissue
 60 Adjacent organs/structures
 80 FURTHER extension
 85 Metastasis
 99 UNKNOWN if extension or metastasis

THYMUS, ADRENAL GLAND, AND OTHER ENDOCRINE GLANDS
C37.9, C74.0-C74.1, C74.9, C75.0-C75.5, C75.8-C75.9

LYMPH NODES

- 0 No lymph node involvement

- 1 REGIONAL Lymph Nodes

- 7 DISTANT Lymph Nodes

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

**KAPOSI'S SARCOMA OF ALL SITES
(M-9140)**

ASSOCIATED WITH HIV*/AIDS

001 Yes/Present
002 No

999 Unknown

EXTENSION

SINGLE LESION

11 Skin

12 Mucosa (e.g., oral cavity,
anus, rectum, vagina, vulva)

13 Visceral (e.g., pulmonary,
gastrointestinal tract,
spleen, other)

MULTIPLE LESIONS

21 Skin

22 Mucosa (e.g., oral cavity,
anus, rectum, vagina, vulva)

23 Visceral (e.g., pulmonary,
gastrointestinal tract,
spleen, other)

24 (21) plus (22)

25 (21) plus (23)

26 (22) plus (23)

27 (21) plus (22) plus (23)

29 Multiple lesions, NOS

99 UNKNOWN; not stated

* Synonyms are HTLV-3 and LAV.

**KAPOSI'S SARCOMA OF ALL SITES
(M-9140)**

LYMPH NODES

0 No lymph node involvement (No clinical adenopathy and either pathologically negative or no pathological statement)

Lymph Nodes

1 Clinically enlarged palpable lymph node(s) (adenopathy), and either pathologically negative nodes or no pathological statement

2 No clinically enlarged palpable lymph nodes(s) (adenopathy); pathologically positive lymph node(s)

3 Both clinically enlarged palpable lymph node(s) (adenopathy) and pathologically positive lymph nodes

9 UNKNOWN; not stated

RETINOBLASTOMA
(M-9510-9512)

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; radiographic report; physical examination--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

10 Tumor(s) ≤25% of retina
12 Tumor(s) >25% - ≤50% of retina
15 Tumors >50% of retina
30 Tumor(s) confined to retina, NOS
40 Tumor cells in the vitreous body
45 Optic disc involved
48 Optic nerve as far as lamina cribrosa
50 Anterior chamber Uvea
55 Intrasccleral invasion
60 Intraocular extension, NOS
70 Optic nerve beyond lamina cribrosa
72 Optic nerve, NOS
75 Other adjacent extraocular extension
80 FURTHER extension
85 Metastasis
99 UNKNOWN if extension or metastasis

**RETINOBLASTOMA
(M-9510-9512)**

LYMPH NODES

0 No lymph node involvement

1 REGIONAL Lymph Nodes

Submandibular

Parotid (preauricular)

Cervical

Regional lymph node(s), NOS

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

HODGKIN'S DISEASE AND NON-HODGKIN'S LYMPHOMA OF ALL SITES
(excl. Mycosis Fungoides and Sezary's Disease)
(M-9590-9595, 9650-9698, 9702-9714)

ASSOCIATED WITH HIV*/AIDS**

- 001 Yes/Present
- 002 No
- 999 Unknown

Note 1: E = Extralymphatic means other than lymph nodes and other lymphatic structures.

These lymphatic structures include spleen, thymus gland, Waldeyer's ring (tonsils), Peyer's patches (ileum) and lymphoid nodules in the appendix.

Any lymphatic structure is to be coded the same as a lymph node region.

Note 2: S = Spleen involvement

Note 3: If there is no mention of extranodal involvement but several diagnostic procedures were done, including laparotomy, interpret as no involvement.

Note 4: Involvement of adjacent soft tissue does not alter the classification.

* Synonyms are HTLV-3 and LAV.

** See Appendix A for cases diagnosed prior to 1990.

EXTENSION

- 10 Involvement of a single lymph node region
Stage I
- 11 Localized involvement of a single extralymphatic organ or site
Stage IE
- 20 Involvement of two or more lymph node regions on the same side of the diaphragm
Stage II
- 21 Localized involvement of a single extralymphatic organ or site and its regional lymph node(s) on the same side of the diaphragm with or without involvement of other lymph node regions on the same side of the diaphragm
Stage IIE
- 30 Involvement of lymph node regions on both sides of the diaphragm
Stage III
- 31 (30) plus localized involvement of an extralymphatic organ or site
Stage IIIIE
- 32 (30) plus involvement of the spleen
Stage IIIS
- 33 (31) + (32)
Stage IIIIES
- 80 Disseminated (multifocal) involvement of one or more extralymphatic organ(s)
Stage IV
- 99 UNSTAGED; not stated

HODGKIN'S DISEASE AND NON-HODGKIN'S LYMPHOMA OF ALL SITES
(excl. Mycosis Fungoides and Sezary's Disease)
(M-9590-9595, 9650-9698, 9702-9714)

SYSTEMIC SYMPTOMS AT DIAGNOSIS

0 No B symptoms (Asymptomatic)

1 Any B symptom:
 Night sweats
 Unexplained fever (above 38° C)
 Unexplained weight loss (gen-
 erally >10% loss of body
 weight in the six months
 before admission)
 B symptoms, NOS

2 Pruritus (if recurrent and
 unexplained)

3 1 plus 2

9 UNKNOWN if symptoms; insufficient
 information

**HEMATOPOIETIC, RETICULOENDOTHELIAL, IMMUNOPROLIFERATIVE,
and MYELOPROLIFERATIVE NEOPLASMS**
(M-9720, 9722-9723, 9731-9732, 9760-9768, 9800-9941, 9950-9989)

SIZE OF PRIMARY TUMOR

EXTENSION

999 Not applicable

10 Localized disease: **Solitary
plasmacytoma only**

80 Systemic Disease: All others

This scheme includes the following*:

- 9720 = Malignant histiocytosis
- 9722 = Letterer-Siwe's disease
- 9723 = True histiocytic lymphoma
- 9731 = Plasmacytoma, NOS
- 9732 = Multiple myeloma
- 9760 = Immunoproliferative disease, NOS
- 9761 = Waldenstrom's macroglobulinemia
- 9762 = Alpha heavy chain disease
- 9763 = Gamma heavy chain disease
- 9764 = Immunoproliferative small intestinal disease
- 9765 = Malignant monoclonal gammopathy
- 9766 = Malignant angiocentric immunoproliferative lesion
- 9767 = Malignant angioimmunoblastic lymphadenopathy
- 9768 = Malignant T-gamma lymphoproliferative disease
- 9800 = Leukemia, NOS
- 9801 = Acute leukemia, NOS
- 9802 = Subacute leukemia, NOS
- 9803 = Chronic leukemia, NOS
- 9804 = Aleukemic leukemia, NOS
- 9820 = Lymphoid Leukemia, NOS
- 9821 = Acute lymphoblastic leukemia
- 9822 = Subacute lymphoid leukemia
- 9823 = Chronic lymphocytic leukemia
- 9824 = Aleukemic lymphoid leukemia
- 9825 = Prolymphocytic leukemia
- 9826 = Burkitt's cell leukemia
- 9827 = Adult T-cell leukemia/lymphoma
- 9830 = Plasma cell leukemia
- 9840 = Erythroleukemia
- 9841 = Acute erythremia
- 9842 = Chronic erythremia
- 9850 = Lymphosarcoma cell leukemia
- 9860 = Myeloid leukemia, NOS
- 9861 = Acute myeloid leukemia
- 9862 = Subacute myeloid leukemia

* Only preferred terms from ICD-0 are given

**HEMATOPOIETIC, RETICULOENDOTHELIAL, IMMUNOPROLIFERATIVE,
AND MYELOPROLIFERATIVE NEOPLASMS**
(M-9720, 9722-9723, 9731-9732, 9760-9768, 9800-9941, 9950-9989)

LYMPH NODES

9 Not applicable

- 9863 = Chronic myeloid leukemia
- 9864 = Aleukemic myeloid leukemia
- 9866 = Acute promyelocytic leukemia
- 9867 = Acute myelomonocytic leukemia
- 9868 = Chronic myelomonocytic leukemia
- 9870 = Basophilic leukemia
- 9880 = Eosinophilic leukemia
- 9890 = Monocytic leukemia, NOS
- 9891 = Acute monocytic leukemia
- 9892 = Subacute monocytic leukemia
- 9893 = Chronic monocytic leukemia
- 9894 = Aleukemic monocytic leukemia
- 9900 = Mast cell leukemia
- 9910 = Acute megakaryoblastic leukemia
- 9930 = Myeloid sarcoma
- 9931 = Acute panmyelosis
- 9932 = Acute myelofibrosis
- 9940 = Hairy cell leukemia
- 9941 = Leukemic reticuloendotheliosis
- 9950 = Malignant polycythemia (rubra) vera
- 9960 = Malignant myeloproliferative disease, NOS
- 9961 = Malignant myelosclerosis with myeloid metaplasia
- 9962 = Malignant idiopathic/essential (hemorrhagic)
thrombocytopenia
- 9970 = Malignant lymphoproliferative disease, NOS
- 9980 = Malignant refractory anemia, NOS
- 9981 = Malignant refractory anemia without sideroblasts
- 9982 = Malignant refractory anemia with sideroblasts
- 9983 = Malignant refractory anemia with excess of blasts
- 9984 = Malignant refractory anemia with excess of blasts
with transformation
- 9989 = Malignant myelodysplastic syndrome, NOS

OTHER AND ILL-DEFINED SITES, UNKNOWN PRIMARY SITE

C76.0-C76.5, C76.7-C76.8, C80.9

C42._ and C77._, Other than hematopoietic, reticuloendothelial,
immunoproliferative and myeloproliferative neoplasms,
Hodgkin's disease and non-Hodgkin's lymphoma, and
Kaposi's sarcoma

SIZE OF PRIMARY TUMOR

EXTENSION

999 Not applicable

99 Not Applicable

OTHER AND ILL-DEFINED SITES, UNKNOWN PRIMARY SITE

C76.0-C76.5, C76.7-C76.8, C80.9

C42._ and C77._, Other than hematopoietic, reticuloendothelial,
immunoproliferative and myeloproliferative neoplasms,
Hodgkin's disease and non-Hodgkin's lymphoma, and
Kaposi's sarcoma

LYMPH NODES

9 Not Applicable

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

As questions arise, answers sometimes necessitate modification of the codes and/or definitions which are then expanded, pared down or otherwise clarified. When a change is made, its impact is evaluated; if it appears that many cases will be affected and/or problems will arise in the analysis of the data, all cases previously entered in the data base (diagnosed 1988 or later) are reviewed and recoded. The following are examples of changes and the rationale which determines the need for review.

1. The addition of "Facial muscle, NOS" to code 55 for Gum and Retromolar Area clarifies the original definition of "Subcutaneous soft tissue of the face" but does not alter the definition. Thus this change should have no effect on previously coded cases.
2. Although the addition of "Submental" to the list of regional lymph nodes for Base of Tongue and Lingual Tonsil alters the definition, no review was required because few, if any, cases were felt to be affected. (Review in such an instance is not cost effective.)
3. For Lung and Bronchus code 50 "Tumor of/involving main stem bronchus <2.0 cm from carina; or primary in the carina" was split into:

50 Tumor of/involving main stem bronchus <2.0 cm from
carina
55 Primary confined to the carina.

At that time review of all cases coded to primary site C34.0 (includes both main stem bronchus and carina) was required. Although few primaries arise in the carina, the distinction between these and those arising in the main stem bronchus was felt to be important enough to require review.
(Note: In 1992, code 55 was converted to 25.)

Changes, such as examples 1 and 2, are included in this appendix to provide a complete history of changes to the codes and definitions. However if substantial differences are seen in cases coded immediately before and after the change, they may be explained by these definition changes (a coding artifact). Care should be exercised when arriving at any conclusions concerning the observed differences. However for changes where review was required (example 3), one can assume that the same definitions were used to code all cases.

This appendix records all substantive changes that have been made to the definitions and/or codes. (Editorial and format changes are not included.) For each change the following are specified:

- o the original definition
- o the new (modified) definition
- o when the original definition was in effect
- o when the new change became effective
- o what review, if any, was required

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

GENERAL INSTRUCTIONS -- I. TUMOR SIZE

<u>OLD DEFINITION</u>	<u>CURRENT DEFINITION</u>
Effective: 1/1/88 diagnoses	Effective: 7/1/91 (No review of previously coded cases was done.)
Do <u>NOT</u> add pieces or chips together to create a whole; they may not be from the same location, or they may represent only a very small portion of a large tumor. However, if an excisional biopsy is performed, and residual tumor is found at time of resection of the primary, code the size of the excisional biopsy tumor.	Do <u>NOT</u> add pieces or chips together to create a whole; they may not be from the same location, or they may represent only a very small portion of a large tumor. However, if an excisional biopsy is performed and residual tumor at time of resection of the primary is found to be larger than the excisional biopsy, code the size of the residual tumor.

**APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988**

LIP (Vermilion or Labial Mucosa)
C00.0-C00.6, C00.8-C00.9

LYMPH NODES

OLD DEFINITION

Effective: 1/1/88 diagnoses

CURRENT DEFINITION

Effective: 5/15/90 (No review of previously coded cases was done.)

REGIONAL Lymph Nodes

Upper Lip:
 Facial: Buccinator
 Submandibular (submaxillary)
 Parotid: Infra-auricular/pre-auricular

Lower Lip:
 Facial: Mandibular
 Submandibular (submaxillary)
 Submental
 Internal jugular (upper deep cervical):
 Jugulodigastric
 Jugulo-omohyoid
 Cervical, NOS

Commissure: All nodes listed above

Regional lymph node(s), NOS

REGIONAL Lymph Nodes

Facial: Buccinator for upper lip
 Mandibular for lower lip
Parotid: Infra-auricular/pre-auricular for upper lip

Submandibular (submaxillary)
Submental
Internal jugular (upper and lower deep cervical):
 Jugulodigastric
 Jugulo-omohyoid
Cervical, NOS

Regional lymph node(s), NOS

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

BASE OF TONGUE, LINGUAL TONSIL
C01.9, C02.4

LYMPH NODES

OLD DEFINITION

Effective: 1/1/88 diagnoses

CURRENT DEFINITION

Effective: 5/15/90 (No review of
previously coded cases was done.)

REGIONAL Lymph Nodes

Submandibular (submaxillary)
Internal jugular (upper and
lower deep cervical):
 Jugulodigastric
 Jugulo-omohyoid
Cervical, NOS
Regional lymph node(s), NOS

REGIONAL Lymph Nodes

Submandibular (submaxillary)
Submental
Internal jugular (upper and
lower deep cervical):
 Jugulodigastric
 Jugulo-omohyoid
Cervical, NOS
Regional lymph node(s), NOS

**APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988**

GUM (Gingiva), RETROMOLAR AREA
C03.0-C03.1, C03.9, C06.2

EXTENSION

OLD DEFINITION

Effective: 1/1/88 diagnoses

CURRENT DEFINITION

Effective: 5/15/90 (No review of previously coded cases was done.)

55 Subcutaneous soft tissue of face

55 Subcutaneous soft tissue of face
Facial muscle, NOS

LYMPH NODES

OLD DEFINITION

Effective: 1/1/88 diagnoses

CURRENT DEFINITION

Effective: 5/15/90 (No review of previously coded cases was done.)

REGIONAL Lymph Nodes

Facial: Mandibular
Submandibular (submaxillary)
Submental for lower gum
Retropharyngeal for upper gum
Internal jugular (upper and lower deep cervical):
 Jugulodigastric
 Jugulo-omohyoid
Cervical, NOS
Regional lymph node(s), NOS

REGIONAL Lymph Nodes

Facial: Mandibular
Submandibular (submaxillary)
Submental
Retropharyngeal for upper gum
Internal jugular (upper and lower deep cervical):
 Jugulodigastric
 Jugulo-omohyoid
Cervical, NOS
Regional lymph node(s), NOS

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

HARD PALATE
C05.0

EXTENSION

OLD DEFINITION

Effective: 1/1/88 diagnoses

74 Nasal cavity
Maxillary antrum (sinus)

CURRENT DEFINITION

Effective: 5/15/90 (No review of previously coded cases was done.)

74 Nasal cavity
Maxillary antrum (sinus)
Sphenoid bone
Pterygoid plate

LYMPH NODES

OLD DEFINITION

Effective: 1/1/88 diagnoses

REGIONAL Lymph Nodes

Submandibular (submaxillary)
Internal jugular (upper and lower deep cervical):
 Jugulodigastric
 Jugulo-omohyoid
Retropharyngeal
Cervical, NOS
Regional lymph node(s), NOS

CURRENT DEFINITION

Effective: 5/15/90 (No review of previously coded cases was done.)

REGIONAL Lymph Nodes

Submandibular (submaxillary)
Submental
Internal jugular (upper and lower deep cervical):
 Jugulodigastric
 Jugulo-omohyoid
Retropharyngeal
Cervical, NOS
Regional lymph node(s), NOS

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

SOFT PALATE, UVULA
C05.1-C05.2

LYMPH NODES

OLD DEFINITION

Effective: 1/1/88 diagnoses

CURRENT DEFINITION

Effective: 5/15/90 (No review of
previously coded cases was done.)

REGIONAL Lymph Nodes

Submandibular (submaxillary)
Retropharyngeal
Internal jugular (upper and
lower deep cervical):
 Jugulodigastric
 Jugulo-omohyoid
Cervical, NOS
Regional lymph node(s), NOS

REGIONAL Lymph Nodes

Submandibular (submaxillary)
Submental
Retropharyngeal
Internal jugular (upper and
lower deep cervical):
 Jugulodigastric
 Jugulo-omohyoid
Cervical, NOS
Regional lymph node(s), NOS

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

OTHER MOUTH

C05.8-C05.9, C06.8-C06.9

LYMPH NODES

OLD DEFINITION

Effective: 1/1/88 diagnoses

CURRENT DEFINITION

Effective: 5/15/90 (No review of previously coded cases was done.)

REGIONAL Lymph Nodes

Submandibular (submaxillary)
Internal jugular (upper and lower deep cervical):
 Jugulodigastric
 Jugulo-omohyoid
Cervical, NOS
Regional lymph node(s), NOS

REGIONAL Lymph Nodes

Submandibular (submaxillary)
Submental
Internal jugular (upper and lower deep cervical):
 Jugulodigastric
 Jugulo-omohyoid
Cervical, NOS
Regional lymph node(s), NOS

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

CHEEK (Buccal) MUCOSA, VESTIBULE
C06.0-C06.1

LYMPH NODES

OLD DEFINITION

Effective: 1/1/88 diagnoses

CURRENT DEFINITION

Effective: 5/15/90 (No review of
previously coded cases was done.)

REGIONAL Lymph Nodes

Facial: Buccinator, mandibular
Submandibular (submaxillary)
Parotid: Preauricular, infra-
auricular
Internal jugular (upper deep
cervical):
 Jugulodigastric
 Jugulo-omohyoid
Cervical, NOS
Regional lymph node(s), NOS

REGIONAL Lymph Nodes

Facial: Buccinator, mandibular
Submandibular (submaxillary)
Parotid: Preauricular, infra-
auricular
Submental
Internal jugular (upper and
lower deep cervical):
 Jugulodigastric
 Jugulo-omohyoid
Cervical, NOS
Regional lymph node(s), NOS

**APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988**

TONSIL, OROPHARYNX

C09.0-C09.1, C09.8-C09.9, C10.0-C10.4, C10.8-C10.9

EXTENSION

<u>OLD DEFINITION</u>	<u>CURRENT DEFINITION</u>
Effective: 1/1/88 diagnoses	Effective: 1/1/88 diagnoses. Change made 5/88. No review needed.
70 Bone Extrinsic muscles: Mylohyoid, hyoglossus, styloglossus	70 Bone Extrinsic muscles of tongue: Mylohyoid, hyoglossus, styloglossus

EXTENSION

<u>OLD DEFINITION</u>	<u>CURRENT DEFINITION</u>
Effective: 1/1/88 diagnoses	Effective: Change made 1/89. No review needed.
10 Invasive tumor confined to one of the following subsites: Anterior wall (incl. valle- cula) One lateral wall Posterior wall	10 Invasive tumor confined to one of the following subsites: Anterior wall (incl. valle- cula and lingual (anter- ior) surface of epiglottis) One lateral wall Posterior wall
40 Soft palate, inferior surface, incl. uvula	40 Soft palate, inferior surface, incl. uvula, or soft palate, NOS
50 Base of tongue Larynx, laryngeal (posterior) surface of epiglottis, or larynx, NOS Floor of mouth Gum (gingiva) Buccal mucosa (inner cheek)	50 Base of tongue Laryngeal (posterior) surface of epiglottis, or larynx, NOS Floor of mouth Gum (gingiva) Buccal mucosa (inner cheek)
60 Prevertebral fascia Soft tissue of neck	60 Prevertebral fascia or muscle Soft tissue of neck

(continued)

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

TONSIL, OROPHARYNX (continued)
C09.0-C09.1, C09.8-C09.9, C10.0-C10.4, C10.8-C10.9

LYMPH NODES

OLD DEFINITION

Effective: 1/1/88 diagnoses

CURRENT DEFINITION

Effective: 5/15/90 (No review of
previously coded cases was done.)

REGIONAL Lymph Nodes

Retropharyngeal
Internal jugular (upper and
lower deep cervical):
 Jugulodigastric
 Jugulo-omohyoid
Cervical, NOS
Regional lymph node(s), NOS

REGIONAL Lymph Nodes

Retropharyngeal
Submandibular (submaxillary)
Submental
Internal jugular (upper and
lower deep cervical):
 Jugulodigastric
 Jugulo-omohyoid
Cervical, NOS
Regional lymph node(s), NOS

**APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988**

NASOPHARYNX

C11.0-C11.3, C11.8-C11.9

LYMPH NODES

OLD DEFINITION

Effective: 1/1/88 diagnoses

CURRENT DEFINITION

Effective: 5/15/90 (No review of previously coded cases was done.)

REGIONAL Lymph Nodes

Retropharyngeal
Internal jugular (upper and lower deep cervical):
 Jugulodigastric
 Jugulo-omohyoid
Cervical, NOS
Regional lymph node(s), NOS

REGIONAL Lymph Nodes

Retropharyngeal
Submandibular (submaxillary)
Submental
Internal jugular (upper and lower deep cervical):
 Jugulodigastric
 Jugulo-omohyoid
Cervical, NOS
Regional lymph node(s), NOS

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

PYRIFORM SINUS, HYPOPHARYNX, LARYNGOPHARYNX
C12.9, C13.0-C13.2, C13.8-C13.9, C14.1

EXTENSION

<u>OLD DEFINITION</u>	<u>CURRENT DEFINITION</u>
Effective: 1/1/88 diagnoses	Effective: Change made 1/89. No review needed.
50 Larynx Cervical esophagus	50 Larynx Cervical (upper) esophagus

LYMPH NODES

<u>OLD DEFINITION</u>	<u>CURRENT DEFINITION</u>
Effective: 1/1/88 diagnoses	Effective: 5/15/90 (No review of previously coded cases was done.)
REGIONAL Lymph Nodes	REGIONAL Lymph Nodes
Retropharyngeal Internal jugular (upper and lower deep cervical): Jugulodigastric Jugulo-omohyoid Cervical, NOS Regional lymph node(s), NOS	Retropharyngeal Submandibular (submaxillary) Submental Internal jugular (upper and lower deep cervical): Jugulodigastric Jugulo-omohyoid Cervical, NOS Regional lymph node(s), NOS

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

PHARYNX NOS AND OTHER ILL-DEFINED ORAL CAVITY SITES
C14.0, C14.2, C14.8

LYMPH NODES

OLD DEFINITION

Effective: 1/1/88 diagnoses

CURRENT DEFINITION

Effective: 5/15/90 (No review of
previously coded cases was done.)

REGIONAL Lymph Nodes

Submandibular (submaxillary)
Internal jugular (upper and
lower deep cervical):
 Jugulodigastric
 Jugulo-omohyoid
Retropharyngeal
Cervical, NOS
Regional lymph node(s), NOS

REGIONAL Lymph Nodes

Submandibular (submaxillary)
Submental
Internal jugular (upper and
lower deep cervical):
 Jugulodigastric
 Jugulo-omohyoid
Retropharyngeal
Cervical, NOS
Regional lymph node(s), NOS

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

ESOPHAGUS

C15.0-C15.5, C15.8-C15.9

LYMPH NODES

OLD DEFINITION

Effective: 1/1/88 diagnoses

6 Supraclavicular

CURRENT DEFINITION

Effective: Change made 1/1/92.
No review needed.

6 Supraclavicular
Scalene

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

STOMACH

C16.0-C16.6, C16.8-C16.9

EXTENSION

OLD DEFINITION

Effective: 1/1/88 diagnoses

CURRENT DEFINITION

Effective: 1/1/88 diagnoses

00* IN SITU: Noninvasive;
intraepithelial

00 IN SITU: Noninvasive;
intraepithelial

05 (Adeno)carcinoma in head of
polyp, stalk not invaded

05 (Adeno)carcinoma in a polyp,
noninvasive

* All cases coded using old definition (diagnosed from 1/1/88 to approximately 5/15/90) were reviewed and recoded.

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

SMALL INTESTINE
C17.0-C17.3, C17.8-C17.9

EXTENSION

<u>OLD DEFINITION</u>	<u>CURRENT DEFINITION</u>
Effective: 1/1/88 diagnoses	Effective: 1/1/88 diagnoses
00* IN SITU: Noninvasive; intraepithelial	00 IN SITU: Noninvasive; intraepithelial
05 (Adeno)carcinoma in head of polyp, stalk not invaded	05 (Adeno)carcinoma in a polyp, noninvasive

* All cases coded using old definition (diagnosed from 1/1/88 to approximately 5/15/90) were reviewed and recoded.

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

COLON (incl. Flexures and Appendix)
C18.0-C18.9

EXTENSION

<u>OLD DEFINITION</u>	<u>CURRENT DEFINITION</u>
Effective: 1/1/88 diagnoses	Effective: Changes made 1/89.
10 Mucosa, NOS	10 Invasive tumor confined to: Mucosa, NOS (incl. intramucosal)
45 Extension to adjacent (connective) tissue: Mesentery (incl. mesenteric fat, mesocolon)--transverse Retroperitoneal fat--ascending and descending colon Greater omentum; gastrocolic ligament--transverse colon Pericolic fat	45 Extension to adjacent (connective) tissue: Mesentery (incl. mesenteric fat, mesocolon)-- all colon sites Retroperitoneal fat-- ascending and descending colon Greater omentum; gastrocolic ligament-- transverse colon Pericolic fat-- all colon sites
60 Cecum, appendix, ascending descending, and sigmoid colon: Greater omentum Spleen--descending Pelvic wall--descending/sigmoid Ureter/kidney, R--ascending/cecum L--descending Liver, R lobe--ascending/cecum	60 Greater omentum-- cecum, appendix, ascending, descending and sigmoid colon Spleen-- descending colon Pelvic wall-- descending colon/sigmoid Liver, right lobe-- ascending colon
Transverse colon and flexures: Stomach Spleen; liver Pancreas Gallbladder/bile ducts Kidney	Transverse colon and flexures: Stomach Spleen; liver Pancreas Gallbladder/bile ducts Kidney
Transverse colon and flexures: Stomach Spleen; liver Pancreas Gallbladder/bile ducts Kidney	All colon sites: Small intestine
All colon sites: Small intestine	66 Ureter/kidney Right--ascending colon Left--descending colon

(continued)

**APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988**

COLON (incl. Flexures and Appendix) (continued)
C18.0-C18.9

EXTENSION

<u>OLD DEFINITION</u>	<u>CURRENT DEFINITION</u>
Effective: 1/1/88 diagnoses	Effective: Changes made 1/89.
70 Cecum, appendix, ascending, descending, and sigmoid colon: Uterus Ovary; fallopian tube Cul de sac--sigmoid	70 Cecum, appendix, ascending, descending, and sigmoid colon: Uterus Ovary; fallopian tube
75 Cecum, appendix, ascending, descending, and sigmoid colon: Urinary bladder--cecum/ ascending/sigmoid Gallbladder for cecum/ascending	75 All colon sites Urinary bladder Gallbladder Adrenal gland Diaphragm Other segment(s) of colon via serosa Fistula to skin
Transverse colon and flexures: Ureter Adrenal gland Diaphragm	
All colon sites Other segment of colon via serosa Fistula to skin	(continued)

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

COLON (incl. Flexures and Appendix) (continued)
C18.0-C18.9

EXTENSION

<u>OLD DEFINITION</u>	<u>CURRENT DEFINITION</u>
Effective: 1/1/88 diagnoses	Effective: 1/1/88 diagnoses (see notes below)
00* IN SITU: Noninvasive; intraepithelial	00 IN SITU: Noninvasive; intraepithelial
05 (Adeno)carcinoma in head of polyp, stalk not invaded	05 (Adeno)carcinoma in a polyp, noninvasive
45 Extension to adjacent (connec- tive) tissue: Mesentery (incl. mesenteric fat, mesocolon)--all colon sites Retroperitoneal fat--ascend- ing and descending colon Greater omentum; gastrocolic ligament--transverse colon Pericolic fat--all colon sites	45**Extension to adjacent (connective) tissue: Mesentery (incl. mesenteric fat, mesocolon)--all colon sites Retroperitoneal fat--ascend- ing and descending colon Greater omentum; gastrocolic ligament--transverse colon/flexures Pericolic fat--all colon sites
* All cases coded using old definition (diagnosed from 1/1/88 to approximately 5/15/90) were reviewed and recoded.	
** Effective: 5/15/90 (No review of previously coded cases was done.)	

EXTENSION

<u>OLD DEFINITION</u>	<u>CURRENT DEFINITION</u>
Effective: 1/1/88 diagnoses	Effective: Change made 1/1/92. No review of cases needed.
75 All colon sites:	75 All colon sites unless otherwise stated above:

LYMPH NODES

<u>OLD DEFINITION</u>	<u>CURRENT DEFINITION</u>
Effective: 1/1/88 diagnoses	Effective: Change made 1/1/92. No review of cases needed.
7 Other than above	7 Other than above, incl. superior mesenteric

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

RECTOSIGMOID, RECTUM
C19.9, C20.9

EXTENSION

OLD DEFINITION

Effective: 1/1/88 diagnoses

00* IN SITU: Noninvasive;
intraepithelial

05 (Adeno)carcinoma in head of
polyp, stalk not invaded

CURRENT DEFINITION

Effective: 1/1/88 diagnoses

00 IN SITU: Noninvasive;
intraepithelial

05 (Adeno)carcinoma in a polyp,
noninvasive

* All cases coded using old definition (diagnosed from 1/1/88 to approximately 5/15/90) were reviewed and recoded.

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

LIVER AND INTRAHEPATIC BILE DUCTS
C22.0-C22.1

EXTENSION

<u>OLD DEFINITION</u>	<u>CURRENT DEFINITION</u>
Effective : 1/1/88 diagnoses	Effective: Change made 5/88.
70 Extension to: Extrahepatic bile duct(s) Diaphragm Pleura	70 Extension to: Extrahepatic bile duct(s) Diaphragm

<u>OLD DEFINITION</u>	<u>CURRENT DEFINITION</u>
Effective: 1/1/88 diagnoses	Effective: Change made 1/89.
20 Single lesion (one lobe) WITH intrahepatic vascular invasion, incl. NOS	20 Single lesion (one lobe) WITH intrahepatic vascular invasion

LYMPH NODES

<u>OLD DEFINITION</u>	<u>CURRENT DEFINITION</u>
Effective: 1/1/88 diagnoses	Effective: 1/1/88 diagnoses. Change made 1/1/92. Cases coded using old definition of code 5 were converted to code 1.
1 Hepatic: Hepatic pedicle, inferior vena cava, hepatic artery, porta hepatis (hilar)	1 Hepatic: Hepatic pedicle, inferior vena cava, hepatic artery, porta hepatis (hilar)
5 Regional lymph node(s), NOS	Regional lymph node(s), NOS

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

GALLBLADDER, OTHER BILIARY, AND BILIARY NOS
C23.9, C24.8-C24.9

LYMPH NODES

OLD DEFINITION

Effective: 1/1/88 diagnoses

- 2 Hepatic: Periportal,
periduodenal, peripancreatic
(near head of pancreas only)

CURRENT DEFINITION

Effective: Change made 1/1/92.
No review of cases needed.

- 2 Periportal
Periduodenal
Peripancreatic (near head of
pancreas only)

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

EXTRAHEPATIC BILE DUCT(S)
C24.0

LYMPH NODES

OLD DEFINITION

Effective: 1/1/88 diagnoses

2 Hepatic: Periportal,
periduodenal, peripancreatic
(near head of pancreas only)

CURRENT DEFINITION

Effective: Change made 1/1/92.
No review of cases needed.

2 Periportal
Periduodenal
Peripancreatic (near head of
pancreas only)

**APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988**

**AMPULLA OF VATER
C24.1**

EXTENSION

<u>OLD DEFINITION</u>	<u>CURRENT DEFINITION</u>
Effective: 1/1/88 diagnoses	Effective: 1/1/88 diagnoses
40* Duodenum Extrahepatic bile ducts	40 Duodenum and/or distal common duct
50 Tumor invasion into pancreas, incl. pancreatic duct, ≤ 2 cm	50 Tumor invasion into pancreas, incl. pancreatic duct, ≤ 2 cm and/or common duct, ≤ 2 cm
60 Tumor invasion into pancreas >2 cm	55 Pancreas, NOS and/or common duct, NOS
	60 Tumor invasion into pancreas >2 cm and/or common duct, >2 cm
	65 Extrahepatic bile ducts
* All cases coded using old definitions (diagnosed from 1/1/88 forward) were reviewed and recoded.	

**APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988**

**PANCREAS: HEAD, BODY, AND TAIL
C25.0-C25.4**

EXTENSION

<u>OLD DEFINITION</u>	<u>CURRENT DEFINITION</u>
Effective: 1/1/88 diagnoses	Effective: 1/1/91 diagnoses (Prior cases were not reviewed and recoded.)
45 Extrahepatic bile ducts (includes external right and left hepatic ducts, common hepatic duct, and common bile duct) Ampulla of Vater Duodenum	44 Head of pancreas: Extrahepatic bile ducts (incl. external right and left hepatic ducts, common hepatic duct, and common bile duct) Ampulla of Vater Duodenum
60 Head of pancreas: Stomach Body and/or tail of pancreas: Left kidney; kidney, NOS Left ureter Spleen Left adrenal (suprarenal) gland Retroperitoneal soft tissue (retroperitoneal space)	Body and/or tail of pancreas: Duodenum 48 Body and/or tail of pancreas: Extrahepatic bile ducts (incl. external right and left hepatic ducts, common hepatic duct, and common bile duct) Ampulla of Vater
65 Head of pancreas: Major blood vessel(s): Hepatic pancreaticoduodenal and/or gastroduodenal arteries, superior mesenteric artery/vein, portal vein Transverse colon, incl. hepatic portal vein Peritoneum, mesentery, mesocolon, mesenteric fat Greater/lesser omentum Body and/or tail of pancreas: Splenic flexure Ileum and jejunum Peritoneum, mesentery, mesocolon, mesenteric fat Major blood vessel(s): Aorta, celiac artery, hepatic artery, splenic artery/vein, superior mesenteric artery/vein, portal vein (continued)	50 Head of pancreas: Adjacent stomach Stomach, NOS Body and/or tail of pancreas: Spleen 52 Head of pancreas: Body of stomach 54 Head of pancreas: Major blood vessel(s): Hepatic, pancreaticoduodenal and/or gastroduodenal arteries, superior mesenteric artery/vein, portal vein Transverse colon, incl. hepatic flexure 56 Body and/or tail of pancreas: Splenic flexure Major blood vessel(s): Aortic, celiac artery, hepatic artery, splenic artery/vein, superior mesenteric artery/vein, portal vein (continued)

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

PANCREAS: HEAD, BODY, AND TAIL (continued)
C25.0-C25.4

EXTENSION

<u>OLD DEFINITION</u> Effective: 1/1/88 diagnoses	<u>CURRENT DEFINITION</u> Effective: 1/1/91 diagnoses (Prior cases were not reviewed and recoded.)
66 Stomach from body and tail	62 Body and/or tail of pancreas: Stomach
67 Liver (incl. porta hepatis) Gallbladder	64 Head of pancreas: Large intestine (other than transverse colon incl. hepatic flexure) Spleen
70 Head of pancreas Kidney Ureter Adrenal gland Retroperitoneum Jejunum Ileum	Body and/or tail of pancreas: Large intestine (other than splenic flexure)
Body and/or tail of pancreas Right kidney/right ureter Right adrenal gland Diaphragm Large intestine (other than splenic flexure	72 Body and/or tail of pancreas: Left kidney; kidney, NOS; left ureter; left adrenal (suprarenal) gland; retro- peritoneal soft tissue (retroperitoneal space)
	74 Head of pancreas: Peritoneum, mesentery, mesocolon, mesenteric fat Greater/lesser omentum
	Body and/or tail of pancreas: Ileum and jejunum Peritoneum, mesentery, mesocolon, mesenteric fat
	76 Liver (incl. porta hepatis); gallbladder
	78 Head of pancreas: Kidney; ure- ter; adrenal gland; retro- peritoneum; jejunum; ileum
	Body and/or tail of pancreas: Right kidney/right ureter; right adrenal gland Diaphragm

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

PANCREAS: OTHER AND UNSPECIFIED
C25.7-C25.9

EXTENSION

<u>OLD DEFINITION</u>	<u>CURRENT DEFINITION</u>
Effective: 1/1/88 diagnoses	Effective: 1/1/91 diagnoses (Prior cases were not reviewed and recoded.)
40 Adjacent connective tissue	40 Peripancreatic tissue
60 Adjacent organ/structures	45 Duodenum Bile ducts Ampulla of Vater
	50 Stomach Spleen Colon Adjacent large vessels

**APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988**

**NASAL CAVITY AND MIDDLE EAR
C30.0-C30.1**

LYMPH NODES

OLD DEFINITION

Effective: 1/1/88 diagnoses

1 REGIONAL Lymph Nodes

CURRENT DEFINITION

Effective: 5/15/90 (No review of
previously coded cases was done.)

1 REGIONAL Lymph Nodes

Submental
Submandibular (submaxillary)
Internal jugular (upper and
lower deep cervical):
 Jugulodigastric
 Jugulo-omohyoid
Retropharyngeal
Cervical, NOS
Regional lymph node(s), NOS

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

MAXILLARY SINUS
C31.0

EXTENSION

<u>OLD DEFINITION</u>	<u>CURRENT DEFINITION</u>
Effective: 1/1/88 diagnoses	Effective: 1/1/88 diagnoses
	65 Invasion of maxilla, NOS
80* FURTHER extension	80 FURTHER extension

* All cases coded using old definition (diagnosed from 1/1/88 to approximately 5/15/90) were reviewed and recoded.

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

LARYNX

C32.0-C32.3, C32.8-C32.9

LYMPH NODES

OLD DEFINITION

Effective: 1/1/88 diagnoses

CURRENT DEFINITION

Effective: 1/1/88 diagnoses

Change made 1/1/92. See note below.*

REGIONAL Lymph Nodes (incl. con-
tralateral or bilateral nodes)

REGIONAL Lymph Nodes (incl. con-
tralateral or bilateral nodes)

Internal jugular (upper and
lower deep cervical) for glottic
and supraglottic:
jugulodigastric
jugulo-omohyoid
Anterior cervical: Prelaryngeal,
pretracheal, paratracheal,
laterotracheal (recurrent
laryngeal)
Submaxillary
Submental
Cervical, NOS

Internal jugular (upper and
lower deep cervical)
Jugulodigastric
Jugulo-omohyoid
Anterior cervical: Prelaryngeal,
pretracheal, paratracheal,
laterotracheal (recurrent
laryngeal)
Submandibular (submaxillary)
Submental
Cervical, NOS

- * All cases primary in subglottic larynx (C32.2) with Lymph Nodes coded 7 (Distant lymph nodes) diagnosed 1/1/88 forward were reviewed and recoded to regional node involvement where necessary.

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

BRONCHUS AND LUNG
C34.0-C34.3, C34.8-C34.9

EXTENSION

<u>OLD DEFINITION</u>	<u>CURRENT DEFINITION</u>
Effective: 1/1/88 diagnoses	Effective: 1/1/88 diagnoses (See note below)
50* Tumor of/involving main stem bronchus <2.0 cm from carina; or primary in the carina	50 Tumor of/involving main stem bronchus <2.0 cm from carina
	55 Primary confined to the carina

* All cases of site C34.0 (includes main stem bronchus and carina) coded using old definition (diagnosed from 1/1/88 to approximately 5/15/90) were reviewed and recoded.

Notes

<u>OLD DEFINITION</u>	<u>CURRENT DEFINITION</u>
Effective: 1/1/88 diagnoses	Effective: 1/1/88 diagnoses
	* Note 7: "Vocal cord paralysis," "superior vena cava syndrome," and "compression of the trachea or the esophagus" are classified as mediastinal lymph node involvement unless there is a statement of involvement by direct extension from the primary tumor.
Note 1: Assume tumor ≥ 2 cm from carina if lobectomy is done.	**Note 1 Assume tumor ≥ 2 cm from carina if lobectomy, segmental resection, or wedge resection is done.

* Note 7 added 1/90.

** Note 1 revised 1/91.

(continued)

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

BRONCHUS AND LUNG (continued)
C34.0-C34.3, C34.8-C34.9

EXTENSION

<u>OLD DEFINITION</u>	<u>CURRENT DEFINITION</u>
Effective: 1/1/88 diagnoses	Effective: 1/1/88 diagnoses. Change made 1/1/92. (See notes below)
55* Primary confined to the carina	25 Primary confined to the carina
70**Carina; trachea; esophagus Mediastinum, extrapulmonary or NOS Major blood vessel(s): Pulmonary artery or vein; superior vena cava (SVC syndrome); aorta	70 Carina; trachea; esophagus Mediastinum, extrapulmonary or NOS Major blood vessel(s): Pulmonary artery or vein; superior vena cava (SVC syndrome); aorta; azygos vein
78**Contralateral lung/MSB	78 Contralateral lung Contralateral MSB

* All cases diagnosed 1/1/88 forward and coded 55 were converted to code 25.

** No review of cases needed.

(continued)

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

BRONCHUS AND LUNG (continued)
C34.0-C34.3, C34.8-C34.9

LYMPH NODES

<u>OLD DEFINITION</u>	<u>CURRENT DEFINITION</u>
Effective: 1/1/88 diagnoses	Effective: 1/1/88 diagnoses. Change made 1/1/92. No review needed.
1 Intrapulmonary Hilar (pulmonary root) Peribronchial	1 Intrapulmonary (incl. interlobar, lobar, segmental) Hilar (proximal lobar) Peribronchial
2 Subcarinal; carinal Mediastinal, anterior, posterior, NOS Paratracheal; pretracheal Paraesophageal Aortic (para-, peri-) (above diaphragm)	2 Subcarinal Carinal Mediastinal, anterior, posterior, NOS Peri/paratracheal (incl. tracheobronchial, lower peritracheal, azygos) Pre- and retrotracheal (incl. precarinal) Peri/paraesophageal Aortic (above diaphragm) (incl. peri/para-aortic, subaortic, aortico-pulmonary window, ascending aorta or phrenic) Pulmonary ligament Pericardial
6 Contralateral hilar or medias- tinal (incl. bilateral) Supraclavicular (transverse cervical) Scalene	6 Contralateral hilar or medias- tinal (incl. bilateral) Supraclavicular (transverse cervical), ipsilateral or contralateral Scalene, ipsilateral or contralateral

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

SKIN (excl. Malignant Melanoma, Kaposi's Sarcoma,
Mycosis Fungoides, Sezary's Disease, and Other Lymphomas)
C44.0-C44.9

EXTENSION

<u>OLD DEFINITION</u>	<u>CURRENT DEFINITION</u>
Effective: 1/1/88 diagnoses	Effective: 1/1/88 diagnoses (see notes below)
10* Lesion(s) confined to dermis For eyelid: Minimal infiltration of dermis (not invading tarsal plate)	10 Lesion(s) confined to dermis For eyelid: Minimal infiltration of dermis (not invading tarsal plate)
20* For eyelid: Infiltrates deeply into dermis (invading tarsal plate)	20 For eyelid: Infiltrates deeply into dermis (invading tarsal plate)
	25 For eyelid: At eyelid margin
60 Adjacent structures for eyelid	60 Adjacent structures for eyelid, incl. orbit
70* Underlying cartilage, bone, skeletal muscle Orbit for eyelid	70 Underlying cartilage, bone, skeletal muscle
* All cases of eyelid (C44.1) coded using old definitions (diagnosed from 1/1/88 to approximately 5/15/90) were reviewed and recoded.	

**APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988**

**MYCOSIS FUNGOIDES AND SEZARY'S DISEASE OF SKIN, VULVA, PENIS, SCROTUM
C44.0-C44.9, C51.0-C51.2, C51.8-C51.9, C60.0-C60.1, C60.8-C60.9, C63.2
(M-9700-9701)**

EXTENSION

<u>OLD DEFINITION</u>	<u>CURRENT DEFINITION</u>
Effective: 1/1/88 diagnoses	Effective: 1/1/88 diagnoses
REGIONAL Lymph Nodes	Lymph Nodes
1 Clinically enlarged palpable regional lymph node(s) (adenopathy), and either pathologically negative regional nodes or no pathological statement	1 Clinically enlarged palpable lymph node(s) (adenopathy), and either pathologically negative nodes or no pathological statement
2 No clinically enlarged palpable regional lymph nodes(s) (adenopathy); pathologically positive regional lymph node(s)	2 No clinically enlarged palpable lymph nodes(s) (adenopathy); pathologically positive lymph node(s)
3 Both clinically enlarged palpable lymph node(s) (adenopathy) and pathologically positive regional lymph nodes	3 Both clinically enlarged palpable lymph node(s) (adenopathy) and pathologically positive lymph nodes
DISTANT Lymph Nodes	
7* Other than above	
8* Lymph Nodes, NOS	
9 UNKNOWN; not stated	9 UNKNOWN; not stated
* All cases coded using old definition (diagnosed from 1/1/88 to approximately 5/15/90) were reviewed and recoded.	

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

BREAST

C50.0-C50.6, C50.8-C50.9

LYMPH NODES

OLD DEFINITION

Effective: 1/1/88 diagnoses

REGIONAL Lymph Nodes (ipsilateral)

Axillary

Level I/low: Adjacent to
tail of breast

Level II/mid: Central, inter-
pectoral, (Rotter's node)

Level III/high: Subclavicular,
apical

Intramammary

Nodule(s) in axillary fat

CURRENT DEFINITION

Effective: 1/1/88 diagnoses

REGIONAL Lymph Nodes (ipsilateral)

Axillary

Level I/low: Adjacent to
tail of breast

Level II/mid: Central, inter-
pectoral, (Rotter's node)

Level III/high: Subclavicular,
apical

Infraclavicular

Intramammary

Nodule(s) in axillary fat

DISTANT Lymph Nodes

8* Cervical, NOS

Contralateral/bilateral axil-
lary and/or internal mammary

Infraclavicular

Supraclavicular (transverse
cervical)

Other than above

DISTANT Lymph Nodes

8 Cervical, NOS

Contralateral/bilateral axillary
and/or internal mammary

Supraclavicular (transverse
cervical)

Other than above

* All cases coded using old definition (diagnosed from 1/1/88 to
approximately 5/15/90) were reviewed and recoded.

LYMPH NODES

OLD DEFINITION

Effective: 1/1/88 diagnoses

Size of largest axillary node,
ipsilateral (codes 1-4):

CURRENT DEFINITION

Effective: 1/1/92 diagnoses

Prior cases were not reviewed.

Size of largest metastasis in
axillary node(s), ipsilateral
(codes 1-4):

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

VAGINA

C52.9

LYMPH NODES

<u>OLD DEFINITION</u>	<u>CURRENT DEFINITION</u>
Effective: 1/1/88 diagnoses	Effective: 1/1/88 diagnoses. Change made 1/1/92. No review needed.
2 Ipsilateral inguinal lymph node(s)	2 Ipsilateral: Inguinal Femoral
3 Bilateral inguinal lymph node(s)	3 Bilateral: Inguinal Femoral

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

CERVIX UTERI

C53.0-C53.1, C53.8-C53.9

EXTENSION

OLD DEFINITION

Effective: 1/1/88 diagnoses

60 Extension to:
 Lower 1/3 of vagina
 Rectal and/or bladder wall
 or NOS
 Bullous edema of bladder
 mucosa
 Ureter, intra- and extramural
FIGO Stage IIIA

CURRENT DEFINITION

Effective: 5/15/90 (No review of
previously coded cases was done.)

60 Extension to:
 Lower 1/3 of vagina; vulva
 Rectal and/or bladder wall
 or NOS
 Bullous edema of bladder
 mucosa
 Ureter, intra- and extramural
FIGO Stage IIIA

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

BODY OF PENIS, OTHER AND UNSPECIFIED MALE GENITAL ORGANS
C60.2, C63.0-C63.2, C63.8-C63.9

LYMPH NODES

OLD DEFINITION

Effective: 1/1/88 diagnoses

- 1 REGIONAL Lymph Nodes
 - External iliac
 - Internal iliac
- 2 Superficial inguinal (femoral)
 - Deep inguinal, Rosenmuller's
 - or Cloquet's node
- Regional lymph nodes, NOS

CURRENT DEFINITION

Effective: Change made 1/1/92.
Prior cases were not reviewed.

- 1 REGIONAL Lymph Nodes
 - External iliac
 - Internal iliac
- 2 Superficial inguinal (femoral)
 - Deep inguinal, Rosenmuller's
 - or Cloquet's node
 - Pelvic, NOS
- Regional lymph nodes, NOS

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

PROSTATE GLAND

C61.9

EXTENSION

OLD DEFINITION

Effective: 1/1/88 diagnoses

25 Multiple nodules confined to prostate--more than one lobe (B)

CURRENT DEFINITION

Effective: 5/15/90 (No review of previously coded cases was done.)

25 Multiple nodules confined to prostate (intracapsular)--more than one lobe (B)

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

BLADDER
C67.0-C67.9

EXTENSION

<u>OLD DEFINITION</u>	<u>CURRENT DEFINITION</u>
Effective: 1/1/88 diagnoses	Effective: 1/1/88 diagnoses. Change made 5/15/90.*
40 Subserosal tissue Perivesical fat	40 Subserosal tissue Perivesical fat/tissue Periureteral fat/tissue

Note 4: Periureteral in code 40 refers only to that portion of the ureter that is intramural to the bladder. All other periureteral involvement would be coded to 60.

* All cases diagnosed 1/1/88 to approximately 5/15/90 and coded 60 were reviewed and recoded as necessary.

<u>OLD DEFINITION</u>	<u>CURRENT DEFINITION</u>
Effective: 1/1/88 diagnoses	Effective: Change made 1/1/92. No review required.
00 Sessile carcinoma-IN SITU; Carcinoma-IN SITU, NOS	00 Sessile (flat) carcinoma -IN SITU; Carcinoma-IN SITU, NOS

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

URETHRA, PARAURETHRAL GLAND
C68.0-C68.1

EXTENSION

<u>OLD DEFINITION</u>	<u>CURRENT DEFINITION</u>
Effective: 1/1/88 diagnoses	Effective: 1/1/88 diagnoses
60* Corpus cavernosum Vagina Bladder neck Seminal vesicle(s)	60 Beyond the prostatic capsule Corpus cavernosum Vagina, anterior or NOS Bladder neck
70* Other adjacent organs	70 Other adjacent organs, incl. seminal vesicle(s)

* All cases coded using old definition (diagnosed from 1/1/88 forward) were reviewed and recoded.

**APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988**

EYE AND LACRIMAL GLAND*
C69.0-C69.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; radiographic report;
physical examination--in priority order)

	<u>OLD DEFINITION</u>		<u>CURRENT DEFINITION</u>
	Effective: 1/1/88 diagnoses		Effective: 1/1/88 diagnoses
000	No mass; no tumor found		
001	Microscopic focus or foci only		
	<u>mm</u>	<u>cm</u>	
002	≤2	≤0.2	Changed only for malignant melanoma of the conjunctiva (C69.0, M-8720-8790) (see page 182)
003	3	0.3	
...			
...			
009	9	0.9	
010	10	1.0	
...			
...			
099	99	9.9	
100	100	10.0	
...			
...			
990	990+	99.0+	
999	Not stated		

EXTENSION

	<u>OLD DEFINITION</u>	<u>CURRENT DEFINITION</u>
	Effective: 1/1/88 diagnoses	Effective: 1/1/88 diagnoses
00	IN SITU	Replaced with individual schemes for each of the following (see code manual for codes):
10	Tumor confined to conjunctiva	
40	Intraocular extension	C69.0 Conjunctiva
50	Adjacent extraocular extension, excluding orbit	C69.0 Malignant Melanoma of Conjunctiva (M-8720-8790)
70	Orbit	C69.1-C69.4, C69.8-C69.9 Uvea and Other Eye
80	FURTHER extension	C69.1-C69.4, C69.8-C69.9 Malignant Melanoma of Uvea and Other Eye (M-8720-8790)
85	Metastasis	C69.5 Lacrimal Gland
99	UNKNOWN if extension or metastasis	C69.6 Orbit NOS
		Retinoblastoma (M-9510-9512)

* All cases (diagnosed 1/1/88 to approximately 5/15/90) were reviewed and recoded. (continued)

**APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988**

EYE AND LACRIMAL GLAND (continued)
C69.1-C69.9

LYMPH NODES

<u>OLD DEFINITION</u>	<u>CURRENT DEFINITION</u>
Effective: 1/1/88 diagnoses	Effective: 5/15/90 (No review of previously coded cases was done.)
0 No lymph node involvement	0 No lymph node involvement
-----	-----
1 REGIONAL Lymph Nodes	1 REGIONAL Lymph Nodes
Submandibular nodes	Submandibular
Parotid (preauricular) nodes	Parotid (preauricular)
Upper cervical	Cervical
Regional lymph node(s), NOS	Regional lymph node(s), NOS
-----	-----
7 DISTANT Lymph Nodes	DISTANT Lymph Nodes
	7 Other than above
-----	-----
8 Lymph Nodes, NOS	8 Lymph Nodes, NOS
9 UNKNOWN; not stated	9 UNKNOWN; not stated

**APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988**

MALIGNANT MELANOMA OF CONJUNCTIVA**
C69.0
(M-8720-8790)

<u>OLD DEFINITION</u>			<u>CURRENT DEFINITION</u>	
Effective: 1/1/88 diagnoses			Effective: 1/1/88 diagnoses	
<u>SIZE OF PRIMARY TUMOR</u>			<u>MEASURED THICKNESS (Depth)* of TUMOR (Breslow's measurement)</u>	
(from pathology report; operative report; radiographic report; physical examination--in priority order)			<u>Record actual measurement (in mm) from Pathology Department</u>	
000	No mass; no tumor found		000	No mass; no tumor found
001	Microscopic focus or foci only			
	<u>mm</u>	<u>cm</u>		<u>mm</u>
002	≤2	≤0.2	001	0.01
003	3	0.3	002	0.02
...			...	
...			...	
009	9	0.9	074	0.74
010	10	1.0	075	0.75
...			076	0.76
...			...	
099	99	9.9	...	
100	100	10.0	103	1.03
...			104	1.04
...			105	1.05
990	990+	99.0+	...	
...			...	
999	Not stated		990	9.90+
			...	
			999	Not stated

*Thickness, NOT size, is coded.

** All cases (diagnosed 1/1/88 to approximately 5/15/90) were reviewed and recoded.

**APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988**

**BRAIN AND CEREBRAL MENINGES
C70.0, C71.0-C71.9***

<u>OLD DEFINITION</u> Effective: 1/1/88 diagnoses	<u>CURRENT DEFINITION</u> Effective: 1/1/88 diagnoses
10 Supratentorial tumor confined to CEREBRAL HEMISPHERE (cerebrum) on one side: Frontal lobe Temporal lobe Parietal lobe Occipital lobe	10 Supratentorial tumor confined to CEREBRAL HEMISPHERE (cerebrum) or MENINGES of CEREBRAL HEMI- SPHERE on one side: Frontal lobe Temporal lobe Parietal lobe Occipital lobe
11 Infratentorial tumor confined to CEREBELLUM on one side: Vermis: Median lobe of cerebellum Lateral lobes	11 Infratentorial tumor confined to CEREBELLUM or MENINGES of CEREBELLUM on one side: Vermis: Median lobe of cerebellum Lateral lobes
12 Infratentorial tumor confined to BRAIN STEM on one side: Thalamus, hypothalamus Midbrain (mesencephalon) Pons Medulla oblongata	12 Infratentorial tumor confined to BRAIN STEM or MENINGES of BRAIN STEM on one side: Thalamus, hypothalamus Midbrain (mesencephalon) Pons Medulla oblongata
	15 Confined to meninges, NOS
30 Confined to ventricles or tumor invades or encroaches upon ventricular system	30 Confined to ventricles or tumor invades or encroaches upon ventricular system
60 Tumor invades: Bone (skull) Meninges (dura) Major blood vessel(s) Nerves--cranial nerves; spinal cord/canal	60 Tumor invades: Bone (skull) Meninges (dura) Major blood vessel(s) Nerves--cranial nerves; spinal cord/canal
* All cases of cerebral meninges (C70.0) (diagnosed 1/1/88 to approximately 5/15/90) were reviewed and recoded.	

<u>OLD DEFINITION</u> Effective: 1/1/88 diagnoses	<u>CURRENT DEFINITION</u> Effective: 7/1/91 (No review of previously coded cases was done.)
15 Confined to meninges, NOS	15 Confined to brain, NOS Confined to meninges, NOS

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

THYROID GLAND
C73.9

LYMPH NODES

OLD DEFINITION

Effective: 1/1/88 diagnoses

3 Mediastinal nodes

CURRENT DEFINITION

Effective: Change made 1/1/92.
Prior cases not reviewed and recoded.

3 Tracheoesophageal (posterior
mediastinal
Upper anterior mediastinal
Mediastinal, NOS

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

**KAPOSI'S SARCOMA OF ALL SITES
(M-9140)**

OLD DEFINITION

Effective: 1/1/88 diagnoses

CURRENT DEFINITION

Effective: 5/15/90 (No review of
previously coded cases was done.)

ASSOCIATED WITH HTLV-4 (AIDS)

001 Yes
002 No

999 Unknown

ASSOCIATED WITH HIV*/AIDS

001 Yes/Present
002 No

999 Unknown

* Synonyms are HTLV-3 and LAV.

LYMPH NODES

OLD DEFINITION

Effective: 1/1/88 diagnoses

CURRENT DEFINITION

Effective: 1/1/88 diagnoses
Change made 5/15/90. See below.

REGIONAL Lymph Nodes

- 1 Clinically enlarged palpable regional lymph node(s) (adenopathy), and either pathologically negative regional nodes or no pathological statement
- 2 No clinically enlarged palpable regional lymph nodes(s) (adenopathy); pathologically positive regional lymph node(s)
- 3 Both clinically enlarged palpable lymph node(s) (adenopathy) and pathologically positive regional lymph nodes

Lymph Nodes

- 1 Clinically enlarged palpable lymph node(s) (adenopathy), and either pathologically negative nodes or no pathological statement
- 2 No clinically enlarged palpable lymph nodes(s) (adenopathy); pathologically positive lymph node(s)
- 3 Both clinically enlarged palpable lymph node(s) (adenopathy) and pathologically positive lymph nodes

7* DISTANT Lymph Nodes

8* Lymph Nodes, NOS

9 UNKNOWN; not stated

9 UNKNOWN; not stated

* All cases coded using old definition (diagnosed from 1/1/88 to approximately 5/15/90) were reviewed and recoded.

APPENDIX A
CHANGES TO DEFINITIONS OF EXTENT OF DISEASE -- 1988

HODGKIN'S DISEASE AND NON-HODGKIN'S LYMPHOMA OF ALL SITES
(excl. Mycosis Fungoides and Sezary's Disease)
(M-9590-9595, 9650-9698, 9702-9714)

OLD DEFINITION

All cases diagnosed prior
to 1/1/90 coded to:

999 Not stated

CURRENT DEFINITION

Effective: all cases diagnosed
1/1/90 forward

ASSOCIATED WITH HIV*/AIDS

001 Yes/Present

002 No

999 Unknown

* Synonyms are HTLV-3 and LAV.

EXTENSION

OLD DEFINITION

Effective: 1/1/88 diagnoses

21 Localized involvement of a
single extralymphatic organ
or site and its associated
regional lymph node(s) on
the same side of the dia-
phragm with or without in-
volvement of other lymph
node regions on the same
side of the diaphragm
Stage IIE

31 (30) plus localized involvement
of an associated extralymph-
atic organ or site
Stage IIIIE

CURRENT DEFINITION

Effective: Change made 1/1/92.
Prior cases were not reviewed.

21 Localized involvement of a
single extralymphatic organ
or site and its regional
lymph node(s) on the
same side of the diaphragm
with or without involvement
of other lymph node regions
on the same side of the
diaphragm
Stage IIE

31 (30) plus localized involvement
of an extralymphatic
organ or site
Stage IIIIE

INDEX

- Abdomen, Ill-defined sites, 3, 162
 - Accessory (paranasal) sinuses, 72
 - Acute (differentiated) progressive histiocytosis, 160
 - Acute leukemia
 - Lymphatic, lymphoblastic, lymphocytic, lymphoid, 160
 - Acute myelomonocytic leukemia, 160
 - Adnexa, definition, 108
 - Adrenal gland, 152
 - Alimentary tract, 66
 - Ambiguous term
 - Compatible with, 1
 - Consistent with, 1
 - Equivocal, 1
 - Fixation, 1
 - Induration, 1, 98, 201
 - Possible, 1
 - Probable, 1
 - Questionable, 1
 - Suggests, 1
 - Suspected, 1
 - Suspicious, 1
 - To, into, onto, encroaching, 1
 - Ampulla of Vater, 60, 189
 - Anal canal, 52
 - Anorectum and anorectal junction, 52
 - Anus, NOS, 52
 - Aortic body and other paraganglia, 152
 - Appendix, 48, 182, 183, 184
 - Aryepiglottic fold, 36, 177
 - Ascites
 - Status of capsule code, 110
 - With malignant cells
 - FIGO stage, 110
 - Without malignant cells
 - FIGO stage, 110

 - Back, Ill-defined sites, 3, 162
 - Bartholin's gland, 100
 - Basement membrane, 10, 40, 41, 107, 124, 125
 - Bile ducts, 54, 186
 - Extrahepatic, 58, 188
 - Intrahepatic, 54, 186
 - Biliary tract, Other and NOS, 56, 187
 - Biopsy, code size of excisional, 3
 - Bladder (See urinary bladder.), 124, 125, 130, 206
 - Blast cell leukemia, 160
 - Blood, 160
 - Body of
 - Pancreas, 62, 190, 191
 - Penis, 118, 204
 - Stomach, 44, 180
 - Bone, 86
 - Marrow, 160
 - Pelvic, sacrum, and coccyx, 86
 - Rib, sternum, and clavicle, 86
- (6/92) SEER EOD-88 2nd ed. 215

- Scapula, 86
 - Short and long
 - Upper and lower limbs, 86
 - Shoulder, 86
 - Skull and face, 86
- Brain, 146, 211
 - Other parts of, 146, 211
 - Stem, 146, 211
- Brain tumors, 5
- Breast, 98, 201
 - Diffuse tumor, 3, 98, 201
- Broad ligament(s), 112
- Bronchogenic, 78, 196
- Bronchopneumonia, 78, 196
- Bronchus, 78, 196
- Buccal mucosa, 28, 173
 - Lip, oral cavity, and pharynx, invasive and noninvasive, 11
- Bulbar conjunctiva, 136, 210
- Burkitt's lymphoma, 158, 214

- Cardia of stomach, 44, 180
- Carina, 78, 196
- Carotid body, 152
- Cartilage, articular, 86
- Caruncle, 136, 210
- Cecum, 48, 182, 183, 184
- Cerebellum, 146, 211
- Cerebral meninges, 146, 211
- Cerebrum, 146, 211
- Cervical esophagus, 42, 179
- Cervical stump, 104, 203
- Cervix uteri, 104, 203
- Cheek (buccal) mucosa, 28, 173
- Choroid, 140
- Ciliary body, 140
- Circulating cells in peripheral blood, 92, 200
- Circumference, entire, 3
- Clinical information, 1
- Clitoris, 100
- Cloacogenic zone, 52
- Colon
 - Appendix, 48, 182, 183, 184
 - Ascending, 48, 182, 183, 184
 - Cecum, 48, 182, 183, 184
 - Colon, NOS, 48, 182, 183, 184
 - Descending, 48, 182, 183, 184
 - Flexures, 48, 182, 183, 184
 - Invasive and noninvasive, 40, 41
 - Sigmoid, 48, 182, 183, 184
 - Transverse, 48, 182, 183, 184
- Colorectal, multiple polyposis, 3, 48, 50, 182, 183, 184, 185
- Columnar epithelium, 107
- Commissure of lip, 12, 167
- Confined to the
 - Endometrium (mucosa)
 - Corpus uteri, 107
 - Epithelium, 40, 41, 124
 - Columnar, 107

- Lip, oral cavity, and pharynx, 10
- Mucosa
 - Digestive system, 40, 41
 - Lip, oral cavity, and pharynx, 10
 - Renal pelvis (kidney), 124
 - Ureters, 124
 - Urinary bladder, 124
- Conjunctiva, 134, 136, 208, 209, 210
- Conjunctival fornix, 136, 210
- Connective tissue, 94
- Cooper's ligament(s), 98, 201
- Corpus uteri, 107, 108
 - Invasive and noninvasive, 107
- Cowper's gland, 132, 207
- Cranial nerve, 148
- Cul de sac, 96
- Curvatures of stomach
 - Lesser and greater, 44, 180
- Cyst, code size of tumor, 3

- Death certificate ONLY Codes, 7
- Definition of EOD, 1
- Definitive therapy, 1
- Di Guglielmo's disease, 160
- Diffuse, 3
- Digestive system, 40, 41, 66
 - Ill-defined sites, 3, 66
- Dimpling of skin of breast, 98, 201
- Duodenum, 46, 181

- Endocervix, 104, 203
- Endocrine glands, 152
- Endometrium, 107, 108
- Epididymis, 118, 204
- Epiglottis
 - Anterior surface, 32, 174, 175
 - Lingual (anterior) surface
 - AJCC definition, 32, 174, 175
- Epithelial layer, 40, 41, 124, 125
 - Lip, oral cavity, and pharynx, 10
- Equivalences in units of mm, cm, in, 4
- Erythremia, acute, chronic, 160
- Erythremic myelosis, acute, NOS, 160
- Erythroleukemia, 160
- Esophagus, 42, 179
 - Abdominal, 42, 179
 - Anatomic limits, 42, 179
 - Cervical, 42, 179
 - Intrathoracic (upper, mid, lower), 42, 179
 - Invasive and noninvasive, 40, 41
 - Lower 1/3, 42, 179
 - Middle 1/3, 42, 179
 - Thoracic, 42, 179
 - Tumor entire circumference, 3
- Ethmoid sinus, 72
- Exocervix, 104, 203
- Exploratory/definitive surgery
 - Lymph node, 108

- Extent of disease, 1
 - Autopsy ONLY cases, 1
 - Death certificate ONLY, 1, 7
 - Definition, 5
 - Definitive surgery after
 - Excisional Bx, 3
 - Extension, 5
 - Adjacent organs, 5
 - General instructions, 1
 - Ignore metastasis after diagnosis, 1
 - Limitations, 1
 - Lymph nodes, 5
 - Metastasis to distant sites, 5
 - Size, 3
 - Equivalences in mm, cm, in, 4
 - Surgical cases pretreated by radiation, 1
 - System identification, 1
 - Time limit for EOD, 1
 - Within organ, 5
- External Ear
 - Skin of, 88, 199
- Extrahepatic bile ducts, 58, 188
- Extramedullary plasmacytoma, 160
- Extranodal sites, lymphoma, 158, 214
- Extraocular extension, 134, 138, 156, 208, 209
- Extremities
 - Skin of arms, shoulder, etc., 88, 199
- Extremities, Ill-defined sites, 162
- Eye, 134, 136, 138, 140, 142, 144, 156, 208, 209, 210
 - Cornea, 136, 210
 - Eyelid, 136, 210
 - Lacrimal gland and duct, 142
 - Melanoma of uvea and other eye, 140
 - Orbit, 134, 136, 144, 208, 209, 210
 - Retina, 156
 - Uvea and other eye, 138
- Eyelid
 - Skin of, 88, 199
- Face
 - Skin and other unspecified parts, 88, 199
- Face, Ill-defined sites, 162
- Fallopian tube, 112
- Familial/multiple polyposis, 3, 48, 50, 182, 183, 184, 185
- Federation of Gynecology and Obstetrics (See FIGO stage.), 104, 203
- Female
 - Genital organs, 114
 - Genitourinary tract, 114
- FIGO stage, 100, 102, 104, 108, 110, 202, 203
 - Ascites with malignant cells, 110
 - Ascites without malignant cells, 110
- Flank
 - Ill-defined sites, 162
- Floor of mouth, 20
 - Invasive and noninvasive, 11
- Fornix of vagina, 102, 202
- Franklin's disease, 160
- Frontal lobe of brain, 146, 211

Frontal sinus, 72
 Fundus of
 Stomach, 44, 180
 Uterus, 108

 Gallbladder, 56, 187
 Gamma heavy chain disease, 160
 Gartner's duct, 102, 202
 Gastrointestinal tract, 66
 Genital tract, female, 114
 Gingiva (See gum.), 18, 169
 Gland
 Adrenal, 152
 Endocrine, 152
 Major salivary, 30
 Parathyroid, 152
 Parotid, 30
 Pineal, 152
 Submandibular, 30
 Suprarenal, 152
 Thymus, 152
 Thyroid, 150, 212
 Gland, Sublingual, 30
 Glans penis, 116
 Glottis including supra- and subglottis, 74, 195
 Gum (gingiva), 18, 169
 Invasive and noninvasive, 10, 11
 Lower, 18, 169
 Upper, 18, 169

 Hairy cell leukemia, 160
 Hard palate, 22, 170
 Invasive and noninvasive, 10, 11
 Head and neck
 Ill-defined sites, 162
 Heart, 80
 Hematopoietic system, 160
 Size not applicable, 3
 Hepatic flexure, 48, 182, 183, 184
 Colon, 48, 182, 183, 184
 Histiocytic medullary reticulosis, 160
 Histiocytic, (true) lymphoma, 158, 214
 Hodgkin's disease, 8, 158, 214
 Homolateral vs ipsilateral, 6, 8
 Hymen, 102, 202
 Hypopharynx (laryngopharynx), 36, 177
 Anatomic limits, 36, 177
 Posterior wall of, 36, 177

 Ileocecal valve and junction, 48, 182, 183, 184
 Ill-defined
 Abdomen, 162
 Head and neck, 162
 Thorax, 162
 Ill-defined digestive and peritoneal sites, 3, 66
 Ill-defined primary sites
 Back, 162
 Diseases, 7
 (6/92)

- Flank, 162
- Intestinal tract, 66
- Intrathoracic organs, 84
- Limbs, upper and lower, 162
- Lip, 38, 178
- Oral Cavity, 38, 178
- Pelvis, 162
- Peritoneum, 66
- Pharynx, 38, 178
- Respiratory system, 96
- Trunk, 162
- Unknown primary site, 162
- Ill-defined respiratory/intrathoracic organs, 3, 84
- Immunoproliferative Disease, 160
- Immunoproliferative small intestinal disease, 160
- Instructions for using EOD, 1
- Intestinal tract, 66
- Intrahepatic bile duct, 54, 186
- Intraocular extension, 134, 138, 156, 208, 209
- Intrathoracic
 - Esophagus, 42, 179
- Intrathoracic organs
 - Ill-defined sites, 3, 84
- Iris, 140
- Islets of Langerhans, 62, 190, 191
- Isthmus uteri, 108

- Jejunum, 46, 181
- Joints, 86

- Kaposi's sarcoma, 154, 213
- Kidney, 126
 - Parenchyma, (renal), 126
 - Renal pelvis (kidney), 128

- Labia majora
 - Skin, malignant melanoma, 90
- Labial mucosa
 - AJCC definition, 12, 167
 - Mucosa of
 - AJCC definition, 28, 173
- Labium majus and minus, 100
- Lacrimal gland and duct, 142, 208
- Lamina propria
 - Digestive system, 40, 41
 - Lip, oral cavity, and pharynx, 10
 - Renal pelvis (kidney), 124, 125
 - Ureters, 124, 125
 - Urinary bladder, 124, 125
- Laryngeal cartilage, 74, 195
- Laryngopharynx, 36, 177
- Larynx, 74, 195
- Lennert's lymphoma, 158, 214
- Letterer-Siwe's disease, 8, 160
- Leukemia
 - Acute megakaryoblastic (megakaryocytic), 160
 - Acute, chronic, subacute, aleukemic, 160
 - Basophilic, 160

- Blast cell, 160
- Coding, 8
- Eosinophilic, 160
- Granulocytic, myeloblastic, myelocytic, myeloid, 160
- Hairy cell, 160
- Lymphosarcoma cell, 160
- Mast cell, 160
- Monocytic, monoblastic, megakaryocytic, 160
- Myeloid, granulocytic, myeloblastic, 160
- NOS, 160
- Plasma cell, plasmacytic, prolymphocytic, 160
- Promyelocytic
 - Myelomonocytic, 160
- Size not applicable, 3
- Undifferentiated, 160
- Leukemic reticuloendotheliosis, 160
- Lingual tonsil, 14, 168
- Linitis plastica, 3
- Lip, 12, 167
 - Commissure, 12, 167
 - Ill-defined sites, 38, 178
 - Invasive and noninvasive, 11
 - Lower, 12, 167
 - Mucosa
 - Head and neck, 12, 167
 - Upper, 12, 167
- Lip, oral cavity, and pharynx, 10, 11
- Liver, 54, 186
- Lobe of lung, entire, 3
- Lower esophagus, 42, 179
- Lung
 - Diffuse tumor, 3
 - Other parts, 78, 196
 - Upper, middle and lower lobes, 78, 196
- Lymph nodes
 - Chest x-ray with no mention of, 5
 - Enlarged, 5
 - Exploratory/definitive surgery, 108
 - First station, 5
 - Fixed, 5
 - Homolateral, 6, 8
 - In situ
 - Code, 5
 - Inaccessible, 5, 6
 - Involved
 - Coding, 5
 - Ipsilateral, 6, 8
 - Localized, NOS, 5
 - Matted, 5
 - Mediastinal mass, 5
 - Mesentery, 5
 - Non-palpable, 5
 - NOS, 5
 - Palpable, 5
 - Pathology review of regional, 5
 - Positive, number examined, 5
 - Regional, NOS, 6, 8
 - Retroperitoneal mass, 5

- Shotty, 5
- Small bilateral nodes, 5
- Unknown involvement
 - Code, 5
 - Visible swelling, 5
- Lymph nodes and lymphoid tissue, 158, 214
 - Coding, 5
- Lymphoepithelial lymphoma, 158, 214
- Lymphoma
 - All sites, 158, 214
 - Burkitt's, 158, 214
 - Extranodal, 8
 - Extranodal sites, 158, 214
 - Hodgkin's disease, 158, 214
 - Lymph nodes
 - Enlarged, 5
 - Visible swelling, 5
 - Nodal, 8
 - Non-Hodgkin's, 158, 214
 - Size not applicable, 3
 - True histiocytic, 158, 214
- Lymphoproliferative disease, NOS, 160
- Lymphosarcoma cell leukemia, 160
- Lymphosarcoma, NOS, 158, 214

- Main stem bronchus, 78, 196
- Major salivary gland, 30
- Male genital organs, 118, 204
- Malignant histiocytosis, 160
- Malignant idiopathic/essential (hemorrhagic) thrombocythemia, 160
- Malignant lymphoma, 158, 214
- Malignant lymphoproliferative disease, NOS, 160
- Malignant melanoma, 90, 136, 140, 210
- Malignant monoclonal gammopathy, 160
- Malignant myelodysplastic syndrome, 160
- Malignant myeloproliferative disease, NOS, 160
- Malignant myelosclerosis with myeloid metaplasia, 160
- Malignant polycythemia (rubra) vera, 160
- Mandible, 86
- Maxillary sinus, 70, 194
- Mediastinal mass, 78, 196
- Mediastinum, anterior and posterior, 80
- Melanoma
 - Malignant, 90
 - Thickness of tumor instead of size, 3
- Melanoma of conjunctiva, 136, 210
- Meninges
 - Cerebral, 146, 211
- Mesentery, 96
- Mesoappendix, 96
- Middle Ear, 68, 193
- Middle Esophagus, 42, 179
- Mouth, 20
 - Anterior floor, 20
 - Floor of, 20
 - Lateral floor, 20
 - Other parts, 26, 172
 - Palate, 26, 172

- Roof, 26, 172
- Vestibule, 28, 173
- Mucosa, lip, oral cavity, and pharynx, 11
- Multiple myeloma, 160
 - Coding, 8
- Muscularis mucosae
 - Digestive system, 41
- Muscularis mucosae, 40, 41
 - Lip, oral cavity, and pharynx, 10, 11
- Muscularis propria
 - Digestive system, 40, 41
 - Lip, oral cavity, and pharynx, 10, 11
 - Renal pelvis (kidney), 124, 125
 - Ureters, 124, 125
 - Urinary bladder, 124, 125
- Mycosis fungoides, 8, 92, 200
 - Size not applicable, 3
- Myelofibrosis, acute, 160
- Myeloma, NOS, 160
- Myelomatosis, 160
- Myeloproliferative disease
 - Size not applicable, 3
- Myometrium, 107, 108

- Nasal cavity, 68, 193
- Nasopharynx, 34, 176
 - Anatomic limits, 34, 176
 - Anterior, lateral, posterior and superior walls, 34, 176
- Nerve, 148
 - Cranial, 148
 - Optic, 148
- Nervous system, 148
 - Meninges, 148
 - Other than brain, 148
 - Spinal cord, 148
- Nipple retraction of breast, 98, 201
- Non-Hodgkin's lymphoma, 8, 158, 214
- Non-lipid reticuloendotheliosis, 160
- Noninvasive tumor, 5
 - Corpus uteri, 107
 - Digestive system, 40, 41
 - Lip, oral cavity, and pharynx, 10
 - Renal pelvis (kidney), 124, 125
 - Ureters, 124, 125
 - Urinary bladder, 124, 125
- Nonpolyp, 48, 182, 183, 184

- Obstructive pneumonitis, 78, 196
- Occipital lobe of brain, 146, 211
- Omentum, 96
- Oper/path information, 1
- Optic nerve, 142
- Oral cavity, 26, 172
 - Ill-defined sites, 38, 178
- Orbit, 144
 - Adjacent paranasal sinuses, 144
 - Cranium, 144
- Oropharynx, 32, 174, 175
 - (6/92)

- Anatomic limits, 32, 174, 175
- Anterior, posterior and lateral walls, 32, 174, 175
- Branchial cleft, 32, 174, 175
- Junctional region, 32, 174, 175
- Superior wall
 - AJCC definition, 32, 174, 175
- Ovary, 110
 - Ascites
 - Status of capsule code, 3, 110
 - Size, two digit code, 3, 110
- Palate, 22, 24, 170, 171
 - Hard, 22, 170
 - Junction of hard and soft, 26, 172
 - Soft, 24, 171
- Palpable lymph nodes, 5
- Palpebral conjunctiva, 136, 210
- Pancreas, 62, 64, 190, 191, 192
 - Body of, 62, 190, 191
 - Head of, 62, 190, 191
 - Tail of, 62, 190, 191
 - Unspecified, 64, 192
- Pancreatic duct, 62, 190, 191
- Panmyelosis, acute, 160
- Parametrium, 112
- Paranasal sinuses, 72
- Parathyroid, 152
- Paraurethral gland, 132, 207
- Parietal lobe of brain, 146, 211
- Parotid gland, 30
- Pathology report, priority, 1
- Pathology review of regional lymph nodes, 5
- Pelvis, Ill-defined sites, 162
- Penis, 116
 - Body of, 118, 204
 - Glans, 116
 - Skin of, 116
 - Kaposi's sarcoma, 90, 116
 - Malignant melanoma, 90, 116
 - Mycosis fungoides, 90, 116
 - Sezary's disease, 90, 116
- Peritoneum, 96
 - Ill-defined sites, 3, 66
- Pharynx, 38, 178
 - Ill-defined sites, 38, 178
- Pineal gland, 152
- Pituitary gland, 152
- Placenta, 108
- Plasma cell leukemia, 160
- Plasma cell tumors, 160
- Plasmacytoma, NOS, 160
- Pleura, parietal and visceral, 82
- Polyp (adenoma), 48, 182, 183, 184
- Polyp, code size of tumor, 3
- Polyposis, familial/multiple, 3
- Positive/excised regional lymph node coding, 5
- Postcricoid area, 36, 177
- Posterior hypopharyngeal wall, 36, 177

Pouch of Douglas, 96
 Prepuce, 116
 Primary site, tumor overlaps boundaries of two or more, 5
 Polymphocytic leukemia, 160
 Prostate gland, 120, 205
 Pylorus including antrum, 44, 180
 Pyriform sinus, 36, 177

 Radiation pretreatment for surgical patients, 1
 Rectosigmoid, 50, 185
 Invasive and noninvasive, 41
 Junction, 50, 185
 Rectouterine pouch, 96
 Rectum, 50, 185
 Invasive and noninvasive, 40, 41
 Other parts of, 52
 Regional nodes, number of positive and examined, 7
 Renal pelvis (kidney), 124, 125, 128
 Invasive and noninvasive, 124, 125
 Respiratory system
 Ill-defined sites, 3, 84
 Upper tract, 84
 Reticuloendothelial system, 160
 Size not applicable, 3
 Reticuloendotheliosis, 8
 Retina, 156
 Retinoblastoma, 138
 Retromolar area, 18, 169
 Retroperitoneum, 96
 Rosenmuller's fossa (pharyngeal recess), 34, 176
 Round ligament(s), 112

 Salivary gland, major, 30
 Sarcoma, myeloid/granulocytic (chloroma), 160
 Scalp and neck
 Skin of, 88, 199
 Scrotum, 118, 204
 Skin, malignant melanoma, 90
 Seminal vesicle(s), 118, 204
 Serosa
 Corpus uteri, 107
 Digestive system, 40, 41
 Renal pelvis (kidney), 124, 125
 Ureters, 124, 125
 Urinary bladder, 124, 125
 Sezary's cells, 92, 200
 Sezary's disease, 8, 92, 200
 Sigmoid colon, 48, 182, 183, 184
 Skin, 88, 199
 Malignant melanoma, 90
 Melanotic tumors, 90
 Mycosis fungoides, 92, 200
 Nonmelanotic tumors, 88, 199
 Sezary's disease, 92, 200
 Small intestine, 46, 181
 Invasive and noninvasive, 40, 41
 Soft palate, 24, 171
 AJCC definition, 24, 32, 171, 174, 175
 (6/92)

- Inferior surface
 - AJCC definition, 32, 174, 175
 - Invasive and noninvasive, 11
- Soft tissue, 94
 - Head, face and neck, 94
 - Pelvis and trunk, 94
 - Shoulder and hip, 94
 - Thorax and abdomen, 94
 - Upper and lower limbs, 94
- Solitary myeloma, 160
- Solitary plasmacytoma, 160
- Spermatic cord, 118, 204
- Sphenoid sinus, 72
- Spinal cord, 148
- Spinal meninges, 148
- Splenic flexure of colon, 48, 182, 183, 184
- Squamocolumnar junction of cervix, 104, 203
- Stomach, 44, 180
 - Anterior and posterior walls, 44, 180
 - Diffuse tumor, 3
 - Invasive and noninvasive, 40, 41
- Stroma (lamina propria)
 - Corpus uteri, 107
- Subcutaneous tissue, 94
- Sublingual gland, 30
- Submandibular gland, 30
- Submucosa
 - Digestive system, 40, 41
 - Lip, oral cavity, and pharynx, 10, 11
 - Renal pelvis (kidney), 124, 125
 - Ureters, 124, 125
 - Urinary bladder, 124, 125
- Suprarenal gland, 152
- Surgery
 - Exploratory/definitive, 108
- Surgical observations, 1
- Systemic disease, 8

- T-cell lymphoma, 158, 214
- T-zone lymphoma, 158, 214
- Temporal lobe of brain, 146, 211
- Testis, 122
 - Undescended, 122
- Tethering of breast tissue, 98, 201
- Thorax, Ill-defined sites, 162
- Thymus gland, 152
- Thyroid gland, 150, 212
- Time limits for EOD, 1
- Tissue, soft, subcutaneous and connective, 94
- Tongue, 14, 16, 168
 - Anterior 2/3's, 16
 - Base (posterior), 14, 16, 168
 - AJCC definition, 14, 32, 168, 174, 175
 - Border, 14, 16, 168
 - Dorsal surface, 14, 16, 168
 - Frenulum linguae, 16
 - Invasive and noninvasive, 11
 - Junctional Zone, 16

- Lingual, 14, 168
- Midline, 16
- Posterior 1/3rd, 14, 168
- Root, 14, 168
- Tip, 16
- Ventral surface, 16
- Tonsil (incl. tonsillar fossa and pillar), 32, 174, 175
- Trachea, 76
- Transverse colon, 48, 182, 183, 184
- True histiocytic lymphoma, 8, 158, 214
- Trunk
 - Skin of, 88, 199
- Trunk, Ill-defined sites, 162
- Tubo-ovarian, 112
- Tumor size
 - Ascites
 - Status of capsule code, 3, 110
 - Centimeters, 3, 4
 - Do NOT add chips or pieces together, 3, 165
 - Equivalences in cm
 - Balls, golf, tennis, etc., 4
 - Doughnut, 4
 - Egg, bantam, goose, etc., 4
 - Eraser on pencil, 4
 - Fist, 4
 - Fruits, 4
 - Lentil, 4
 - Marble, 4
 - Match (head), 4
 - Microscopic, 4
 - Millet, 4
 - Money, 4
 - Nuts, 4
 - Vegetables, 4
 - In situ lesions, 3
 - Inches, 4
 - Millimeters, 4
 - Priority of code '998', 3
 - SEER rules for coding
 - Encouraged, 4
 - Required, 3
 - Size of tumor, not polyp, ulcer, or cyst, 3
 - Surgical cases pretreated by radiation, 1
- Tunica vaginalis, 118, 204

- Ulcer, code size of tumor, 3
- Undescended testis, 122
- Undifferentiated leukemia, 160
- Unknown and not applicable
 - Extension of tumor, 7
 - Lymph nodes, 7
 - Size of tumor, 7
- Unknown primary site, 162
 - Codes for, 7
 - Size not applicable, 3
- Unstaged codes, 7
- Upper esophagus, 42, 179
- Urachus, 130, 206

Ureteric orifice, 130, 206
 Ureters, 124, 125, 128
 Invasive and noninvasive, 124, 125
 Urethra, 132, 207
 Urethrovaginal septum, 114
 Urinary system, 128
 (See urinary bladder, renal pelvis and ureters.), 130, 206
 Bladder, 124, 125, 130, 206
 Invasive and noninvasive, 124, 125
 Uteri, 104, 203
 Cervix, 104, 203
 Corpus, 108
 Uterine adnexa, 112
 Other parts of, 112
 Uterine cervix, 104, 203
 Utero-ovarian, 112
 Uterus, 108
 Uvea, 140
 Uvula, 24, 171
 AJCC definition, 24, 32, 171, 174, 175

 Vagina, 102, 202
 Vallecula epiglottica, 32, 174, 175
 Ventricle of brain, 146, 211
 Vermilion border, 12, 167
 Vertebral column, 86
 Vesicocervical tissue, 114
 Vesicovaginal septum, 114
 Vestibule of mouth, 28, 173
 Vocal cords, 74, 195
 Vulva, 100
 Skin of, 100
 Kaposi's sarcoma, 154
 Malignant melanoma, 90, 154
 Mycosis fungoides, 154
 Sezary's disease, 154

 Waldenstrom's macroglobulinemia, 160
 Waldeyer's ring, 38, 178
 Widespread, 3

 X-ray no mention of nodes, 78, 196

NATIONAL
CANCER
INSTITUTE

NIH Publication No. 92-2313